

# 第2日

7月19日(金)

D A Y 2

Friday, July 19, 2019

有吉寛先生追悼講演

**SL** ..... 172

Special Presidential Session / 会長特別企画

**SPS2** Basic Lecture on Cancer Genome Medicine

がんゲノム医療時代に役立つ、ゲノム診断・橋渡し研究データの解釈のための基礎講義  
..... 186

Asia Oceania/JSMO Joint Symposium / Asia Oceania/JSMO 合同シンポジウム

**AOJS** Joint Symposium of Asian Medical Oncology Societies

~ To Further Develop Relationship for Asian Patients ~ ..... 207

Joint Symposium / 合同シンポジウム

**JS4** Clinical Implementation in Cancer Genome Medicine

がんゲノム医療の臨床実装 ..... 204

Presidential Symposium / 会長企画シンポジウム

**PSY4** Promising Treatment of Tomorrow ..... 194

**PSY5** Utilization of Big Data in Cancer Care

がん診療におけるビッグデータの活用 ..... 195

**PSY6** Accelerating Drug Development and Approval Utilizing a Platform Trial in Japan

..... 202

**PSY7** Genome Based Clinical Trials: What is Next Generation Clinical Trials? ..... 207

Symposium / シンポジウム

**SY8** Circulating Biomarkers ..... 175

**SY9** Changes in Investigator-initiated Clinical Trials after Implementation of the Clinical Research Act

臨床研究法で研究者主導試験はどう変わったか ..... 177

**SY10** Sequential Treatment Strategy after the Failure of First-line Tyrosine Kinase Inhibitor for Lung Cancer

肺癌における最強の TKI 後の治療戦略 ..... 187

**SY11** The Appropriate Selection of Anti-cancer Drugs According to Cost Effectiveness

費用対効果を考えた今後の適正な薬剤使用 ..... 203

**SY12** New Strategy of Peri-operative Therapy for Resectable Gastric Cancer

胃癌周術期治療の新たな展開 ..... 204

**SY13** Molecular Abnormalities and Clinical Development of New Drugs for Thyroid Cancer

甲状腺がんの分子遺伝子異常と新規治療開発 ..... 206

Mini Symposium / ミニシンポジウム

**MS3** Revisiting the PARP Inhibitors in New Era for Ovarian Cancer  
卵巣癌における PARP 阻害剤の使用について再考する ..... 205

Panel Discussion / パネルディスカッション

**PD2** The Safety Management of Chemotherapy - Anticancer Drug Exposure, Prevention and Education  
抗がん剤投与の安全性を改めて考える - 曝露対策から予防教育まで ..... 180

Workshop / ワークショップ

**WS2** Support for Working Cancer Survivors : Healthcare Providers' Role in Hospital Settings  
がん治療と仕事の両立 : 医療者に求められる具体的な支援のかたち ..... 181

Educational Lecture / 教育講演

**EL17** 大腸癌 ..... 174  
**EL18** 肝臓癌 ..... 174  
**EL19** 胆道・膵臓癌 ..... 174  
**EL20** 小細胞肺癌 ..... 174  
**EL21** 非小細胞肺癌 ..... 175  
**EL22** 乳癌 (初期薬物療法) ..... 175  
**EL23** 卵巣癌 ..... 176  
**EL24** 子宮頸癌・子宮体癌 ..... 176  
**EL25** 乳癌 (再発薬物療法) ..... 178  
**EL26** 泌尿器癌 (腎、尿路、前立腺) ..... 178  
**EL27** 骨軟部腫瘍・転移性骨腫瘍 ..... 178  
**EL28** 悪性リンパ腫 ..... 179  
**EL29** 白血病 ..... 196

Distinguished Expert Lecture

**DL7** Current and Future Directions for the Treatment of Advanced Thyroid Cancer ... 208  
**DL8** Current approach to the treatment for the elderly myeloma patients ..... 208  
**DL9** Speeding Drug Development Through Neoadjuvant Therapy ..... 208  
**DL10** A Patient-centric Approach to Pancreatic Cancer Research: the Pancreatic Cancer Action Network Experience ..... 208  
**DL11** CLINICAL PROFILE AND TREATMENT OUTCOMES OF LYMPHOMA PATIENTS: A REAL WORLD EXPERIENCE ..... 209  
**DL12** Reference centers and precision medicine trials in sarcoma ..... 209

Meet the Experts

**ME7** Evolving Management Paradigm of Advanced NSCLC ..... 210

<b>ME8</b>	Novel Targeted Therapies in Gastric Cancer, Moving Beyond PD1 .....	210
<b>ME9</b>	How to Implement Personalized Medicine .....	210
<b>ME10</b>	Immuno-precision Medicine in Gastric Cancer; How to Select The Proper Patients? .....	210
<b>ME11</b>	Understanding Response and Resistance Mechanisms to I-O therapy .....	211
<b>ME12</b>	Liquid Biopsy for NSCLC: From Research to Practice .....	211
JSMO Membership Committee Program / 日本臨床腫瘍学会 会員委員会企画		
<b>MC</b>	Promotion of Work Style Reform of Medical Staff 医療従事者の働き方を考える .....	194
JSMO Committee on Public Information and Negotiation Program / 日本臨床腫瘍学会 広報渉外委員会企画		
<b>PIN</b>	Tobacco Control Session 禁煙推進セッション .....	202



## 国立京都国際会館 1階 メインホール

8:20-9:35 Oral Abstract Session 2-1

### O2-1 Gastrointestinal Cancer1 消化管 1

Chairs : Kentaro Yamazaki (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
Sun Young Rha (Yonsei Cancer Center, Yonsei University College of Medicine, Korea)  
Discussant : Daisuke Sakai (Center for Cancer Genomics and Personalized Medicine, Osaka University Hospital)  
司会 : 山崎 健太郎 (静岡県立静岡がんセンター 消化器内科)  
Sun Young Rha (Yonsei Cancer Center, Yonsei University College of Medicine, Korea)  
ディスカッサント: 坂井 大介 (大阪大学医学部附属病院 がんゲノム医療センター)

### O2-1-1 Pembrolizumab (pembro) in Mismatch Repair-Deficient (dMMR) Advanced Colorectal Cancer (CRC): KEYNOTE-164 Japan Subgroup

Hiroya Taniguchi (Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Japan)

### O2-1-2 A multicenter retrospective study of Paclitaxel vs. Paclitaxel plus Ramucirumab for advanced gastric cancer patients

Hiroshi Imazeki (Division of Gastrointestinal Oncology, National Cancer Center Hospital)  
今関 洋 (国立がん研究センター中央病院消化器内科)

### O2-1-3 Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer

Yohei Kubota (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
久保田 洋平 (国立がん研究センター東病院 消化器内科)

### O2-1-4 Development of novel *in vitro* diagnostics to predict the efficacy of anti-EGFR treatment based on DNA methylation status

Kota Ouchi (Department of Medical Oncology, Tohoku University Hospital / Department of Clinical Oncology, Institute of Development, Aging and Cancer (IDAC), Tohoku University)  
大内 康太 (東北大学病院 腫瘍内科 / 東北大学加齢医学研究所 臨床腫瘍学分野)

9:35-10:50 Oral Abstract Session 2-2

### O2-2 Hepatobiliary/Pancreatic Cancer 肝胆膵

Chairs : Takuji Okusaka (National Cancer Center Hospital)  
Chen Ming Huang (Taipei Veterans General Hospital, Taipei, Taiwan/National Yang-Ming University, Taipei, Taiwan)  
Discussant : Mitsuhito Sasaki (National Cancer Center Hospital East Hepatobiliary Pancreatic Oncology)  
司会 : 奥坂 拓志 (国立がん研究センター中央病院)  
Chen Ming Huang (Taipei Veterans General Hospital, Taipei, Taiwan/National Yang-Ming University, Taipei, Taiwan)  
ディスカッサント: 佐々木 満仁 (国立がん研究センター東病院 肝胆膵内科)

### O2-2-1 KEYNOTE-240: pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC)

Encore

Masatoshi Kudo (Kindai University Faculty of Medicine, Japan)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
4/F  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
5<5  
5<5  
D-1/1/1-A  
D-2/1/1-A  
F-1/1/1-A  
Room C-1  
Room C-2  
Room B-2  
Room 104

Day 1 (Thu)	<b>02-2-2</b>	<b>A multicenter retrospective study of GEM+nab-PTX or FOLFIRINOX in metastatic pancreatic cancer patients: NAPOLEON study</b> Yujiro Ueda (Department of Hematology and Oncology, Japanese Red Cross Kumamoto Hospital) 上田 裕二郎 (熊本赤十字病院 血液・腫瘍内科)
Day 2 (Fri)	<b>02-2-3</b> <b>Encore</b>	<b>Phase II trial of GEMOX for the advanced pancreatic cancer with family/personal history of HBOC related cancer</b> Hidetaka Tsumura (Hyogo cancer center) 津村 英隆 (兵庫県立がんセンター)
Day 3 (Sat)	<b>02-2-4</b>	<b>Phase I study of nivolumab or nivolumab/cisplatin/gemcitabine to treat unresectable/recurrent biliary tract cancer</b> Chigusa Morizane (National Cancer Center Hospital) 森実 千種 (国立がん研究センター中央病院)
Annex 1		
Annex 2	14:30-14:40	有吉寛先生追悼講演
Room A	<b>SL</b>	<b>有吉寛先生追悼講演</b>
Room B-1	Chair :	Ryuzo Ueda (Department of Tumor Immunology, Aichi Medical University School of Medicine)
Room D	司会 :	上田 龍三 (愛知医科大学 医学部・腫瘍免疫寄付講座)
Room E		Masahiro Fukuoka (Department of Medical Oncology, Izumi City General Hospital) 福岡 正博 (和泉市立総合医療センター 腫瘍内科)
Room E	16:00-18:00	Presidential Session 2
Room E	<b>PS2</b>	<b>Presidential Session 2</b>
Room E	Chairs :	Eishi Baba (Department of Oncology and Social Medicine Graduate School of Medical Sciences) Kazuhito Yamamoto (Aichi Cancer Center, Department of Hematology and Cell Therapy)
Room E	司会 :	馬場 英司 (九州大学大学院 医学研究院 社会環境医学講座 連携社会医学分野) 山本 一仁 (愛知県がんセンター 血液・細胞療法部)
Room C-1	<b>PS2-1</b> <b>Encore</b>	<b>A phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy (NCCH1503)</b> Natsuko Okita (Gastrointestinal Medical Oncology Division, National Cancer Center Hospital) 沖田 南都子 (国立がん研究センター中央病院 消化管内科)
Room C-2	Discussant :	Daisuke Kotani (Department of gastrointestinal oncology, National Cancer Center Hospital East)
Room C-2	ディスカッサント:	小谷 大輔 (国立がん研究センター東病院 消化管内科)
Room C-1	<b>PS2-2</b> <b>Encore</b>	<b>SUNRISE-DI Study: Decision Impact of the 12-Gene RS Assay on Adjuvant Chemotherapy for Stage II and IIIA/B Colon Cancer</b> Koji Ando (Department of Surgery and Science, Kyushu University) 安藤 幸滋 (九州大学大学院 消化器・総合外科)
Room C-2	Discussant :	Zev Wainberg (UCLA School of Medicine, U.S.A.)
Room B-2	<b>PS2-3</b> <b>Encore</b>	<b>Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results</b> Jorge E. Cortes (Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States)
Room 104		

Discussant : Tatsuya Suzuki (Department of Hematology, National Cancer Center Hospital)  
ディスカッサント: 鈴木 達也 (国立がん研究センター 中央病院 血液腫瘍科)

**PS2-4 The novel risk classification (PLaCT) for malignant ureteral obstruction;  
A multicenter prospective validation study**

Kouji Izumi (Department of Urology, Kanazawa University)  
泉 浩二 (金沢大学泌尿器科)

Discussant : Chihiro Kondoh (Toranomon Hospital, Department of Medical Oncology)  
ディスカッサント: 近藤 千紘 (虎の門病院 臨床腫瘍科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

キックオフ

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

セミナー

ランチ

Day 4 (Sun)

Room A-1

Room C-1

Room C-2

Room B-2

Room 104

国立京都国際会館 1階 Annex1

8:20-8:50 Educational Lecture 17 / 教育講演 17 : 応用編

EL17 大腸癌

Chair : Yasuko Murakawa (Miyagi Cancer Center, Medical Oncology)  
司会 : 村川 康子 (宮城県立がんセンター 腫瘍内科)

Latest Advance and Future Perspective for the Treatment of Metastatic Colorectal Cancer (mCRC)

Takayuki Yoshino (Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East)  
吉野 孝之 (国立がん研究センター東病院)

8:50-9:20 Educational Lecture 18 / 教育講演 18 : 応用編

EL18 肝臓癌

Chair : Koji Miyanishi (Department of Medical Oncology, Sapporo Medical University, School of Medicine)  
司会 : 宮西 浩嗣 (札幌医科大学 腫瘍内科学講座 (第四内科))

Primary Liver Cancer

Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

肝臓癌

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

9:20-9:50 Educational Lecture 19 / 教育講演 19 : 応用編

EL19 胆道・膵臓癌

Chair : Makoto Yoshida (Department of Clinical Oncology, Sapporo Medical University)  
司会 : 吉田 真誠 (札幌医科大学 腫瘍内科)

The Progress and Management of the Chemotherapy in Biliary and Pancreatic Cancer

Makoto Ueno (Kanagawa Cancer Center, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division)

胆膵癌化学療法の進歩と、実臨床での工夫

上野 誠 (神奈川県立がんセンター)

9:50-10:20 Educational Lecture 20 / 教育講演 20 : 応用編

EL20 小細胞肺癌

Chair : Hiroshige Yoshioka (Kansai Medical University Hospital, Department of Thoracic Oncology)  
司会 : 吉岡 弘鎮 (関西医科大学附属病院 呼吸器腫瘍内科)

Small Cell Lung Cancer

Katsuyuki Hotta (Center for Clinical Innovative Medicine, Okayama University Hospital)

小細胞肺癌

堀田 勝幸 (岡山大学病院 新医療研究開発センター臨床研究部)



10:20-10:50 Educational Lecture 21 / 教育講演 21 : 応用編

**EL21** 非小細胞肺癌

Chair : Makoto Maemondo (Iwate Medical University Department of Internal Medicine Division of Respiratory Medicine, Allergy, and Rheumatology)  
司会 : 前門戸 任 (岩手医科大学 内科学講座 呼吸器・アレルギー・膠原病内科学分野)

**Advance of Treatment for Lung Cancer**

Makoto Nishio (Department of Thoracic Medical Oncology, The Cancer Institute Hospital of JFCR)

**肺癌の薬物療法の進歩**

西尾 誠人 (がん研究会有明病院)

10:50-11:20 Educational Lecture 22 / 教育講演 22 : 応用編

**EL22** 乳癌 (初期薬物療法)

Chair : Yutaka Yamamoto (Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University)  
司会 : 山本 豊 (熊本大学大学院生命科学研究部 乳腺・内分泌外科学)

**Recent Development of Treatment Strategy for Early Breast Cancer**

Shigehira Saji (Fukushima Medical University, Dept of Medical Oncology)

**乳癌 (周術期薬物療法)**

佐治 重衡 (福島県立医科大学)

15:10-17:10 Symposium 8 / シンポジウム 8

**SY8** Circulating Biomarkers

Chairs : Toshiro Nishida (National Cancer Center Hospital)  
Toshiaki Saeki (Department of Breast Oncology, International Medical Center Saitama Medical University)  
司会 : 西田 俊朗 (国立がん研究センター中央病院 院長)  
佐伯 俊昭 (埼玉医科大学国際医療センター 包括的がんセンター乳腺腫瘍科)

**SY8-1** **Early Detection and Characterization of Cancer Using Noninvasive Liquid Biopsies**

Victor Velculescu (Johns Hopkins Kimmel Cancer Center, U.S.A.)

**SY8-2** **Precision Medicine in Prostate Cancer**

Shinichi Sakamoto (Chiba University Graduate School of Medicine)

**前立腺癌におけるプレシジョンメディスン**

坂本 信一 (千葉大学大学院医学研究院 泌尿器科学)

**SY8-3** **Clinical application of cfDNA analysis in colorectal cancer**

Katsuya Tsuchihara (EPOC, National Cancer Center)  
土原 一哉 (国立がん研究センター先端医療開発センター)

**SY8-4** **Exosome Diagnosis Presents a Novel Platform for Liquid Biopsy**

Takahiro Ochiya (Tokyo Medical University)

**体液診断の新しい戦略としてのエクソソーム**

落谷 孝広 (東京医科大学)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
会場  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
会場  
会場  
会場  
会場  
Room C-1  
Room C-2  
Room B-2  
Room 104

17:10-17:40 Educational Lecture 23 / 教育講演 23 : 応用編

**EL23** 卵巣癌

Chair : Mihoko Doi (Department of Clinical Oncology, Hiroshima Prefectural Hospital)  
司会 : 土井 美帆子 (県立広島病院 臨床腫瘍科)

**Ovarian Cancer**

Koji Matsumoto (Medical oncology Division, Hyogo Cancer Center)

**卵巣癌**

松本 光史 (兵庫県立がんセンター)

17:40-18:10 Educational Lecture 24 / 教育講演 24 : 応用編

**EL24** 子宮頸癌・子宮体癌

Chair : Satomi Aihara (Saiseikai Hita Hospital)  
司会 : 相原 聡美 (大分県済生会日田病院 腫瘍内科)

**Treatment for Patients with Endometrial Cancer and Cervical Cancer**

Mayu Yunokawa (Gynecology Oncology and Medical Oncology Department, The Cancer Institute Hospital of JFCR)

**子宮頸がん・子宮体がんの治療**

温泉川 真由 (がん研究会有明病院 婦人科 兼 総合腫瘍科)

## 国立京都国際会館 1階 Annex2

8:20-10:20 Symposium 9 / シンポジウム 9

### SY9 Changes in Investigator-initiated Clinical Trials after Implementation of the Clinical Research Act 臨床研究法で研究者主導試験はどう変わったか

Chairs : Takeharu Yamanaka (Department of Biostatistics, Yokohama City University)  
Shimon Tashiro (Tohoku University Graduate School of Arts and Letters)

司会 : 山中 竹春 (横浜市立大学医学部 臨床統計学)  
田代 志門 (東北大学大学院文学研究科)

### SY9-1 Support for investigators who conducts specified clinical trials at CRIETO

Tadao Takano (Clinical Research, Innovation, and Education Center, Tohoku University Hospital (CRIETO))

**東北大学病院臨床研究推進センター (CRIETO) における研究責任医師支援の取り組み**  
高野 忠夫 (東北大学病院 臨床研究推進センター)

### SY9-2 How to address the issues for investigator-initiated clinical trials under the Clinical Trials Act in NCCH

Hiroshi Katayama (Clinical Research Support Office, National Cancer Center Hospital)

**臨床研究法下の研究者主導試験に対する国立がん研究センター中央病院 (NCCH) の取り組み**  
片山 宏 (国立がん研究センター中央病院 臨床研究支援部門)

### SY9-3 Response to Clinical Trials Act at Kyoto University

Hiroi Kasai (Kyoto University Hospital)

**臨床研究法 一京都大学医学部附属病院における取り組み**  
笠井 宏委 (京都大学医学部附属病院)

### SY9-4 Situation of Clinical Research Act, and promotion policy of clinical research

Haruhiko Hakuno (Research promotion division, Ministry of Health, Labor and Welfare)

**臨床研究法の施行状況と臨床研究の推進方策について**  
伯野 春彦 (厚生労働省 医政局 研究開発振興課)

10:20-11:35 Oral Abstract Session 2-3

### O2-3 Clinical Trial Facilitation Program 臨床試験推進プログラム

Chairs : Kozo Kataoka (Department of Surgery, Hyogo College of Medicine)  
Shoichiro Ohtani (Division of Breast surgery, Hiroshima Citizens Hiroshima City Hospital)

Discussant : Akihiro Sato (National Cancer Center Hospital East)  
司会 : 片岡 幸三 (兵庫医科大学病院 外科学講座 下部消化管外科)

大谷 彰一郎 (広島市立広島市民病院 乳腺外科)  
ディモカソント: 佐藤 暁洋 (国立がん研究センター東病院)

### O2-3-1 Data standardization for Regulatory-grade Real World Data - Initiatives in the SCRUM-Japan Registry

Wataru Okamoto (National Cancer Center Hospital East)

岡本 渉 (国立がん研究センター東病院)

### O2-3-2 Phase 1 to 3 of the update of the EORTC Quality of Life Gastric module QLQ-STO22

Mitsumi Terada (medical department, EORTC)

寺田 参省 (medical department, EORTC)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Annex 1 Annex 2 Room A Room B-1 Room D Room E 655 2701 Room C-1 Room C-2 Room B-2 Room 104

**02-3-3 Cancer types where registry data can be applicable in efficacy evaluation**  
 Yuka Kato (Office of New Drug V, Pharmaceuticals and Medical Devices Agency / Center for Innovative Clinical Medicine, Okayama University Hospital)

**レジストリデータが有効性評価に活用できる可能性のある癌腫についての考察**  
 加藤 有加 (医薬品医療機器総合機構 新薬審査第五部 / 岡山大学病院 新医療研究開発センター)

**02-3-4 A Platform (Basket/Umbrella) Trial with a Registry Study for Rare Cancers: MASTER KEY Project**  
 Hitomi Okuma (National Cancer Center Hospital)  
**MASTER KEY プロジェクト：希少がんを対象としたレジストリ研究とバスケット型臨床試験**  
 大熊 ひとみ (国立がん研究センター中央病院)

15:20-15:50 Educational Lecture 25 / 教育講演 25 : 応用編

**EL25 乳癌 (再発薬物療法)**

Chair : Yasuhiro Yanagita (Gunma Prefectural Cancer Center)  
 司会 : 柳田 康弘 (群馬県立がんセンター)

**Systemic therapy for metastatic breast cancer**  
 Toshimi Takano (Department of Medical Oncology, Toranomon Hospital)

**転移性乳癌薬物療法**  
 高野 利実 (虎の門病院 臨床腫瘍科)

15:50-16:20 Educational Lecture 26 / 教育講演 26 : 応用編

**EL26 泌尿器癌 (腎、尿路、前立腺)**

Chair : Takashi Yoshioka (Yamagata University)  
 司会 : 吉岡 孝志 (山形大学 第二内科学講座臨床腫瘍学分野)

**Systemic Therapy for Genitourinary Cancers**  
 Hiroshi Kitamura (Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama)

**泌尿器がん (腎、尿路上皮、前立腺)**  
 北村 寛 (富山大学大学院 医学薬学研究部 腎泌尿器科学講座)

16:20-16:50 Educational Lecture 27 / 教育講演 27 : 応用編

**EL27 骨軟部腫瘍・転移性骨腫瘍**

Chair : Kohichi Takada (Department of Medical Oncology, Sapporo Medical University School of Medicine)  
 司会 : 高田 弘一 (札幌医科大学附属病院 腫瘍内科学講座、血液内科学)

**Recent Topics on Primary Bone and Soft Tissue Tumors and Metastatic Bone Tumors**  
 Hiroshi Urakawa (Clinical Oncology and Chemotherapy, Nagoya University Hospital)

**原発性骨軟部腫瘍・転移性骨腫瘍に関する最近のトピックス**  
 浦川 浩 (名古屋大学医学部附属病院化学療法部)

**EL28 悪性リンパ腫**

Chair : Hiroshi Matsuoka (Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine)  
 司会 : 松岡 広 (神戸大学大学院医学研究科 腫瘍・血液内科)

**Recent Advances in Therapeutics for Malignant Lymphoma**

Yasuhito Terui (Dept. Hematology Oncology, Cancer Institute Hospital of JFCR)  
 照井 康仁 (がん研究会有明病院)

## 17:20-18:10 Mini-Oral Abstract Session 2-1

**MO2-1 Cross-sectional Program1 (Cancer Genomic Testing)  
臓器横断プログラム1 (がんゲノム検査)**

Chair : Hideaki Bando (Department of Clinical Oncology, Aichi Cancer Center)  
 司会 : 坂東 英明 (愛知県がんセンター 薬物療法部)

**MO2-1-1 Clinical utility of comprehensive genome profiling using FoundationOne CDx® in Japanese population (PROFILE-F study)**

Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)

**FoundationOne CDx® 検査を用いたがんゲノム解析の有用性の検討 (PROFILE-F study)**

池田 貞勝 (東京医科歯科大学 腫瘍センター)

**MO2-1-2 リキッドバイオプシー-Guardant360 で疑われた遺伝性腫瘍の検討 (PROFILE Study)**

Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)

池田 貞勝 (東京医科歯科大学 腫瘍センター)

**MO2-1-3 Feasibility and clinical utility of the NGS-based "NCC-Oncopanel" test in a clinical setting**

Kuniko Sunami (Department of Clinical Laboratories, National Cancer Center Hospital)

角南 久仁子 (国立がん研究センター中央病院 臨床検査科)

**MO2-1-4 Association between preanalytical factors and tumor mutational burden estimated by NGS-based multiplex gene panel assay****Encore**

Quy Pham Nguyen (Department of Medical Oncology, Kyoto University)

**次世代シーケンサーを用いたがん遺伝子パネル検査により推定された遺伝子変異量 (TMB) と検体特徴との関連**

ファム グエンクイ (京都大学医学部附属病院 腫瘍内科)

**MO2-1-5 20癌種706検体のミスマッチ修復酵素免疫染色から全固形癌スクリーニングは有用である**

Kenji Amemiya (Genome Analysis Center, Yamanashi Central Hospital)

雨宮 健司 (山梨県立中央病院ゲノム解析センター)

**MO2-1-6 Adoption of multigene panel testing for hereditary cancer "CancerNext" in Tohoku University Hospital**

Keigo Komine (Department of Medical Oncology, Tohoku University Hospital)

**東北大学病院における遺伝性腫瘍患者を対象とした生殖細胞系列遺伝子パネル検査「CancerNext」の導入**

小峰 啓吾 (東北大学病院 腫瘍内科)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 4/F 5/F Annex 1 Annex 2 Room A Room B-1 Room D Room E 6/F 7/F 8/F 9/F 10/F

**国立京都国際会館 2階 Room A**

8:20-9:35 Oral Abstract Session 2-4

**O2-4** Multidisciplinary Team Program  
多職種連携プログラム

Chairs : Yoshiko Kitagawa (National Hospital Organization Kyusyu Cancer Center Department of Nursing)  
Reiko Matsui (National Cancer Center Hospital East)  
Discussant : Teruhisa Azuma (Shirakawa-Satellite for Teaching And Research in general medicine, Fukushima Medical University)  
司会 : 北川 善子 (九州がんセンター 看護部)  
松井 礼子 (国立がん研究センター東病院 薬剤部)  
ディスカッサント : 東 光久 (福島県立医科大学白河総合診療アカデミー)

**O2-4-1** Multidisciplinary team Management System for Adverse Events Occurring in New Cancer Immunotherapies

Miki Kondo (National Cancer Center Hospital East / Nursing Division)  
**新規がん免疫療法における有害事象に対する体制構築**  
近藤 美紀 (国立がん研究センター東病院 看護部)

**O2-4-2** Influence of physical symptoms on distress in patients with colorectal cancer undergoing outpatient chemotherapy

Miwa Aoki (Osaka University Graduate School of Medicine)  
**薬物治療を受ける大腸がん患者の身体症状がストレスに与える影響**  
青木 美和 (大阪大学大学院医学系研究科)

**O2-4-3** The effect of exercise and nutritional intervention during and after chemotherapy for early breast cancer

Mihoko Doi (Department of Clinical Oncology, Hiroshima Prefectural Hospital)  
**周術期乳がん化学療法による体組成、QOLの変化に対する運動療法、栄養管理の有効性についての検討**  
土井 美帆子 (県立広島病院)

**O2-4-4** Improvement quality of life in elderly metastatic colorectal cancer patients receiving ambulatory chemotherapy

Phichai Chansriwong (Medical Oncology Unit, Internal medicine Department, Ramathibodi Hospital, Mahidol University, Thailand)

9:35-11:35 Panel Discussion 2 / パネルディスカッション 2

**PD2** The Safety Management of Chemotherapy - Anticancer Drug Exposure, Prevention and Education  
抗がん剤投与の安全性を改めて考える - 曝露対策から予防教育まで

Chairs : Hirokazu Nakanishi (Doshisha Women's College, Education and Research Center for Pharmacy Practice)  
Nobuhiko Seki (Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine)  
司会 : 中西 弘和 (同志社女子大学 臨床薬学教育研究センター)  
関 順彦 (帝京大学 医学部内科学講座腫瘍内科)

**PD2-1** Summary of Guidelines for Preventing Occupational Exposure in Cancer Chemotherapy Drugs version 2019

Masanobu Takahashi (Department of Clinical Oncology, IDAC, Tohoku University)  
**がん薬物療法における職業性曝露対策ガイドライン 2019年版の概要**  
高橋 雅信 (東北大学加齢医学研究所 臨床腫瘍学分野)

PD2-2	<p><b>Risk management for occupational exposure in cancer chemotherapy drugs</b> Koji Hama (School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University)</p> <p><b>がん薬物療法の曝露対策はリスクマネジメント</b> 濱 宏仁 (武庫川女子大学 薬学部)</p>	Day 1 (Thu)
PD2-3	<p><b>The global standard for the safe handling of Hazardous Drugs</b> Sumiyo Iwamoto (Nippon Becton Dickinson Company, Ltd.)</p> <p><b>抗がん薬曝露対策の世界的な動向</b> 岩本 寿美代 (日本ベクトン・ディッキンソン株式会社)</p>	Day 2 (Fri)
PD2-4	<p><b>Consider training and education for hospital staff and healthcare workers handling of cytotoxic drugs</b> Tomohiro Miyake (Department of Pharmacy, Ise Red Cross Hospital)</p> <p><b>院内の職員および抗がん薬を取り扱う医療従事者への研修と教育を考える</b> 三宅 知宏 (伊勢赤十字病院)</p>	Annex 1
PD2-5	<p><b>Care for patients receiving cancer drug therapy at home</b> Keiko Iino (National College of Nursing, Japan)</p> <p><b>がん薬物療法を受けている患者の在宅でのケア</b> 飯野 京子 (国立看護大学校)</p>	Annex 2
PD2-6	<p><b>Team work on Hazardous drugs exposure handling measures and future prospects</b> Kenjiro Aogi (Division of Clinical Research Promotion, NHO Shikoku Cancer Center)</p> <p><b>チームで取り組むHazardous drugs曝露対策と今後の展望</b> 青儀 健二郎 (四国がんセンター 臨床研究推進部)</p>	Room A
15:10-17:10 Workshop 2 / ワークショップ 2		
WS2	<p><b>Support for Working Cancer Survivors : Healthcare Providers' Role in Hospital Settings</b> がん治療と仕事の両立 : 医療者に求められる具体的な支援のかたち</p> <p>Chairs : Hisakazu Nishimori (Department of Hematology and Oncology, Okayama University Hospital) Miyako Takahashi (Center for Cancer Control and Information Services, National Cancer Center)</p> <p>司会 : 西森 久和 (岡山大学病院 血液・腫瘍内科) 高橋 都 (国立がん研究センター中央病院 がんサバイバーシップ支援研究部)</p>	Room B-1
WS2-1	<p><b>Support for working cancer survivors: toward collaboration among stakeholders in hospitals, workplaces, and communities</b> Miyako Takahashi (Center for Cancer Control and Information Services, National Cancer Center)</p> <p><b>がん治療と仕事の両立～医療機関・職場・地域の連携に向けて</b> 高橋 都 (国立がん研究センター がん対策情報センター)</p>	Room D
WS2-2	<p><b>The practice of supporting the balance between cancer treatment and employment throughout the hospital</b> Toshiyuki Sawa (Cancer Center, Gifu Municipal Hospital)</p> <p><b>病院ぐるみの両立支援の実際</b> 澤 祥幸 (岐阜市民病院 がんセンター)</p>	Room E
WS2-3	<p><b>Support for both medical treatment and work ~Perspective of an occupational health physician ~</b> Hideki Morimoto (Morimoto Occupational Health Physician office)</p> <p><b>がん治療と仕事の両立支援 医療者に求められる具体的な支援のかたち ~産業医の立場から~</b> 森本 英樹 (森本産業医事務所)</p>	Room F

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) Annex 1 Annex 2 Room A Room B-1 Room D Room E Room C-1 Room C-2 Room B-2 Room 104

**WS2-4 Corporate Viewpoint: Effects of support for balancing work and treatment in small and medium-sized companies**

Tomoko Saito (MATSUSHITA INDUSTRY Co.,Ltd. Human Resource Center)

**企業の視点  
—中小企業における両立支援の効果—**

齋藤 朋子 (株式会社松下産業 ヒューマンリソースセンター)

**WS2-5 What cancer patients want from hospitals and medical professionals**

Ruri Maeda (Non profit organization Kyoto Working Survivor)

**働くがん患者が病院や医療者に望むもの**

前田 留里 (NPO法人京都ワーキング・サバイバー)

17:10-18:00 Mini-Oral Abstract Session 2-2

**MO2-2** Gastrointestinal Cancer7  
消化管 7

Chair : Keisho Chin (Division GI Oncology, Cancer Institute Hospital, Tokyo)

司会 : 陳 勁松 (がん研究会有明病院 消化器化学療法科)

**MO2-2-1 The impact of UGT1A1 single-hetero regarding the toxicity of fixed dose irinotecan therapy for advanced gastric cancer**

Shintaro Nakano (Hokkaido university hospital)

中野 真太郎 (北海道大学病院 消化器内科)

**MO2-2-2 Multi-center Phase II trial of 5-FU plus I-LV regimen as salvage line chemotherapy for advanced gastric cancer:HGCSG1502**

Kazuteru Hatanaka (Department of Gastroenterology, Hakodate Municipal Hospital)

畑中 一映 (市立函館病院 消化器内科)

**MO2-2-3 2nd line bevacizumab (BEV) continuation chemotherapy (Cx) beyond early progression for metastatic colorectal cancer (mCRC)**

Masato Komoda (Department of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center)

薦田 正人 (九州がんセンター 消化管・腫瘍内科)

**MO2-2-4 Rectal swab gene expression as a non-invasive biomarker for CRC screening**

Lui Ng (The University of Hong Kong, Hong Kong)

**MO2-2-5 The efficacy and safety of neoadjuvant mFOLFOXIRI and XELOX for locally advanced rectal cancer: A retrospective study**

Hiroyuki Kodama (Department of Cancer Chemotherapy Center, Osaka Medical Collage Hospital)

児玉 紘幸 (大阪医科大学附属病院 化学療法センター)



9:00-9:50 Mini-Oral Abstract Session 2-3

**MO2-3** Breast Cancer2  
乳腺 2

Chair : Ken-ichi Ito (Department of Breast and Endocrine Surgery, Shinshu University School of Medicine)

司会 : 伊藤 研一 (信州大学医学部 乳腺内分泌外科)

**MO2-3-1** Validation of QLQ-BR23 Questionnaire in Measurement of Quality of Life of Breast Cancer Patients : A Pilot Study

Cindy Virliani (Faculty of Medicine, Pelita Harapan University, Indonesia)

**MO2-3-2** Scalp cooling with Cool Cap can palliate or avoid alopecia of adverse event by chemotherapy for breast cancer

Koji Yamashita (Department of Breast Surgery, International University of Health and Welfare)  
山下 浩二 (国際医療福祉大学医学部 乳腺外科)

**MO2-3-3** Analysis of epidemiological characteristics and treatment for male breast cancer patients in Japan

Taisuke Ishii (Division of Health Services Research, National Cancer Center)  
石井 太祐 (国立がん研究センター がん臨床情報部)

**MO2-3-4** Assessment of "hereditary" risk of patients with bilateral breast cancer

Hiroshi Nakagomi (Department of Breast Surgery, Yamanashi Prefectural Central Hospital)  
中込 博 (山梨県立中央病院 乳腺外科)

**MO2-3-5** Awareness Towards Breast and Cervical Cancer Risk factors and its prevention among students and patients in Bangladesh

Md Shariful Islam (Biotechnology and Genetic Engineering Department, Mawlana Bhashani Science and Technology University, Tangail-1902, Bangladesh)

**MO2-3-6** Knowledge and Awareness of Early Detection Methods and Risk Factors towards Breast and Cervical Cancer in Bangladesh

Md Shariful Islam (Biotechnology and Genetic Engineering Department, Mawlana Bhashani Science and Technology University, Tangail-1902, Bangladesh)

9:50-10:40 Mini-Oral Abstract Session 2-4

**MO2-4** Breast Cancer3  
乳腺 3

Chair : Kazuhiro Araki (Gunma Prefectural Cancer Center, Medical Oncology)

司会 : 荒木 和浩 (群馬県立がんセンター腫瘍内科)

**MO2-4-1** Sequential Anthracycline-Taxane Chemotherapy in Node-positive Breast Cancer Amongst Asian Patients - Real-world Outcomes

Nisha Shariff (Clinical Oncology Unit, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia)

**MO2-4-2** Cardiac monitoring among stage 0-III and stage IV breast cancer patients treated with trastuzumab

Taisuke Ishii (Division of Health Services Research, National Cancer Center)  
石井 太祐 (国立がん研究センター がん臨床情報部)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
Room C-1  
Room C-2  
Room B-2  
Room 104

- MO2-4-3 Hematological Toxicity in Low Muscle Mass Breast Cancer Patient Underwent Chemotherapy: A Preliminary Study**  
Felix Wijovi (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- MO2-4-4 Prognostic impact of neoadjuvant chemotherapy due to estrogen receptor expression in HER2-positive breast cancer**  
Hiromi Miyamoto (Department of breast surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital)  
宮本 博美 (がん・感染症センター都立駒込病院 外科 (乳腺))
- MO2-4-5 ROLE OF POST MASTECTOMY RADIOTHERAPY (PMRT) IN T1,T2 LESIONS WITH 1-3 POSITIVE AXILLARY LYMPH NODES**  
MANISH A SADHWANI (Surgical Oncology department, Gujarat cancer and research institute, India)
- MO2-4-6 Comparison of concurrent, sequential, and sandwich chemoradiation modalities in breast cancer therapy: A Meta Analysis**  
Citra Aryanti (Division of Surgical Oncology, Department of Surgery, Indonesia)
- 10:40-11:30 Mini-Oral Abstract Session 2-5
- MO2-5 Head and Neck Cancer1**  
**頭頸部がん 1**  
Chair : Nadarajah Jeyakumaran (Department of Clinical Oncology, National Cancer Institute of Sri Lanka (NCISL), Maharagama, Sri Lanka)
- MO2-5-1 Feasibility of concurrent chemoradiotherapy with cisplatin in elderly patients with head and neck cancer**  
Mayu Yunokawa (Medical Oncology Department, The Cancer Institute Hospital of JFCR)  
温泉川 真由 (がん研究会有明病院 総合腫瘍科)
- MO2-5-2 Is prophylactic percutaneous endoscopic gastrostomy necessary for chemoradiotherapy after total laryngectomy?**  
Hidenori Kimura (Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan)  
木村 英憲 (静岡県立静岡がんセンター 消化器内科)
- MO2-5-3 The importance of percutaneous endoscopic gastrostomy in head and neck cancer patients receiving chemoradiotherapy**  
Xiaofei Wang (Medical Oncology Department, The cancer institute hospital of JFCR)  
王 曉斐 (がん研究会有明病院 総合腫瘍内科)
- MO2-5-4 Carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer unfit for treatment with cisplatin**  
Satoshi Hamauchi (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
濱内 諭 (静岡県立静岡がんセンター 消化器内科)
- MO2-5-5 Successful conversion to chemoradiotherapy after palliative chemotherapy for far advanced head and neck cancer**  
Shiro Kimbara (Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital)  
金原 史朗 (神戸大学医学部附属病院 腫瘍・血液内科)

**MO2-5-6** **Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis**  
Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan)

15:10-16:00 Mini-Oral Abstract Session 2-6

**MO2-6** Head and Neck Cancer2  
頭頸部がん2

Chair : Yoshihiro Okita (Department of Clinical Oncology, Kagawa University Hospital)  
司会 : 大北 仁裕 (香川大学医学部附属病院)

**MO2-6-1** **Prognostic value of the modified Glasgow Prognostic Score for head and neck cancer in the era of immunotherapy**  
Yoshinori Imamura (Medical Oncology/Hematology, Kobe University Hospital)  
今村 善宣 (神戸大学医学部附属病院 腫瘍・血液内科)

**MO2-6-2** **Association of immune-related adverse events and efficacy in patients with head and neck cancer treated with nivolumab**  
Koto Fujiishi (Department of Medical Oncology, Osaka International Cancer Institute)  
藤石 琴 (大阪国際がんセンター 腫瘍内科)

**MO2-6-3** **Matrisomal abnormality: a predictive biomarker for cancer immunotherapy**  
Su Bin Lim (NUS Graduate School for Integrative Sciences and Engineering, National University of Singapore, Singapore / Department of Biomedical Engineering, National University of Singapore)

**MO2-6-4** **Pre-treatment tumor size may have an impact on response by nivolumab in head and neck squamous-cell carcinoma (HNSCC)**  
Hiroto Inoue (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
井上 博登 (静岡県立静岡がんセンター 消化器内科)

**MO2-6-5** **Hyperprogressive disease after Nivolumab treatment in patients with recurrent and/or metastatic head and neck cancer**  
Masahiro Nakayama (Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, University of Tsukuba)  
中山 雅博 (筑波大学附属病院 耳鼻咽喉科・頭頸部外科)

**MO2-6-6** **Anti-EGFR antibody-resistant head and neck squamous cell carcinoma maintained sensitivity to pan-HER inhibitor afatinib**  
Kimio Yonesaka (Department of Medical Oncology, Kindai University Faculty of Medicine)  
米阪 仁雄 (近畿大学医学部腫瘍内科)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

キヌキ-1

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

α&S

α7α7

Dr.Y./Il-1

D-XI-1

F-I/Il-1

Room C-1

Room C-2

Room B-2

Room 104

国立京都国際会館 1階 Room D

9:00-10:20 Special Presidential Session 2 / 会長特別企画 2

**SPS2** Basic Lecture on Cancer Genome Medicine  
がんゲノム医療時代に役立つ、ゲノム診断・橋渡し研究データの解釈のための基礎講義

Chair : Kenji Tsuchihashi (Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital)

司会 : 土橋 賢司 (九州大学病院 血液・腫瘍・心血管内科)

**SPS2-1** Molecular analysis methods used in translational research

Takashi Kohno (National Cancer Center Research Institute)

**TR、創薬研究で用いる遺伝子解析技術や解釈**

河野 隆志 (国立がん研究センター研究所 ゲノム生物)

**SPS2-2** How to Interpret Next-Generation Sequencer Data in Clinical Sequencing

Kuniko Sunami (Department of Laboratory Medicine, National Cancer Center Hospital)

**クリニカルシーケンスにおける次世代シーケンサーデータの読み方**

角南 久仁子 (国立がん研究センター中央病院 臨床検査科)

10:20-11:35 Oral Abstract Session 2-5

**O2-5** Rare Cancer (Soft Tissue Sarcoma)  
希少がん (肉腫)

Chairs : Kan Yonemori (Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan)  
Jean-Yves Blay (Centre Leon Berard)

Discussant : Yuki Kojima (Breast and Medical Oncology, National Cancer Center Hospital)

司会 : 米盛 勲 (国立がん研究センター中央病院 乳腺・腫瘍内科)

Jean-Yves Blay (Centre Leon Berard)

ディスカッサント : 小島 勇貴 (国立がん研究センター 中央病院 乳腺・腫瘍内科)

**O2-5-1** Prognostic factors for post-progression survival after trabectedin treatment in patients with soft tissue sarcoma

**Encore** Shintaro Iwata (Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital)

岩田 慎太郎 (国立がん研究センター中央病院 骨軟部腫瘍・リハビリテーション科)

**O2-5-2** Final results of perioperative chemotherapy for soft tissue sarcomas: Japan Clinical Oncology Group study JCOG0304

**Encore** Kazuhiro Tanaka (Department of Orthopaedic Surgery, Oita University)

田仲 和宏 (大分大学整形外科)

**O2-5-3** Regorafenib as second line therapy for imatinib-resistant gastrointestinal stromal tumor (GIST): A phase II study

Yoichi Naito (National Cancer Center Hospital East)

内藤 陽一 (国立がん研究センター東病院)

**O2-5-4** Prevalence and prognostic impact of comorbidities in sarcomas: A population-based study of 3746 patients in Hong Kong

Herbert HF Loong (The Chinese University of Hong Kong, Hong Kong / Prince of Wales Hospital, Hong Kong)

15:10-17:10 Symposium 10 / シンポジウム 10

**SY10 Sequential Treatment Strategy after the Failure of First-line Tyrosine Kinase Inhibitor for Lung Cancer**  
肺癌における最強のTKI後の治療戦略

Chairs : Nobuyuki Yamamoto (Wakayama Medical University, Internal Medicine III)  
Toshiaki Takahashi (Division of Thoracic Oncology, Shizuoka Cancer Center)  
司会 : 山本 信之 (和歌山県立医科大学 内科学第三講座)  
高橋 利明 (静岡県立静岡がんセンター 呼吸器内科)

**SY10-1 Updated treatment for ALK positive advanced NSCLC**

Solange Peters (Oncology Department CHUV, Lausanne University, Switzerland)

**SY10-2 Novel targeted therapy beyond EGFR and ALK: ROS1, BRAF, RET and MET**

Kiyotaka Yoh (Department of Thoracic Oncology, National Cancer Center Hospital East)

**ROS1、BRAF、RET、MET陽性肺癌の治療戦略**

葉 清隆 (国立がん研究センター東病院 呼吸器内科)

**SY10-3 Future treatment strategy with third generation EGFR-TKIs**

Hirotsugu Kenmotsu (Division of Thoracic Oncology, Shizuoka Cancer Center)

**第3世代EGFR-TKIsを用いた今後の治療**

釵持 広知 (静岡県立静岡がんセンター)

**SY10-4 Still need for 1st/2nd generation EGFR-TKIs for EGFR mutated NSCLC**

Hidetoshi Hayashi (Department of medical oncology, Kindai University)

**第1/第2世代EGFR-TKIは必要か？**

林 秀敏 (近畿大学病院)

**SY10-5 Novel treatment strategies for EGFR mutant lung cancer**

Pasi A. Janne (Lowe Center for Thoracic Oncology; Dana Farber Cancer Institute, United States)

17:10-18:25 Oral Abstract Session 2-6

**O2-6 Cross-sectional Program**  
臓器横断プログラム

Chairs : Toshio Shimizu (Department of Experimental Therapeutics, National Cancer Center Hospital)  
Qiang Liu (Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China)  
Discussant : Tomoyuki Goto (Shiga General Hospital, Department of Cancer Chemotherapy)  
司会 : 清水 俊雄 (国立がん研究センター中央病院 先端医療科)  
Qiang Liu (Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China)  
ディスカッサント : 後藤 知之 (滋賀県立総合病院 化学療法部)

**O2-6-1 Clinical utility of multigene panel testing for diagnosis of hereditary tumor syndromes**

Moriya Iwaizumi (Department of Laboratory Medicine, Hamamatsu University School of Medicine / Molecular & Genetics Center, Hamamatsu University Hospital)

**遺伝性腫瘍診断のための多重遺伝子パネル検査の臨床的有用性**

岩泉 守哉 (浜松医科大学 臨床検査医学 / 浜松医科大学医学部附属病院 遺伝子診療部)

**O2-6-2 NCC オンコパネルを用いたがん遺伝子プロファイリング研究 (TOP-GEAR project第2期) の生殖細胞系列病的バリエーション検出症例の特徴**

Noriko Tanabe (Department of Genetic Medicine and Services, National Cancer Center Hospital)  
田辺 記子 (国立がん研究センター中央病院 遺伝子診療部門)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 会場A-11 Annex 1 Annex 2 Room A Room B-1 Room D Room E 会場5 会場7 会場11/12-1 会場13-1 会場14/15-1 Room C-1 Room C-2 Room B-2 Room 104

**02-6-3 The microbiome in cancer patients treated with programmed death-1 inhibitor**  
Motoo Nomura (Department of Medical Oncology, Kyoto University Graduate School of Medicine)  
**PD-1 抗体治療患者における腸内細菌叢の検討**  
野村 基雄 (京都大学 腫瘍内科)

**02-6-4 The PD-1 expression balance between effector and regulatory T cell predicts the clinical efficacy of PD-1 blockade**  
**Encore**  
Yosuke Togashi (Division of Cancer Immunology, National Cancer Center)  
富樫 庸介 (国立がん研究センター研究所腫瘍免疫研究分野/免疫TR分野)

**MO2-7** Palliative Care/Symptom Management1  
緩和ケア・支持療法 1

Chair : Yusuke Takagi (Department of Palliative Medicine, Teikyo University School of Medicine)  
司会 : 高木 雄亮 (帝京大学医学部 緩和医療学講座)

**MO2-7-1** **Efficacy of information prescription booklet and video material on patient adherence for chemotherapy induced dermatopathy**

Junya Sato (Shizuoka Cancer Center, Department of Pharmacy / Shizuoka Cancer Center, Department of Outpatient Chemotherapy Treatment Unit)

化学療法の皮膚障害対策の患者アドヒアランスに及ぼす情報処方冊子および映像教育の有効性  
佐藤 淳也 (静岡県立静岡がんセンター 薬剤部/静岡県立静岡がんセンター 化学療法センター)

**MO2-7-2** **ALOE VERA: AS A NATURAL MEDICAMENT IN PALLIATIVE CARE PATIENTS**

JITENDRA ACHARYA (government medical college PALLIATIVE CARE DEPARTMENT, India)

**MO2-7-3** **Efficacy of zinc acetate hydrate against dysgeusia induced by gastrointestinal cancer chemotherapy**

Junichirou Nasu (Department of Internal Medicine, Okayama Saiseikai General Hospital)

消化器癌化学療法中の味覚障害に対する酢酸亜鉛水和物の有効性の検討  
那須 淳一郎 (岡山済生会総合病院 内科)

**MO2-7-4** **The use of herbal preparations as complementary and alternative medicine in advanced lung cancer**

Pu Rong (Oncology department, Chengdu Fuxing Hospital, China)

**MO2-7-5** **Quality of medical care in end-of-life lung cancer patients previously received immunotherapy**

Emi Kubo (National Cancer Center Japan)

がん免疫治療を行った肺癌患者の死亡期直前の医療の質  
久保 絵美 (国立がん研究センター中央病院)

**MO2-7-6** **An analysis of 30-day mortality after the last cycle of immune checkpoint inhibitors treatment**

Akane Ryuge (Department of Medical Oncology, Ichinomiya Municipal Hospital)  
龍華 朱音 (一宮市立市民病院)

**MO2-8** Palliative Care/Symptom Management2  
緩和ケア・支持療法 2

Chair : Tomohiro Nishi (Kawasaki Municipal Ida Hospital, Kawasaki Comprehensive Care Center)  
司会 : 西 智弘 (川崎市立井田病院 かわさき総合ケアセンター)

**MO2-8-1** **NK-1 receptor antagonists with carboplatin regimens in Japanese cancer patients: a systematic review and meta-analysis**

Hiroyuki Watanabe (Department of pharmacy, Nara Medical University Hospital)

カルボプラチンレジメンにおけるNK-1 受容体拮抗薬の有用性に関する日本の試験を対象とした systematic review と Meta-analysis

渡邊 裕之 (奈良県立医科大学附属病院 薬剤部)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
X/YY-YY  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
E&S  
EOP  
EY/YY-YY  
E-YY-YY  
E-YY/YY-YY  
Room C-1  
Room C-2  
Room B-2  
Room 104

**MO2-8-2 Cost-utility analysis of aprepitant for patients who truly need it in Japan**  
Akihito Kubo (Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine)

アプレピタントの必要性を考慮した費用対効果分析  
久保 昭仁 (愛知医科大学)

**MO2-8-3 Propensity score matching analysis of palonosetron for nausea due to moderately emetogenic chemotherapies**  
Naohisa Yoshida (Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine)

中等度催吐性レジメンにおけるパロノセトロン of 悪心に対する propensity score matching を用いた比較検討  
吉田 直久 (京都府立医科大学)

**MO2-8-4 A retrospective study of a dexamethasone-sparing in preventing emesis by CapeOX with aprepitant for colorectal cancer**  
Miho Nakatsuka (Department of Pharmacy, Osaka University Medical Hospital)

大腸がん CapeOX 療法におけるデキサメタゾンの投与日数と悪心・嘔吐の制御に関する後方視的研究  
中塚 美穂 (大阪大学医学部附属病院 薬剤部)

**MO2-8-5 A pharmacokinetics study of edoxaban in NSCLC patients harboring an EGFR mutation combined with venous thromboembolism**  
Takamasa Hotta (Department of Internal Medicine, Division of Clinical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine)

堀田 尚誠 (島根大学医学部附属病院 呼吸器臨床腫瘍学)

**MO2-8-6 Thrombocytopenia caused by pegfilgrastim in patients with breast cancer**  
Kokoro Kobayashi (Department of Breast medical Oncology, Cancer Institute Hospital of JFCR)

小林 心 (がん研究会有明病院 乳腺内科)

10:40-11:30 Mini-Oral Abstract Session 2-9

**MO2-9 Palliative Care/Symptom Management3**  
緩和ケア・支持療法 3

Chair : Chieko Kudo (Division of Medical Oncology, Faculty of Medicine Tohoku Medical and Pharmaceutical University Hospital)

司会 : 工藤 千枝子 (東北医科薬科大学病院 腫瘍内科)

**MO2-9-1 The efficacy and safety of denosumab in GI cancer patients receiving periodic steroid premedication (ESPRESSO-02)**

Encore

Michio Nakamura (Department of Gastroenterology, Sapporo City General Hospital)

消化器癌薬物療法のステロイド前投薬による骨密度減少に対するデノスマブの有効性・安全性を検討する前向き介入研究 (ESPRESSO-02)

中村 路夫 (市立札幌病院 消化器内科)

**MO2-9-2 Risk Factors for Skeletal-Related Events in Non-Small-Cell Lung Cancer Patients Treated with Bone-Modifying Agents**

Go Saito (Department of Respirology, Chiba University)

齋藤 合 (千葉大学医学部附属病院 呼吸器内科)



- MO2-9-3** **The bacteria which were detected by blood culture of 2015-2017: Mouth care and bacteremia during anticancer therapy**  
Yumi Jo (Shimane University Hospital, infection control division)  
**2015-2017年度 抗がん薬治療中の血液培養検出菌：口腔ケアと菌血症**  
城 有美 (島根大学医学部附属病院 感染制御部)
- MO2-9-4** **Incidence, risk factors and clinical features of febrile neutropenia in malignant lymphoma patients in our institution**  
Ai Mogi (Division of Medical Oncology, Hematology and Infectious Disease, Department of Internal medicine, Fukuoka University)  
茂木 愛 (福岡大学病院 腫瘍血液感染症内科)
- MO2-9-5** **Late-onset folliculitis during EGFR inhibitor therapy is caused by staphylococcal infection**  
Mikiko Tohyama (National Hospital Organization Shikoku Cancer Center)  
藤山 幹子 (国立病院機構四国がんセンター)
- MO2-9-6** **Prospective study to investigate the clinical efficacy of G-CSF for DTX+CDDP+5-FU chemotherapy in patients with ESCC**  
Mitsuhiro Sugawara (Department of Pharmacy, Kitasato University Hospital)  
**食道扁平上皮癌に対する Docetaxel+Cisplatin+5-Fluorouracil (DCF) 療法における G-CSF の臨床効果に関する前向き調査**  
菅原 充広 (北里大学病院 薬剤部)

15:40-16:30 Mini-Oral Abstract Session 2-10

- MO2-10** Translational Research2  
TR2
- Chair : Takashi Kojima (National Cancer Center Hospital East, Department of Gastroenterology and Gastrointestinal Oncology)  
司会 : 小島 隆嗣 (国立がん研究センター東病院 消化管内科)
- MO2-10-1** **Development of a novel microRNA-based signature for prediction of rectal neuroendocrine tumor invasion and metastasis**  
Jinsei Miyoshi (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)  
**直腸 NET の microRNA 網羅的発現解析を用いた転移機序の解明と新規転移予測バイオマーカーの探索**  
三好 人正 (徳島大学大学院 医歯薬学研究部 消化器内科学分野)
- MO2-10-2** **Aged donor derived CAR-T exhibits enhanced effector functions but shorter persistence and less memory-like phenotypes**  
Hiroshi Kotani (Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute)  
小谷 浩 (Clinical Science Division, H. Lee Moffitt Cancer Center and Research Institute)
- MO2-10-3** **Clinical sequencing with a multiplex gene panel (OncoPrime) in patients with advanced solid cancers**  
Junko Kikuchi (Division of Clinical Cancer Genomics, Hokkaido University Hospital, Sapporo, Japan / First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan)  
**当院における進行固形癌患者に対する遺伝子パネル検査 (OncoPrime) を用いたクリニカルシーケンスの経験**  
菊地 順子 (北海道大学病院がん遺伝子診断部/北海道大学病院内科1)

Day 1 (Thu) Day 2 (Fri) Day 3 (Sat) 4/28-30 Annex 1 Annex 2 Room A Room B-1 Room D Room E 5/5 5/6 5/7-8 5/9-10 5/11-12 Room C-1 Room C-2 Room B-2 Room 104

**MO2-10-4 Novel cancer mouse models based on transplantation of syngeneic tumor initiating cells using organoid culture system**  
 Akiyoshi Kasuga (Keio University / Keio University School of Medicine, Division of Gastroenterology and Hepatology / Keio University School of Medicine, Division of Gene Regulation / Cancer Institute Hospital, Department of Gastroenterology)  
**オルガノイド技術を用いたヒトがん遺伝子を導入したシンジェニックマウスモデルの開発**  
 春日 章良 (慶應義塾大学 医学部/慶應義塾大学 医学部 消化器内科/慶應義塾大学 医学部 遺伝子制御部門/がん研有明病院 消化器内科)

**MO2-10-5 TSGA10 and H2AX competition over binding HIF-1 in breast cancer**  
 Kamran Mansouri (Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Islamic Republic of)

**MO2-10-6 ACTL6A is a novel oncogene and prognostic biomarker for prostate cancer**  
 Chih-Pin Chuu (Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan)

16:30-17:20 Mini-Oral Abstract Session 2-11

**MO2-11** Translational Research3 TR3

Chair : Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)  
 司会 : 久保木 恭利 (国立がん研究センター東病院 消化管内科)

**MO2-11-1 Biomarkers and clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040**  
 Ignacio Melero (Universidad de Navarra, Pamplona, Spain)

**MO2-11-2 Current status and clinical application of MSI testing in daily practice of clinical oncology**  
 Hiromichi Shirasu (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
**日常臨床におけるMSI検査の現状**  
 白数 洋充 (静岡県立静岡がんセンター)

**MO2-11-3 BRCA variant classification is improved by Japanese SNP data and correlate with response to PARP inhibition in MH GUIDE**  
 Yosuke Hirotsu (Genome Analysis Center, Yamanashi Central Hospital, Japan)

**MO2-11-4 Impact of Japanese SNP on clinical cancer panel test**  
 Keita Fukuyama (Department of Hepato-pancreato-biliary Surgery and Transplantation, Graduate School of Medicine, Kyoto University)  
**がん遺伝子パネル検査における日本人SNPの影響**  
 福山 啓太 (京都大学大学院医学研究科 肝胆膵・移植外科)

**MO2-11-5 Mutational analysis of multiple lung cancers: Discrimination between primary and metastatic cancers by genomic profile**  
 Taichiro Goto (Dept. of General Thoracic Surgery, Yamanashi Prefectural Central Hospital)  
 後藤 太郎 (山梨県立中央病院)

MO2-11-6 **Viral DNA-capture-seq is a useful tool to clarify pathogenesis of virus-associated human cancers: HTLV-1 as an example**

Hiroo Katsuya (The International Research Center for Medical Sciences, Kumamoto University / Center for AIDS Research, Kumamoto University)

**ウイルスDNAカプチャーシークエンスはウイルス関連ヒト悪性腫瘍の病原性解明に有用である：HTLV-1を例として**

勝屋 弘雄 (熊本大学 国際先端医学研究機構 / 熊本大学エイズ学研究センター)

17:20-18:10 Mini-Oral Abstract Session 2-12

MO2-12 Translational Research4  
TR4

Chair : Daisuke Sugiyama (Kyushu University Incubation Center for Advanced Medical Science)

司会 : 杉山 大介 (九州大学 先端融合医療創成センター)

MO2-12-1 **No effects of rabeprazole intake on systemic exposures of capecitabine and its three metabolites**

Masae Sekido (Division of Cancer Cell Biology, Department of Pharmaceutical Science, Showa University School of Pharmacy)

**ラベプラゾールの併用はカペシタビンと代謝物の体内動態に影響しない**

関戸 匡恵 (昭和大学薬学部基礎薬学講座腫瘍細胞学部門)

MO2-12-2 **U3-1402, a HER3-targeting ADC, sensitizes tumors with HER3 expression to PD-1 blockade: A preclinical research**

Koji Haratani (Department of Medical Oncology, Kindai University Faculty of Medicine)

原谷 浩司 (近畿大学医学部腫瘍内科)

MO2-12-3 **Antitumor activity/safety of MK-1308 + pembrolizumab (P) in non-small cell lung cancer (NSCLC): updated interim results**

Encore

Kiyotaka Yoh (National Cancer Center Hospital East, Kashiwa, Japan)

MO2-12-4 **Preliminary Phase 1 Results of the PD-1 Inhibitor ABBV-181 in Japanese vs Western Patients With Advanced Solid Tumors**

Yasutoshi Kuboki (Department of Experimental Therapeutics, National Cancer Center Hospital East)

久保木 恭利 (国立がん研究センター東病院 先端医療科)

MO2-12-5 **Temporal annotation changes of similar mutations in a multiplex gene panel test**

Keita Fukuyama (Department of Hepato-pancreato-biliary Surgery and Transplantation, Graduate School of Medicine, Kyoto University)

**がん遺伝子パネル検査における同一変異に対する注釈の経時変化**

福山 啓太 (京都大学大学院医学研究科 肝胆膵・移植外科)

MO2-12-6 **Comparison of variant detection power between small and medium size panel in clinical sequencing for Japanese patients**

Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)

池田 貞勝 (東京医科歯科大学 腫瘍センター)

国立京都国際会館 1階 さくら

8:30-9:30 JSMO Membership Committee Program / 日本臨床腫瘍学会 会員委員会企画

**MC** Promotion of Work Style Reform of Medical Staffs  
医療従事者の働き方を考える

Chairs : Yasuhito Terui (Dpt of Hematology Oncology, Cancer Institute Hospital of JFCR)  
Shigeki Ito (Hematology & Oncology, Iwate Medical University School of Medicine)  
司会 : 照井 康仁 (がん研究会有明病院 血液腫瘍科)  
伊藤 薫樹 (岩手医科大学 血液腫瘍内科)

**MC-1** Influence of long working hours on health and work-related outcomes

Akizumi Tsutsumi (Kitasato University School of Medicine)

長時間労働が健康および就業上の帰結に及ぼす影響

堤 明純 (北里大学医学部)

**MC-2** Work Style Reform for physicians at the Cancer Institute Hospital of JFCR by middle-up-down management

Noriko Nishimura (The Cancer Institute Hospital of Japanese Foundation for Cancer Research)

ミドル・アップダウンによる当院の医師の働き方改革

西村 倫子 (がん研究会有明病院)

**MC-3** Thinking about how to work - How should our division do its job with a limited number of people?

Tomoko Yamazaki (Division of Head and Neck Cancer Oncology, Miyagi Cancer Center)

「働き方を考える」宮城県立がんセンター 頭頸部内科の場合

～少人数で仕事をすすめるにはどうしたらよいか～

山崎 知子 (宮城県立がんセンター 頭頸部内科)

**MC-4** 当院のCRCの働き方

Yumiko Saito (Japanese Foundation for Cancer Research)

齋藤 由美子 (公益財団法人 がん研究会有明病院 臨床試験支援部)

9:30-11:00 Presidential Symposium 4 / 会長企画シンポジウム 4

**PSY4** Promising Treatment of Tomorrow



Chairs : Bruce A. Chabner (Harvard Medical School and the Massachusetts General Hospital, U.S.A.)  
Sasaki Yasutsuna (Director, Musashino Tokusyuikai Hospital Oncology Center)

司会 : Bruce A. Chabner (Harvard Medical School and the Massachusetts General Hospital, U.S.A.)  
佐々木 康綱 (武蔵野徳洲会病院 オンコロジーセンター)

**PSY4-1** Introduction to the Current Status of Treatment Research in Pancreatic and Biliary Tract Cancers

Bruce A. Chabner (Harvard Medical School and the Massachusetts General Hospital, U.S.A.)

**PSY4-2** Next generation CAR T cells for Glioblastoma

Bryan D. Choi (Massachusetts General Hospital, Harvard University, USA)

**PSY4-3** Late Recurrences in ER Positive Breast Cancer: Incorporating New Technologies

Daniel F. Hayes (University of Michigan Rogel Cancer Center, United States)

**PSY4-4** **Expressed Intergenic Fusions are Frequent Drivers of Adverse Outcomes in Hormone Receptor Positive Breast Cancer**  
Leif W. Ellisen (Mass General Hospital Cancer Center/Harvard Med School, United States)

15:40-17:40 Presidential Symposium 5 / 会長企画シンポジウム 5

**PSY5** Utilization of Big Data in Cancer Care  
がん診療におけるビッグデータの活用



Chairs : Hitoshi Nakagama (National Cancer Center)  
Tomomitsu Hotta (NHO Nagoya Medical Center)  
司会 : 中釜 斉 (国立がん研究センター 理事長)  
堀田 知光 (名古屋医療センター 名誉院長)

**Special Comment** **特別発言**  
Ken Carson (Flatiron Health, New York, USA)

**PSY5-1** **Policy and its aim of Act on Anonymously Processed Medical Information to Contribute to Medical Research and Development**  
Shiho Yoshii (Cabinet Secretariat, Government of Japan)  
**「次世代医療基盤法」の取組と今後の展望**  
吉井 史歩 (内閣府日本医療研究開発機構・医療情報基盤担当室)

**PSY5-2** **Medical big data application and personal privacy protection**  
Hiromi Ishikawa (Japan Medical Association)  
**医療のビッグデータの利活用と個人情報保護**  
石川 広己 (日本医師会)

**PSY5-3** **データ駆動型社会におけるメディカルイメージングアナリティクス**  
Masaru Kitsuregawa (National Institute of Informatics /Institute of Industrial Science, the University of Tokyo)  
喜連川 優 (国立情報学研究所 / 東京大学生産技術研究所)

**PSY5-4** **Expansion of cancer registration and its future**  
Tetsu Hayashida (Department of Surgery, Keio University School of Medicine)  
**NCDの果たしてきた役割と今後**  
林田 哲 (慶應義塾大学)

**PSY5-5** **The Current Status of Policy for Genome Medicine in Finland**  
Haruka Nakada (Division of Bioethics and Healthcare Law, Center for Public Health Sciences, National Cancer Center Japan)  
**ゲノム医療時代の医療情報活用にかかる法的基盤の国際動向ーフィンランドを例に**  
中田 はる佳 (国立がん研究センター 社会と健康研究センター生命倫理・医事法研究部)

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

4/27(土)

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

さく5

スポン

D-Fill-A

D-ZU-A

F-Fill-A

Room C-1

Room C-2

Room B-2

Room 104

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
Room C-1  
Room C-2  
Room B-2  
Room 104

17:40-18:10 Educational Lecture 29 / 教育講演 29 : 応用編

**EL29 白血病**

Chair : Shingo Yano (Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine)  
司会 : 矢野 真吾 (東京慈恵会医科大学附属病院 血液・腫瘍内科)

**The latest advancements in precision therapy and immunotherapy for adult leukemia**

Yoshinobu Maeda (Department of Hematology and Oncology, Okayama University Hospital)

**白血病に対するがんゲノム医療および免疫・細胞療法の進歩**

前田 嘉信 (岡山大学病院 血液・腫瘍内科)

国立京都国際会館 1階 スワン

9:00-9:50 Mini-Oral Abstract Session 2-13

**MO2-13** Lung Cancer/Thoracic Cancer2 (NSCLC/Others2)  
呼吸器2 (非小細胞肺がん・その他2)

Chair : Shunichi Sugawara (Sendai Kousei Hospital)  
司会 : 菅原 俊一 (仙台厚生病院)

**MO2-13-1** **Randomized phase II trial of CBDCA+nab-PTX vs CDDP+GEM in patients with chemo-naïve squamous cell lung cancer: NJLGG1302**

Yuka Fujita (Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center)  
藤田 結花 (旭川医療センター)

**MO2-13-2** **A phase II study of carboplatin and nab-paclitaxel in advanced non-small cell lung cancer with interstitial lung disease**

Kenya Kanazawa (Department of Pulmonary Medicine, Fukushima Medical University School of Medicine)  
金沢 賢也 (福島県立医科大学医学部呼吸器内科学講座)

**MO2-13-3** **A Randomized Study of Forced Diuretics to Prevent Cisplatin-induced Nephrotoxicity in NSCLC: OLCSG1406 Trial**

Go Makimoto (Department of Hematology, Oncology, and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan)  
横本 剛 (岡山大学大学院医歯薬学総合研究科 血液・腫瘍・呼吸器内科学)

**MO2-13-4** **A Japanese Lung Cancer Registry Study of Demographics and Treatment Modalities in Medically Treated Patients**

Ikuo Sekine (Department of Medical Oncology, Faculty of Medicine, University of Tsukuba)  
関根 郁夫 (筑波大学 医学医療系 臨床腫瘍学)

**MO2-13-5** **Racial disparities in lung cancer incidence and mortality over the last two decades; a Population-Based Study**

Mahmad wafa Ahmad oussama Khoudeir (Faculty of Medicine, Ain Shams University, Cairo, Egypt)

**MO2-13-6** **Evaluating NSCLC treatment options using real world data: Findings from an oncology survey across eight countries**

Shujiro Takeno (IQVIA Solutions Japan, Japan)

9:50-10:40 Mini-Oral Abstract Session 2-14

**MO2-14** Lung Cancer/Thoracic Cancer3 (Locally Advanced Lung Cancer)  
呼吸器3 (局所進行肺がん)

Chair : Yoshitsugu Horio (Aichi Cancer Center Hospital, Department of Outpatient Services)  
司会 : 堀尾 芳嗣 (愛知県がんセンター 外来部)

**MO2-14-1** **Randomized phase II study of CDDP+S-1 vs CDDP+PEM combined with thoracic RT for locally advanced non-squamous NSCLC**

Atsushi Horiike (Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
堀池 篤 (公益財団法人 がん研究会 有明病院 呼吸器内科)

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
Room C-1  
Room C-2  
Room B-2  
Room 104

MO2-14-2	<b>Phase I/II study of nab-paclitaxel with cisplatin (C) and radiotherapy in pts with unresectable stage III NSCLC (ABCDRT)</b> Hidetoshi Hayashi (Department of medical oncology, Kindai University) 林 秀敏 (近畿大学医学部内科学腫瘍内科)
MO2-14-3 Encore	<b>Comparison between pemetrexed and UFT in addition to cisplatin with involved field radiation for non-Sq NSCLC: NJLCG1001</b> Ryosuke Chiba (Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University) 千葉 亮祐 (岩手医科大学 内科学講座 呼吸器・アレルギー・膠原病内科分野)
MO2-14-4	<b>Pre-PACIFIC era: Real world study of CRT in unresectable stage III NSCLC using consecutive data (SOLUTION study)</b> Hidehito Horinouchi (Department of Thoracic Oncology, National Cancer Center Hospital) 堀之内 秀仁 (国立がん研究センター中央病院呼吸器内科)
MO2-14-5	<b>Long-term results of a randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC (JCOG1011)</b> Ikuo Sekine (Department of Medical Oncology, Faculty of Medicine, University of Tsukuba) 関根 郁夫 (筑波大学 医学医療系 臨床腫瘍学)
MO2-14-6	<b>Were the more examined lymph nodes the better for stage IA NSCLC patients? A Population Study of the US SEER Database</b> Liu Huang (Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China)
10:40-11:30 Mini-Oral Abstract Session 2-15	
MO2-15	Lung Cancer/Thoracic Cancer4 (NSCLC - EGFR-TKIs) 呼吸器 4 (非小細胞肺がん- EGFR-TKI)
Chair :	Solange Peters (Oncology Department CHUV, Lausanne University, Switzerland)
MO2-15-1 Encore	<b>Antitumor activity of TAK-788 in NSCLC With EGFR exon 20 insertions</b> Pasi A. Jänne (Dana-Farber Cancer Institute, Boston, MA, United States)
MO2-15-2 Encore	<b>Updated results of phase 1 study of [fam-] trastuzumab deruxtecan in HER2-expressing or -mutated advanced NSCLC</b> Kazuhiko Nakagawa (Kindai University Faculty of Medicine) 中川 和彦 (近畿大学医学部)
MO2-15-3	<b>TORG1425: A Multicenter Phase II Study of Low-dose Erlotinib in Frail Patients with EGFR Mt+ NSCLC(Final results)</b> Hiromi Aono (Mitsui Memorial Hospital, Department of respiratory medicine) 青野 ひろみ (三井記念病院 呼吸器内科)
MO2-15-4	<b>The different frequencies of histologic transformation after different EGFR-TKIs in EGFR-mutant adenocarcinomas</b> Jin Kang (Division of Pulmonary Oncology, Cancer Center, Guangdong Lung Cancer Institute (GLCI), Guangdong Provincial People's Hospital (GDPH), China)
MO2-15-5	<b>Tepotinib in NSCLC patients with METex14 mutations: interim results from the phase II VISION study</b> Hiroshi Sakai (Saitama Cancer Center, Japan)



MO2-15-6	<b>Safety and efficacy of osimertinib: final report of the Japan-local All-patient Clinical Experience Investigation</b> Terufumi Kato (Department of Thoracic Oncology, Kanagawa Cancer Center) 加藤 晃史 (神奈川県がんセンター 呼吸器内科)	Day 1 (Thu)
15:40-16:30 Mini-Oral Abstract Session 2-16		Day 2 (Fri)
MO2-16	Lung Cancer/Thoracic Cancer5 (NSCLC) 呼吸器 5 (非小細胞肺がん)	Day 3 (Sat)
Chair :	Katsuyuki Kiura (Okayama University Hospital, Dept of Allergy and Respiratory Medicine)	キウキウ
司会 :	木浦 勝行 (岡山大学病院 呼吸器・アレルギー内科)	キウキウ
MO2-16-1	<b>Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site</b> Shinya Uematsu (Division of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation For Cancer Research) 植松 慎矢 (がん研究会有明病院)	Annex 1
MO2-16-2	<b>Irreversible severe cardiotoxicities except for QTc interval prolongation associated with Osimertinib</b> Kei Kunimasa (Department of Thoracic Oncology, Osaka International Cancer Institute) 國政 啓 (大阪国際がんセンター 呼吸器内科)	Annex 2
MO2-16-3	<b>Population PK/PD Analysis of Necitumumab: Dose justification for Squamous Cell Lung Cancer (SqCLC) Patients in Japan</b> Hanaka Mimura (Eli Lilly Japan K.K.) 三村 花華 (日本イーライリリー株式会社)	Room A
MO2-16-4	<b>Exploratory analysis of JFCM: Predictive value of rash, EGFR expression, and EGFR copy for necitumumab in squamous NSCLC</b> Yasushi Goto (Department of Thoracic Oncology, National Cancer Center Hospital) 後藤 悌 (国立がん研究センター中央病院 呼吸器内科)	Room B-1
MO2-16-5	<b>The impact of the tumor shrinkage by initial EGFR-TKI according to the detection of T790M mutation in NSCLC patients</b> Ryosuke Hamashima (Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital) 濱島 良介 (京都第一赤十字病院 呼吸器内科)	Room D
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room E
MO2-16-6	<b>The impact of the tumor shrinkage by initial EGFR-TKI according to the detection of T790M mutation in NSCLC patients</b> Ryosuke Hamashima (Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital) 濱島 良介 (京都第一赤十字病院 呼吸器内科)	Room F
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room G
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room H
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room I
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room J
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room K
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room L
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room M
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room N
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room O
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room P
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room Q
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room R
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room S
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room T
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room U
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room V
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room W
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room X
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room Y
MO2-16-6	<b>Impact of interaction with acid-reducing agents on efficacy of erlotinib in patients with advanced EGFR-mutated NSCLC</b> Chiyo Imamura (Advanced Cancer Translational Research Institute, Showa University / Department of Clinical Pharmacokinetics and Pharmacodynamics, Keio University School of Medicine) 今村 知世 (昭和大学 先端がん治療研究所 / 慶應義塾大学医学部 臨床薬理学)	Room Z

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
Room C-1  
Room C-2  
Room B-2  
Room 104

16:30-17:20 Mini-Oral Abstract Session 2-17

**MO2-17** Lung Cancer/Thoracic Cancer6 (NSCLC - Immune Checkpoint Inhibitors1)  
呼吸器 6 (非小細胞肺がん-免疫チェックポイント阻害薬 1)

Chair : Motohiro Tamiya (Department of Thoracic Oncology, Osaka International Cancer Institute)  
司会 : 田宮 基裕 (大阪国際がんセンター 呼吸器内科)

**MO2-17-1 Association of radiographic features of pneumonitis with prognosis in NSCLC patients treated with anti-PD-1 therapy**

Satoshi Watanabe (Niigata University Graduate School of Medical and Dental Sciences)  
渡部 聡 (新潟大学 呼吸器・感染症内科)

**MO2-17-2 Radiotherapy is an independent prognostic marker of favorable prognosis after treatment of NSCLC patients with nivolumab**

Ou Yamaguchi (Department of Respiratory Medicine, Saitama Medical University International Medical Center)  
山口 央 (埼玉医科大学国際医療センター)

**MO2-17-3 Long-term survival with nivolumab in pts with previously treated advanced NSCLC: Impact of disease control and response**

Encore

David P. Carbone (James Cancer Center, The Ohio State University Medical Center, United States)

**MO2-17-4 Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia:A phase II trial**

Makiko Yomota (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital)  
四方田 真紀子 (がん・感染症センター東京都立駒込病院 呼吸器内科)

**MO2-17-5 Efficacy of ICIs for advanced lung cancer with pulmonary emphysema on the CT findings**

Natsumi Tanaka (Tottori Red Cross Hospital)  
田中 那津美 (鳥取赤十字病院)

**MO2-17-6 Association of immune-related pneumonitis with the preexisting ILD in patients with NSCLC receiving anti-PD-1 antibody**

Ryota Shibaki (Department of Experimental Therapeutics, National Cancer Center Hospital / Department of Thoracic oncology, National Cancer Center Hospital)  
柴木 亮太 (国立がん研究センター中央病院 先端医療科 / 国立がん研究センター中央病院 呼吸器内科)

17:20-18:10 Mini-Oral Abstract Session 2-18

**MO2-18** Lung Cancer/Thoracic Cancer7 (NSCLC - Immune Checkpoint Inhibitors2)  
呼吸器 7 (非小細胞肺がん-免疫チェックポイント阻害薬 2)

Chair : Kaname Nosaki (Department of Thoracic Oncology, National Cancer Center Hospital East)  
司会 : 野崎 要 (国立がん研究センター東病院 呼吸器内科)

**MO2-18-1 PD-1 Inhibitors Followed by Subsequent Chemotherapy versus Chemotherapy Alone in Patients with NSCLC (WJOG10217L)**

Encore

Ryoji Kato (Department of Medical Oncology, Kindai University Faculty of Medicine)  
加藤 了資 (近畿大学医学部内科学腫瘍内科部門)

- MO2-18-2** **Previous immuncheckpoint inhibitor might increase the efficacy of docetaxel and ramucirumab combination chemotherapy**  
 Daijiro Harada (Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center)  
 原田 大二郎 (国立病院機構 四国がんセンター 呼吸器内科)
- MO2-18-3** **演題取下**
- MO2-18-4** **Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients with non-small cell lung cancer**  
 Satoshi Wasamoto (Division of Respiratory Medicine, Saku Central Hospital Advanced Care Center)  
 和佐本 諭 (佐久総合病院 佐久医療センター 呼吸器内科)
- MO2-18-5** **Real-World Effectiveness and Safety of Nivolumab in Special Subgroups of NSCLC pts: A Multicenter-Retrospective Study**  
 Satoru Kitazono (Department of Thoracic Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research / Nivolumab Japan Real World Study Group)  
 北園 聡 (がん研究会有明病院 / Nivolumab Japan Real World Study Group)
- MO2-18-6** **Real-World Effectiveness and Safety of Nivolumab in NSCLC pts in Japan: A Multicenter-Retrospective Observational Study**  
 Haruhiro Saito (Kanagawa Cancer Center / Nivolumab Japan Real World Study Group)  
 斉藤 春洋 (神奈川県立がんセンター / Nivolumab Japan Real World Study Group)

## グランドプリンスホテル京都 1階 ロイヤルルーム

9:00-10:00 JSMO Committee on Public Information and Negotiation Program / 日本臨床腫瘍学会 広報渉外委員会企画

**PIN** Tobacco Control Session  
禁煙推進セッション

Chair : Minoru Fukuda (Clinical Oncology Center, Nagasaki University Hospital / JSMO Public relations committee)

司会 : 福田 実 (長崎大学病院 がん診療センター、JSMO広報渉外委員)

### **PIN-1 JSMO Tobacco Control Action**

Minoru Fukuda (Clinical Oncology Center, Nagasaki University Hospital / JSMO Public relations committee)

#### 禁煙に対するJSMOの取り組み

福田 実 (長崎大学病院 がん診療センター、JSMO広報渉外委員会)

### **PIN-2 世界の喫煙・禁煙事情**

Mami Iida (Gifu Prefectural General Medical Center)

飯田 真美 (地方独立行政法人岐阜県総合医療センター)

### **PIN-3 Partial Revision of the Health Promotion Act**

Tomoyasu Hirano (Ministry of Health, Labour and Welfare)

#### 健康増進法の一部を改正する法律の概要について

平野 公康 (厚生労働省 健康局健康課 たばこ対策専門官)

10:00-11:30 Presidential Symposium 6 / 会長企画シンポジウム 6

### **PSY6 Accelerating Drug Development and Approval Utilizing a Platform Trial in Japan**

Chairs : Emi Noguchi (Department of Breast and Medical Oncology, National Cancer Center Hospital)  
Nozomu Fuse (Regulatory Affairs Management Section, Clinical Research Support Office/  
Gastroenterology, National Cancer Center Hospital East)

司会 : 野口 瑛美 (国立がん研究センター中央病院 乳腺・腫瘍内科)

布施 望 (国立がん研究センター東病院 臨床研究支援部門薬事管理室/消化管内科)

### **PSY6-1 Platform trial in National Cancer Center Hospital**

Kenichi Nakamura (National Cancer Center Hospital)

#### 国立がん研究センターにおけるプラットフォーム試験

中村 健一 (国立がん研究センター中央病院)

### **PSY6-2 Expectations for the academia platform trial**

Ryosuke Urano (Solid Tumor clinical Development, Japan Development, Novartis Pharma K.K.)

#### アカデミアプラットフォーム試験に期待すること

浦野 良祐 (ノバルティス ファーマ株式会社 開発本部 固形腫瘍臨床開発)

### **PSY6-3 Regulatory perspective for platform trials in oncology**

Junichi Asano (Office of New Drug IV/ Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency)

#### 悪性腫瘍領域のプラットフォーム試験におけるレギュラトリーからの視点

浅野 淳一 (医薬品医療機器総合機構 新薬審査第四部/再生医療製品等審査部)

**SY11** The Appropriate Selection of Anti-cancer Drugs According to Cost Effectiveness  
 費用対効果考えた今後の適正な薬剤使用

Chairs : Hiroki Iwata (Aichi Cancer Center, Breast Oncology)  
 Tadahiko Shien (Dept. of Breast and Endocrine Surgery, Okayama University Hospital)

司会 : 岩田 広治 (愛知県がんセンター 乳腺科)  
 枝園 忠彦 (岡山大学病院 乳腺・内分泌外科)

**SY11-1** **The NICE reimbursement process for pharmaceuticals in the UK. Are cancer drugs a special case?**  
 Nick Freemantle (Institute of Clinical Trials and Methodology, University College London, United Kingdom)

**SY11-2** **Estimation of Willingness-to-Pay for breast cancer treatments through Contingent Valuation Method in Japan (JCOG1709A)**  
 Tsuguo Iwatani (Department of Breast Surgery, National Cancer Center Hospital East)  
 岩谷 胤生 (国立がん研究センター東病院 乳腺外科)

**SY11-3** **Health technology assessment & cost-effectiveness evaluation: Current status in policy making from academic perspective**  
 Takeru Shiroiwa (Center for Outcomes Research and Economic Evaluation for Health, National Institute of Public Health)  
**医療技術評価、医療経済評価の政策応用の現状: アカデミアの立場から**  
 白岩 健 (国立保健医療科学院 保健医療経済評価研究センター)

**SY11-4** **Overview of Introduction of Cost-Effectiveness Evaluations in Japan**  
 Yasushi Sakuramoto (Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare)  
**日本における費用対効果評価の取り組み –費用対効果評価制度の概要–**  
 櫻本 恭司 (厚生労働省保険局医療課)

**SY11-5** **Current status, issue and future perspectives for biosimilars in Japan from the viewpoint of cost-effectiveness**  
 Yoshihiro Nanbu (The Japan Biosimilar Association, Nippon Kayaku CO. LTD.)  
**費用対効果からみた本邦におけるバイオシミラーの現状、課題と展望**  
 南部 静洋 (バイオシミラー協議会・日本化薬株式会社)

## グランドプリンスホテル京都 地下1階 ローズルーム

8:20-10:20 Joint Symposium 4 (JCA/JSCO/JSMO) / 合同シンポジウム 4 (日本癌学会/日本癌治療学会/日本臨床腫瘍学会)

### JS4 Clinical Implementation in Cancer Genome Medicine

がんゲノム医療の臨床実装

Chairs : Yasushi Yatabe (Dept.of Diagnostic Pathology, National Cancer Center Hospital)  
Natsuko Okita (Regulatory Affairs Management Section, Research Management Division, Clinical Research Support Office, National Cancer Center Hospital)

司会 : 谷田部 恭 (国立がん研究センター中央病院 病理診断科)  
沖田 南都子 (国立がん研究センター中央病院臨床研究支援部門研究企画推進部事業管理室)

#### JS4-1 Crucial role of molecular pathologist for cancer precision medicine

Hiroshi Nishihara (Genomics Unit, Keio Cancer Center, Keio University School of Medicine)

がんゲノム医療において病理専門医の果たすべき役割

西原 広史 (慶應義塾大学)

#### JS4-2 Selection of cancer gene panel testing

Kazuto Nishio (Kindai University Faculty of Medicine)

がん遺伝子パネル検査の選択

西尾 和人 (近畿大学医学部)

#### JS4-3 Cancer Genomic Medicine in Japan

Natsuko Okita (Clinical Research Support Office, National Cancer Center Hospital)

がんゲノム医療中核拠点病院・連携病院・C-CATの役割

沖田 南都子 (国立がん研究センター中央病院)

#### JS4-4 Issues on clinical implemtation of genome medicine based on the experiences in SCRUM-Japan

Encore

Atsushi Ohtsu (National Cancer Center Hospital East)

SCRUM-Japanからみたがんゲノム医療実装上の課題

大津 敦 (国立がん研究センター東病院)

#### JS4-5 Treatment options in cancer precision medicine

Hideyuki Hayashi (Genomics Unit, Keio Cancer Center, Keio University School of Meicine)

がんプレジジョンメディシンにおける治療選択

林 秀幸 (慶應義塾大学医学部 腫瘍センター ゲノム医療ユニット)

#### JS4-6 Genetic counseling system in cancer genome medicine

Takahiro Yamada (Clinical Genetics Unit, Kyoto University Hospital)

がんゲノム医療における遺伝カウンセリング体制

山田 崇弘 (京都大学医学部附属病院遺伝子診療部)

10:30-11:30 Symposium 12 / シンポジウム 12

### SY12 New Strategy of Peri-operative Therapy for Resectable Gastric Cancer

胃癌周術期治療の新たな展開

Chairs : Salah-Eddin Al-Batran (Institute of Clinical Cancer Research, Krankenhaus Nodwest)  
Takako Nakashima (St. Marianna University School of Medicine)

司会 : Salah-Eddin Al-Batran (Institute of Clinical Cancer Research, Krankenhaus Nodwest)  
中島 貴子 (聖マリアンナ医科大学 臨床腫瘍学講座)

#### SY12-1 New strategy of peri-operative therapy for resectable gastric cancer

Salah-Eddin Al-Batran (Medical Oncologist, Germany)

<b>SY12-2</b> Encore	<b>Addition of docetaxel to S-1 improves efficacy in patients with stage III gastric cancer (JACCRO GC-07)</b>	Day 1 (Thu)
	Wataru Ichikawa (Medical Oncology, Showa University Fujigaoka Hospital) 市川 度 (昭和大学藤が丘病院 腫瘍内科・緩和医療科)	Day 2 (Fri)
<b>SY12-3</b>	<b>Clinical trials of neoadjuvant DOS for gastric cancer</b> Yukinori Kurokawa (Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan) <b>胃癌に対する術前DOS療法の臨床試験</b> 黒川 幸典 (大阪大学 消化器外科)	Day 3 (Sat) X-1/Fri-Sat
<b>SY12-4</b> Encore	<b>Perioperative intraperitoneal chemotherapy for curatively resectable gastric cancer with serosal invasion:phase II study</b> Shugo Ueda (Department of Gastroenterological Surgery and Oncology, Kitano Hospital, Tazuke Kofukai Medical Research Institute) <b>根治切除可能な漿膜浸潤陽性胃癌に対する腹腔内投与併用の周術期化学療法を検証する第II相試験 (GAPS study)</b> 上田 修吾 (田附興風会医学研究所 北野病院 消化器外科)	Annex 1 Annex 2 Room A
15:00-16:30 Mini Symposium 3 / ミニシンポジウム 3		
<b>MS3</b>	<b>Revisiting the PARP Inhibitors in New Era for Ovarian Cancer</b> 卵巢癌における PARP 阻害剤の使用について再考する Chairs : Noriomi Matsumura (Department of Obstetrics and Gynecology, Kindai University) Koji Matsumoto (Medical Oncology Division, Hyogo Cancer Center) 司会 : 松村 謙臣 (近畿大学医学部 産科婦人科学教室) 松本 光史 (兵庫県立がんセンター)	Room B-1 Room D Room E
<b>MS3-1</b>	<b>Revisiting the PARP inhibitors in new era</b> Eric Pujade-Lauraine (ARCAGY-GINECO Medical Director, France)	E&S
<b>MS3-2</b>	<b>Homologous recombination deficiency in Japanese ovarian cancer patients</b> Kosuke Yoshihara (Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences) <b>本邦における卵巢癌の相同組換え修復異常</b> 吉原 弘祐 (新潟大学大学院医歯学総合研究科 産婦人科)	E7/Fri E7/Fri-Sat
<b>MS3-3</b>	<b>Treatment strategy for patients with platinum-sensitive ovarian cancer using PARP inhibitors</b> Koji Matsumoto (Medical Oncology Division, Hyogo Cancer Center) <b>プラチナ感受性卵巢がんにおける PARP 阻害薬の治療戦略</b> 松本 光史 (兵庫県立がんセンター)	E-XI-Sat E-XI/Sat-Sun
<b>MS3-4</b>	<b>Poly ADP ribose polymerase (PARP) for the treatment of BRCA-mutated advanced ovarian cancer</b> Mayu Yunokawa (Gynecology Oncology and Medical Oncology Department, The Cancer Institute Hospital of JFCR) <b>初回卵巢がん治療における poly ADP ribose polymerase (PARP) 阻害剤の位置づけ</b> 温泉川 真由 (がん研究会有明病院 婦人科 兼 総合腫瘍科)	Room C-1 Room C-2 Room B-2 Room 104

**MS3-5 Latest development of PARP inhibitors in ovarian cancer**  
 Kenichi Harano (Department of Developmental Therapeutics/Breast Medical Oncology, National Cancer Center Hospital East)  
**卵巣癌における PARP 阻害剤の最新治験について**  
 原野 謙一 (国立がん研究センター東病院 先端医療科/乳腺腫瘍内科)

16:30-17:35 Symposium 13 / シンポジウム 13

**SY13 Molecular Abnormalities and Clinical Development of New Drugs for Thyroid Cancer**  
 甲状腺がんの分子遺伝子異常と新規治療開発  
 Chairs : Naomi Kiyota (Kobe University Hospital Cancer Center)  
 Junichi Tomomatsu (Japanese Foundation for Cancer Research)  
 司会 : 清田 尚臣 (神戸大学医学部附属病院 腫瘍センター)  
 友松 純一 (がん研究会有明病院 総合腫瘍科)

**SY13-1 Novel treatment for thyroid cancer, targeting genetic alterations**  
 Ezra Cohen (Cohen Consulting, USA)

**SY13-2 Immunotherapy with molecular targeted drug for thyroid cancer**  
 Yoshitaka Homma (National Cancer Center Hospital)  
**甲状腺がんに対する免疫チェックポイント阻害薬と分子標的薬の併用療法**  
 本間 義崇 (国立がん研究センター中央病院)

**SY13-3 Ongoing clinical trials of molecular targeted agents for thyroid cancer in precision medicine**  
 Susumu Okano (National Cancer Center Hospital East)  
 岡野 晋 (国立がん研究センター東病院)



## グランドプリンスホテル京都 地下2階 ゴールドルーム

9:00-11:00 Asia Oceania/JSMO Joint Symposium / Asia Oceania/JSMO 合同シンポジウム

### AOJS Joint Symposium of Asian Medical Oncology Societies ~ To Further Develop Relationship for Asian Patients ~



Chairs : Hironobu Minami (Medical Oncology / Hematology, Department of Medicine Kobe University Hospital & Kobe University Graduate School of Medicine)  
Kazuo Tamura (General Medical Research Center, Fukuoka University)  
司会 : 南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科)  
田村 和夫 (福岡大学医学部 総合医学研究センター)

#### AOJS-1 Introduction of Korean Society of Medical Oncology (KSMO) : Friendship between Korean and Japanese Oncology Community

Joung-Soon Jang (Korean Society of Medical Oncology (KSMO) / Chung-Ang University College of Medicine, Chung-Ang University Hospital, Korea)

#### AOJS-2 An overview of innovative cancer drug clinical development in China

Junli Xue (Oncology Department, Shanghai East Hospital, Tongji University, China)

#### AOJS-3 Social Responsibilities of Oncology Medical Association in Taiwan

Li-Tzong Chen (President of Taiwan Oncology Society (TOS) / National Institute of Cancer Research National Health Research Institutes, Taiwan)

#### AOJS-4 Challenges of Cancer Care in Singapore

Su Pin Choo (Singapore Society of Oncology, Singapore)

#### AOJS-5 JSMO Activity in Medical Oncology in Asia

Hironobu Minami (Medical Oncology/Hematology, Internal Medicine, Kobe University School of Medicine / Japanese Society of Medical Oncology)  
南 博信 (神戸大学大学院医学研究科 腫瘍・血液内科 / 日本臨床腫瘍学会)

15:30-17:10 Presidential Symposium 7 / 会長企画シンポジウム 7

### PSY7 Genome Based Clinical Trials: What is Next Generation Clinical Trials?



Chairs : Daniel Hayes (University of Michigan Comprehensive Cancer Center, U.S.A.)  
Takashi Shimamoto (Oncology Science Unit, MSD K.K.)  
司会 : Daniel Hayes (University of Michigan Comprehensive Cancer Center, U.S.A.)  
嶋本 隆司 (MSD株式会社 オンコロジーサイエンスユニット)

#### PSY7-1 Genome Based Clinical Trials in the United States: What Are The Challenges?

Naoko Takebe (National Institutes of Health USA, United States)

#### PSY7-2 Challenges of genome-based clinical trials in France and Europe

Sophie Postel-Vinay (DITEP, Drug Development Department; U981 INSERM ATIP-Avenir; Gustave Roussy Cancer Campus, France)

#### PSY7-3 Single pivotal basket trials for rare cancer drug development in Japan

Akihiro Hirakawa (Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo)  
平川 晃弘 (東京大学大学院 医学系研究科 生物統計情報学)

Co-host: IQVIA Services Japan K.K. / IQVIA サービスーズ ジャパン株式会社

Day 1 (Thu) 国立京都国際会館 2階 Room B-2

8:40-9:30 Distinguished Expert Lecture 7

DL7 Current and Future Directions for the Treatment of Advanced Thyroid Cancer

Chair : Shunichiro Iwasawa (Department of Respiriology, Chiba University)  
司会 : 岩澤 俊一郎 (千葉大学医学部附属病院 呼吸器内科)

**Current and Future Directions for the Treatment of Advanced Thyroid Cancer**  
Naiyarat Prasongsook (Phramongkutklao Hospital, Thailand)

9:40-10:30 Distinguished Expert Lecture 8

DL8 Current approach to the treatment for the elderly myeloma patients

Chair : Kensuke Ohta (Hematology Ohta Clinic, Shinsuibashi)  
司会 : 太田 健介 (血液内科太田クリニック・心斎橋)

**Current approach to the treatment for the elderly myeloma patients**

Thierry R. Facon (Hematology Service des Maladies du Sang, University of Lille, Lille, France)

10:40-11:30 Distinguished Expert Lecture 9

DL9 Speeding Drug Development Through Neoadjuvant Therapy

Chair : Tetsuhiro Yoshinami (Department of Breast and Endocrine Surgery Graduate School of Medicine, Osaka University)  
司会 : 吉波 哲大 (大阪大学大学院医学系研究科 乳腺・内分泌外科)

**Speeding Drug Development Through Neoadjuvant Therapy**

Hope S. Rugo (UCSF Helen Diller Family Comprehensive Cancer Center, USA)

15:00-15:50 Distinguished Expert Lecture 10

DL10 A Patient-centric Approach to Pancreatic Cancer Research: the Pancreatic Cancer Action Network Experience

Chair : Izumi Ohno (Department of Gastroenterology, Chiba University, Graduate School of Medicine)  
司会 : 大野 泉 (千葉大学 消化器内科)

**A Patient-centric Approach to Pancreatic Cancer Research: the Pancreatic Cancer Action Network Experience**

Lynn M. Matrisian (Pancreatic Cancer Action Network, United States)

---

16:20-17:10 Distinguished Expert Lecture 11

---

**DL11** CLINICAL PROFILE AND TREATMENT OUTCOMES OF LYMPHOMA PATIENTS: A REAL WORLD EXPERIENCE

Chair : Hidetsugu Kawai (Department of Hemaology / Oncology, Tokai University School of Medicine)  
司会 : 川井 英嗣 (東海大学医学部 血液・腫瘍内科)

---

**CLINICAL PROFILE AND TREATMENT OUTCOMES OF LYMPHOMA PATIENTS: A REAL WORLD EXPERIENCE**

Priscilla B. Caguioa (University of Santo Tomas Hospital, St. Lukes Medical Center Quezon City, Philippines)

---

---

17:20-18:10 Distinguished Expert Lecture 12

---

**DL12** Reference centers and precision medicine trials in sarcoma

Chair : Taizo Hirata (Department of Medical Oncology, Kure Medical Center and Chugoku Cancer Center)  
司会 : 平田 泰三 (呉医療センター・中国がんセンター 腫瘍内科)

---

**Reference centers and precision medicine trials in sarcoma**

Jean Yves Blay (Centre Leon Berard, France)

---

Day 1 (Thu)  
Day 2 (Fri)  
Day 3 (Sat)  
X  
Y  
Annex 1  
Annex 2  
Room A  
Room B-1  
Room D  
Room E  
E<S  
S<O  
O<Y  
Y<I  
I<X  
X<I  
I<S  
S<I  
Room C-1  
Room C-2  
Room B-2  
Room 104

Day 1 (Thu) **国立京都国際会館 1F Room 104**

8:20-9:20 Meet the Experts 7

**ME7 Evolving Management Paradigm of Advanced NSCLC**

Moderators: Katsuyuki Hotta (Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama Japan)  
Eiki Ichihara (Department of Allergy and Respiratory Medicine, Okayama University Hospital)  
モデレーター: 堀田 勝幸 (岡山大学病院 新医療研究開発センター)  
市原 英基 (岡山大学病院 呼吸器・アレルギー内科)

**Evolving Management Paradigm of Advanced NSCLC**

Keunchil Park (Samsung Med Ctr, Sungkyunkwan Univ School of Med, Korea)

9:20-10:20 Meet the Experts 8

**ME8 Novel Targeted Therapies in Gastric Cancer, Moving Beyond PD1**

Moderators: Takako Nakashima (St. Marianna University School of Medicine)  
Toshiki Masuishi (Department of Clinical Oncology, Aichi Cancer Center Hospital)  
モデレーター: 中島 貴子 (聖マリアンナ医科大学 臨床腫瘍学講座)  
舩石 俊樹 (愛知県がんセンター 薬物療法部)

**Novel Targeted Therapies in Gastric Cancer, Moving Beyond PD1**

Zev A. Wainberg (UCLA School of Medicine, U.S.A.)

10:20-11:20 Meet the Experts 9

**ME9 How to Implement Personalized Medicine**

Moderators: Chikako Shimizu (Department of Breast Medical Oncology, National Center for Global Health and Medicine)  
Chiaki Inagaki (Department of Frontier Science for Cancer and Chemotherapy)  
モデレーター: 清水 千佳子 (国立国際医療研究センター病院 乳腺センター 乳腺腫瘍内科)  
稲垣 千晶 (大阪大学大学院医学系研究科 先進薬物療法開発学寄附講座)

**How to Implement Personalized Medicine**

Sibylle Loibl (GBG, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany)

15:00-16:00 Meet the Experts 10

**ME10 Immuno-precision Medicine in Gastric Cancer; How to Select The Proper Patients?**

Moderators: Daisuke Takahari (Department of Gastrointestinal chemotherapy Cancer Institute Hospital of Japanese Foundation For Cancer Research)  
Hiroki Hara (Department of Gastroenterology, Saitama Cancer Center)  
モデレーター: 高張 大亮 (がん研究会 有明病院 消化器内科)  
原 浩樹 (埼玉県立がんセンター 消化器内科)

**Immuno-precision Medicine in Gastric Cancer; How to Select The Proper Patients?**

Sun Young Rha (Yonsei Cancer Center, Yonsei University College of Medicine, Korea)

---

16:20-17:20 Meet the Experts 11

---

**ME11** Understanding Response and Resistance Mechanisms to I-O therapy

Moderators: Junji Suzumiya (Shimane University Hospital Innovative Cancer Center/Hematology-Oncology)  
Mamiko Sakata-yanagimoto (Department of Hematology, Faculty of Medicine, University of Tsukuba)

モデレーター: 鈴宮 淳司 (鳥根大学医学部附属病院 先端がん治療センター /腫瘍・血液内科)  
坂田 (柳元) 麻実子 (筑波大学 医学医療系血液内科)

---

**Understanding Response and Resistance Mechanisms to I-O therapy**

Thomas Gajewski (The University of Chicago, U.S.A.)

---

---

17:20-18:20 Meet the Experts 12

---

**ME12** Liquid Biopsy for NSCLC: From Research to Practice

Moderators: Takayasu Kurata (Department of Thoracic Oncology, Kansai Medical University Hospital)  
Hiroyasu Kaneda (Department of Clinical Oncology, Osaka City University of Graduate School of Medicine)

モデレーター: 倉田 宝保 (関西医科大学附属病院 呼吸器腫瘍内科)  
金田 裕靖 (大阪市立大学大学院医学研究科 臨床腫瘍学)

---

**Liquid Biopsy for NSCLC: From Research to Practice**

Yi-Long Wu (Guangdong Lung Cancer Insitute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, China)

---

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

キックオフ

Annex 1

Annex 2

Room A

Room B-1

Room D

Room E

セミナー

ランチ

Day 1 (Thu)

Day 2 (Fri)

Day 3 (Sat)

Room C-1

Room C-2

Room B-2

Room 104

## 国立京都国際会館 ニューホール

12:40-13:35 Poster Session 2-1 / ポスターセッション 2-1

**P2-1** Gastrointestinal Cancer4 (Gastric Cancer - Chemotherapy)  
消化管 4 (胃-化学療法)Chair : Masaru Fukahori (Kurume University Hospital Multidisciplinary Cancer Treatment Center)  
司会 : 深堀 理 (久留米大学病院 がん集学治療センター)**P2-001** Evaluation of clinical trial eligibility for chemotherapy in real-world patients with gastrointestinal cancerTakahiro Aida (Keio University School of Medicine)  
會田 卓弘 (慶應義塾大学医学部)**P2-002** Safety and efficacy of chemotherapy for gastric cancer in elderly patientsTetsuya Katayama (Department of Internal medicine, Hiroshima City Hiroshima Citizens Hospital)  
**高齢者における胃癌化学療法の安全性、有効性の検討**  
片山 哲也 (広島市立広島市民病院 内科)**P2-003** A multivariate analysis of factors predicting feasibility to proceed with chemotherapy in gastric cancerTatsuma Morikita (Division of Medical Oncology, Saiseikai Kumamoto Hospital)  
**胃癌化学療法における治療継続のリスク因子の検討**  
森北 辰馬 (済生会熊本病院 腫瘍内科)**P2-004** Successful cases of patients with advanced gastric cancer treated with chemotherapy, retrospective analysisAyano Nakazono (Gastroenterology department, Tokyo metropolitan Tama Medical Center)  
**当院における進行胃癌に対する化学療法の奏功症例の後方視的検討**  
中園 綾乃 (東京都立多摩総合医療センター 消化器内科)**P2-005** An analysis of the use in our department of modified-DCF therapy for advanced gastric cancerKazunori Otsuka (Miyagi cancer center)  
**当科での進行胃癌に対する modified-DCF 療法についての解析**  
大塚 和令 (宮城県立がんセンター)**P2-006** Use of Ramucirumab in patients with unresectable advanced or recurrent gastric cancerIchiko Yamakita (Department of Surgery, Hiroshima City Asa Citizens Hospital)  
**切除不能進行・再発胃癌におけるラムシルマブの使用**  
山北 伊知子 (広島市立安佐市民病院 外科)**P2-007** 切除不能進行・再発胃癌二次治療における Taxane ± ラムシルマブ (RAM) 療法の検討Akio Nakasya (Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center)  
中舎 晃男 (国立病院機構四国がんセンター 消化器内科)

12:40-13:35 Poster Session 2-2 / ポスターセッション 2-2

**P2-2** Gastrointestinal Cancer5 (Gastric Cancer/Others)  
消化管 5 (胃・その他)

Chair : Shuji Arita (Dep. of Internal Medicine/Chemotherapy (Oncology), Miyazaki-Prefectural Miyazaki Hospital)  
司会 : 在田 修二 (宮崎県立宮崎病院 内科・化学療法科 (腫瘍内科))

**P2-008** 演題取下

**P2-009** Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy by taxane

Ryo Otsuka (Department of Pharmacy, Nation cancer center hospital)  
大塚 亮 (国立がん研究センター中央病院 薬剤部)

**P2-010** usefulness of neutrophil lymphocyte ratio as a prognostic factor in unresectable advanced and recurrent gastric cancer

Michio Inukai (Okayama Saiseikai General Hospital)

切除不能進行再発胃癌における予後因子としての好中球リンパ球比の有用性に関する検討  
犬飼 道雄 (岡山済生会総合病院)

**P2-011** Retrospective analysis of 18 cases of gastric cancer with peritoneal metastases resulting in conversion surgery

Encore

Toshizo Takayama (Department of Medical Oncology, Tonan Hospital)

腹腔内化学療法により Conversion surgery を行えた腹膜播種陽性胃癌 18 例についての検討  
高山 歳三 (斗南病院 腫瘍内科)

**P2-012** Role of LGR5 and CD133 in patients with gastric adenocarcinoma

Thipok Wiangpon (Institute of medicine, Suranaree University of Technology, Thailand)

**P2-013** Role of MMP- 7 in patients with gastric adenocarcinoma

Suksan Pinsuwan (Institute of medicine, Suranaree University of Technology, Thailand)

**P2-014** Novel biomarkers for detecting gastric adenocarcinoma

Taweesak Tongtawee (School of surgery, Suranaree University of Technology, Thailand / Translational medicine, Suranaree University of Technology)

12:40-13:35 Poster Session 2-3 / ポスターセッション 2-3

**P2-3** Gastrointestinal Cancer6  
消化管 6

Chair : Yasunori Emi (Department of Surgery, Saiseikai Fukuoka General Hospital)  
司会 : 江見 泰徳 (福岡県済生会福岡総合病院 外科)

**P2-015** ラムシルマブ (FOLFIRI 併用) の結腸・直腸癌患者を対象とした特定使用成績調査 中間報告 : 日常診療下での安全性

Yucherng Chen (Eli Lilly Japan K.K.)  
陳 祐晟 (日本イーライリリー株式会社)

**P2-016** A retrospective analysis of the elderly and non-elderly of TAS-102 for advanced colorectal cancer in clinical practice

Kenichiro Tsukada (JA Toyama Kouseiren Takaoka Hospital)

実地臨床における当科の切除不能進行大腸癌に対する TAS-102 療法の高齢者と非高齢者の比較検討  
塚田 健一郎 (富山県厚生農業協同組合連合会高岡病院)

- P2-017 Retrospective study of TAS-102 plus Bevacizumab vs Regorafenib in patients with mCRC refractory to standard chemotherapy**  
 Yoshimitsu Kobayashi (Medical Oncology Department, Kushiro Rosai Hospital / Gastroenterology department, Kushiro Rosai Hospital)  
 小林 良充 (釧路労災病院 腫瘍内科 / 釧路労災病院 消化器内科)
- P2-018 Retrospective study of TAS-102 plus Bevacizumab vs TAS-102 in patients with mCRC refractory to standard chemotherapy**  
 Ayumu Yoshikawa (Internal Medicine, Kushiro Rosai Hospital)  
 吉河 歩 (釧路労災病院 内科)
- P2-019 Optimal choice of salvage line tretment in metastatic colorectal cancer**  
 Hiroko Hasegawa (National Hospital Organization Osaka National Hospital)  
 長谷川 裕子 (国立病院機構 大阪医療センター 消化器内科)
- P2-020 当院におけるFOLFOX+P-mab療法とXELOX+P-mab療法の有害事象の比較検討**  
 Hiromi Fujimori (Department of Pharmacy, Okayama Saiseikai General Hospital)  
 藤森 浩美 (岡山済生会総合病院薬剤科)
- P2-021 The efficacy and safety of FTD/TPI + Mbab in later line chemotherapy for metastatic colorectal cancer patients**  
 Yasuhiro Sakamoto (Department of Medical Oncology, Osaki Citizen Hospital)  
**転移性大腸癌の後方ライン化学療法におけるFTD/TPI + Mbab併用療法の効果と安全性の後方視的検討**  
 坂本 康寛 (大崎市民病院 腫瘍内科)
- P2-022 Survival benefit of targeted therapy in metastatic colorectal cancer: A real world experience in Thailand**  
 Ekaphop Sirachainan (Division of medical Oncology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Thailand)
- P2-023 進行・再発胃癌患者における静脈血栓塞栓症の後方視的検討**  
 Koki Uehara (Department of Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital)  
 上原 康輝 (九州大学病院 血液腫瘍心臓血管内科)
- P2-024 経口フッ化ピリミジン系製剤の内服で溶血性貧血を起こしたが、治療継続が可能であった横行結腸癌の1例**  
 Terumi Aso (Medical Oncology Department, Fukuyama City Hospital)  
 麻生 光美 (福山市民病院 腫瘍内科)

12:40-13:35 Poster Session 2-4 / ポスターセッション 2-4

**P-2-4** Gastrointestinal Cancer7 (Esophageal Cancer/Gastric Cancer/GIST)  
 消化管7 (食道・胃・GIST)

Chair : Shinji Kitamura (Department of Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)

司会 : 北村 晋志 (徳島大学大学院 医歯薬学研究部 消化器内科学)

**P2-025 Down-staging and histological effects might be predictive factors for DOC+CDDP+5-FU for esophageal cancer**

Kazuma Kobayashi (Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences)

小林 和真 (長崎大学大学院 移植・消化器外科)



- P2-026** **Chronology and risk-dependence of age-related remodelling of oesophageal epithelia**  
**Encore** Akira Yokoyama (Department of Pathology and Tumor Biology, Kyoto University / Department of Clinical Oncology, Kyoto University Hospital)  
 横山 顕礼 (京都大学 腫瘍生物学講座 / 京都大学 腫瘍内科)
- 
- P2-027** **Impact of chemotherapy on overall survival and hospitalization in elderly patients with gastric cancer**  
 Yasuko Murakawa (Medical Oncology Department, Miyagi Cancer Center)  
 村川 康子 (宮城県立がんセンター)
- 
- P2-028** **Study of the prognostic factors of non-resected advanced gastric cancer in very elderly patients**  
 Satoko Ito (Higashisapporo hospital)  
 伊藤 智子 (東札幌病院)
- 
- P2-029** **Clinical benefit of palliative radiation therapy in bleeding gastric cancer**  
 Yoshiaki Mihara (Department of Gastroenterological Oncology, Saitama Medical University International Medical Center)  
 三原 良明 (埼玉医科大学国際医療センター 消化器腫瘍科)
- 
- P2-030** **The efficacy of nivolumab for patients with advanced gastric cancer with PS2 or peritoneal effusion**  
 Kohei Ogawa (Department of Gastroenterology, Toyama Prefectural Central Hospital)  
 小川 浩平 (富山県立中央病院 消化器内科)
- 
- P2-031** **Geriatric assessment of elderly patients with unresectable gastric cancer**  
 Aya Sugimoto (Department of Gastroenterology, Toyonaka Municipal Hospital)  
 杉本 彩 (市立豊中病院)
- 
- P2-032** **An integrated approach of deleterious polymorphism between Gastric and Lung Cancer for Novel Biomarker discovery**  
 Mohammad Uzzal Hossain (Bioinformatics Division, National Institute of Biotechnology, Dhaka-1349, Bangladesh)
- 
- P2-033** **A case of pseudoprogression in patient with recurrent gastric cancer treated with nivolumab**  
 Shinichi Furutachi (Gastroenterology Department, Okayama medical center)  
 古立 真一 (岡山医療センター 消化器内科)
- 
- P2-034** **Retrospective analysis of the efficacy and safety of regorafenib in patients with advanced GIST**  
 Hiroshi Nakatsumi (Division of Cancer Center, Hokkaido University Hospital)

12:40-13:35 Poster Session 2-5 / ポスターセッション 2-5

**P2-5** Hepatobiliary/Pancreatic Cancer3 (Liver Cancer - Systemic Chemotherapy)  
 肝胆腫3 (肝臓 - 全身薬物療法)

Chair : Tomohiro Yamaguchi (Oncology Clinical Development, MSD K.K.)  
 司会 : 山口 智宏 (MSD株式会社 オンコロジー臨床開発部)

- P2-035** **Analysis of prognostic factors and treatment outcomes for survival in hepatocellular carcinoma patients**  
 Chanchai Charonpongsuntorn (Medical oncology department, Srinakharinwirot University, Thailand)

- P2-036 Dose Intensity of Lenvatinib in Hepatocellular Carcinoma**  
 Miyuki Uoi (Department of Pharmacy, National Hospital Organization Kyushu Cancer Center)  
**肝細胞癌におけるLenvatinibのDose Intensityの検討**  
 魚井 みゆき(国立病院機構 九州がんセンター 薬剤部)
- 
- P2-037 Systemic therapy for unresectable hepatocellular carcinoma: A single-institution retrospective analysis**  
 Takayuki Iwamoto (Department of gastroenterology, Kansairosai hospital)  
 岩本 剛幸(関西労災病院 消化器内科)
- 
- P2-038 Efficacy and safety of Lenvatinib in patients with unresectable hepatocellular carcinoma**  
 Kazuyo Miyagi (Department of Pharmacy,National Hospital Organization Osaka National Hospital)  
**切除不能肝細胞癌に対するレンバチニブの有効性と安全性に関する検討**  
 宮城 和代(独立行政法人 国立病院機構 大阪医療センター 薬剤部)
- 
- P2-039 レンバチニブ導入により著明に縮小した局所再発肝細胞癌 (Vp4) の一例**  
 Mayumi Kondou (Department of Gastroenterology, Toshima Hospital of the Tokyo Metropolitan Health and Hospitals Corporation)  
 近藤 真由美(東京保健医療公社豊島病院 消化器内科)
- 
- P2-040 Clinical experience of lenvatinib for patients with advanced hepatocellular carcinoma**  
 Reina Kurata (Department of pharmacy, Mie Central Medical Center)  
**当院における肝細胞癌でのレンバチニブの使用経験**  
 倉田 玲奈(独立行政法人 国立病院機構 三重中央医療センター 薬剤部)

12:40-13:35 Poster Session 2-6 / ポスターセッション 2-6

- P2-6 Hepatobiliary/Pancreatic Cancer4 (Liver Cancer - Others)**  
**肝胆腫 4 (肝臓-その他)**
- Chair : Atsushi Naganuma (Department of Gastroenterology, NHO Takasaki General Medical Center)  
 司会 : 長沼 篤(国立病院機構 高崎総合医療センター 消化器内科)
- 
- P2-041 Quality of life in correlation with C-reactive protein among patients with primary liver cancers**  
 Winnie Yeo (Chinese University of Hong Kong, Hong Kong)
- 
- P2-042 Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma**  
**Encore**  
 Chong-Chi Chiu (Department of General Surgery, Chi Mei Medical Center, Liouying and Tainan, Taiwan / Department of Electrical Engineering, Southern Taiwan University of Science and Technology, Tainan, Taiwan)
- 
- P2-043 A clinical research based on Apatinib plus TACE treatment among HCC patients**  
 Zhenyu Dai (Yancheng Third people's hospital, China)
- 
- P2-044 Stimulation of a nuclear protein-1 by thyroid hormone enhances angiogenesis in liver cancer**  
 Kwang-Huei Lin (Department of Biochemistry, Chang-Gung University, Taoyuan, Taiwan)
- 
- P2-045 Radiotherapy (3D-CRT) for hepatocellular carcinoma with macroscopic vascular invasion**  
 Akinori Asagi (Department of Gastrointestinal Medical Oncology, Shikoku Cancer Center)  
**脈管浸潤を有する肝細胞癌への放射線治療 (3D-CRT) の検討**  
 浅木 彰則(四国がんセンター)

**P2-046 A case of hepatocellular carcinoma with portal invasion and lymph node metastasis treated with multidisciplinary therapy**

Noriaki Yuasa (Department of Radiology, Steel Memorial Muroran Hospital)

**肝細胞癌門脈浸潤およびリンパ節転移へ集学的治療を施行した1例**

湯浅 憲章 (製鉄記念室蘭病院 放射線科)

12:40-13:35 Poster Session 2-7 / ポスターセッション 2-7

**P2-7 Hepatobiliary/Pancreatic Cancer5 (Pancreatic Cancer)**  
 肝胆膵5 (膵臓)

Chair : Yasushi Sato (Department of Community Medicine for Gastroenterology and Oncology, Tokushima University Graduate School of Biomedical Sciences)

司会 : 佐藤 康史 (徳島大学大学院医歯薬学研究所 地域消化器・総合内科学)

**P2-047 Establishment of molecular barcode detection system for pancreatic malignancies; comparison with deep sequencing by NGS**

Hiroshi Ohyama (Department of Gastroenterology, Yamanashi Central Hospital / Department of Gastroenterology, Graduate School of Medicine, Chiba University)

大山 広 (山梨県立中央病院 消化器内科 / 千葉大学大学院医学研究院消化器内科学)

**P2-048 Circulating tumour RNA based molecular profiling of pancreatic adenocarcinoma**

Aditya R Kunte (Department of Surgical Oncology, Gujarat Cancer and Research Institute, Ahmedabad, India)

**P2-049 Early detection of pancreatic ductal adenocarcinoma by measuring the abnormal urinary fragmentation ratios of kininogen**

Motoyasu Kan (Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East)

菅 元泰 (国立がん研究センター東病院 肝胆膵内科)

**P2-050 Everolimus for advanced pancreatic neuroendocrine carcinoma refractory or intolerant to platinum-based chemotherapy**

Encore

Masafumi Ikeda (National Cancer Center Hospital East)

池田 公史 (国立がん研究センター東病院 肝胆膵内科)

**P2-051 Multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer**

Satoshi Kobayashi (Department of Gastroenterology, Kanagawa Cancer Center)

小林 智 (神奈川県立がんセンター 消化器内科)

**P2-052 Efficacy and safety of second-line nab-paclitaxel plus gemcitabine following FOLFIRINOX for metastatic pancreatic cancer**

Kunihiro Fushiki (Shizuoka Cancer Center)

伏木 邦博 (静岡県立静岡がんセンター)

**P2-053 演題取下**

**P2-054 Comparison of FOLFIRINOX and gemcitabine plus nab-paclitaxel for patients with pancreatic cancer: retrospective analysis**

Kunihiro Tsuji (Departments of Gastroenterology, Ishikawa Prefectural Central Hospital)

辻 国広 (石川県立中央病院)

**P2-055 FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis**

Toshihiko Matsumoto (Himeji red cross hospital)

松本 俊彦 (姫路赤十字病院)

**P2-056 Efficacy of S-1 in 2L chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer**

Kiyotsugu Iede (Department of Clinical Oncology, Higashiosaka city medical center)  
家出 清継 (市立東大阪医療センター 臨床腫瘍科)

12:40-13:35 Poster Session 2-8 / ポスターセッション 2-8

**P2-8 Hepatobiliary/Pancreatic Cancer6**  
肝胆腫6

Chair : Yoshito Hayashi (Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine)

司会 : 林 義人 (大阪大学大学院医学系研究科 消化器内科学)

**P2-057 Incidence and Mortality Trends of Hepatocellular Carcinoma among Patients of Asian Descent; A Population-Based Study**

Anas M Saad (Faculty of Medicine, Ain Shams University, Egypt)

**P2-058 Chinese herbal formula KuNong (AH05) preparation inhibits hepatocellular carcinoma in vitro and vivo**

Encore

LI Xianyong (Oncology department, Chengdu Fuxing Hospital, China)

**P2-059 Therapeutic efficacy of miriplatin in combination with radiotherapy for advanced hepatocellular carcinoma**

Encore

Hironori Tanaka (Institute of Biomedical Sciences, Tokushima University Graduate School)  
田中 宏典 (徳島大学大学院医歯薬学研究部 消化器内科学)

**P2-060 A case of recurrent HCC successfully treated with lenvatinib**

Akinori Sugaya (Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center / Kasumigaura Medical Center)

菅谷 明徳 (茨城県立中央病院・茨城県地域がんセンター／霞ヶ浦医療センター)

**P2-061 Clinical response to pembrolizumab in MSI-high neuroendocrine carcinoma of biliary duct origin. A case report**

Mihoko Doi (Department of Clinical Oncology, Hiroshima Prefectural Hospital)

土井 美帆子 (県立広島病院)

**P2-062 Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer**

Osamu Maeda (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)

前田 修 (名古屋大学医学部附属病院 化学療法部)

**P2-063 Gastrointestinal bleeding in patients with pancreatic cancer**

Yasushi Kojima (National Center for Global Health and Medicine)

小島 康志 (国立国際医療研究センター病院)

**P2-064 Bile juice replicates genomic profile of biliary tract malignancies**

Hiroshi Ohyama (Department of Gastroenterology, Yamanashi Central Hospital / Department of Gastroenterology, Graduate School of Medicine, Chiba University)

大山 広 (山梨県立中央病院 消化器内科／千葉大学大学院医学研究院消化器内科学)

- P2-9** Lung Cancer/Thoracic Cancer6 (Small Cell Lung Cancer)  
呼吸器 6 (小細胞肺癌)
- Chair : Kazuhiko Shibata (Division of Medical Oncology, Kouseiren Takaoka Hospital)  
司会 : 柴田 和彦 (厚生連高岡病院 腫瘍内科)
- 
- P2-065** 小細胞肺癌治療が抗腫瘍免疫に及ぼす影響  
Fuyumi Nishihara (Saitama medical university international medical center)  
西原 冬実 (埼玉医科大学国際医療センター 呼吸器内科)
- 
- P2-066** Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702)  
Masahiro Watanabe (Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center)  
渡邊 雅弘 (北海道がんセンター 呼吸器内科)
- 
- P2-067** TP53-mutant Clone Occupies Major Prevalence in De Novo SCLC Transformation from EGFR-mutated Adenocarcinoma  
Kei Kunimasa (Department of Thoracic Oncology, Osaka International Cancer Institute)  
國政 啓 (大阪国際がんセンター 呼吸器内科)
- 
- P2-068** The investigation of KL-6 as a prognostic marker in small cell lung cancer patients  
Yusuke Araki (Department of Respiratory Medicine, Hiroshima University Hospital)  
小細胞肺癌患者におけるKL-6の予後予測因子としての検討  
荒木 佑亮 (広島大学病院 呼吸器内科)
- 
- P2-069** The efficacy of amrubicin salvage chemotherapy in patients with relapsed extensive-disease small-cell lung cancer  
Kei Sonehara (First Department of Internal Medicine, Shinshu University School of Medicine)  
曾根原 圭 (信州大学医学部内科学第一教室)
- 
- P2-070** Phase I study of amrubicin and cisplatin with concurrent thoracic radiotherapy in limited-disease small cell lung cancer  
Midori Shimada (Second Department of Internal Medicine, Nagasaki University Hospital)  
限局型小細胞肺癌 (LD-SCLC) に対するアムルビシン/シスプラチンと放射線同時併用療法の第I-II相試験  
嶋田 緑 (長崎大学病院 第二内科)
- 
- P2-071** Efficacy and safety of carboplatin and etoposide for ED-SCLC in elderly patients with poor PS  
Nobuaki Mamesaya (Division of Thoracic Oncology, Shizuoka Cancer Center)  
PS不良かつ高齢の進展型小細胞肺癌患者に対するカルボプラチン・エトポシド療法の有効性および安全性の検討  
豆鞆 伸昭 (静岡県立静岡がんセンター)
- 
- P2-072** Weekly nab-PTX vs weekly PTX for Relapsed and Refractory Small Cell Lung Cancer  
Hajime Oi (Department of Respiratory medicine and Allergy, Tosei General Hospital)  
再発小細胞肺癌に対するweekly nab-PTX療法とweekly PTX療法の検討  
大井 肇 (公立陶生病院 呼吸器・アレルギー疾患内科)

**P2-073** **Incidence and survival of patients who developed limited-stage small cell lung cancer as a second malignancy**

Encore

Miho Kono (research institute for radiation biology and medicine / Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center)  
河野 美保 (広島大学原爆放射線医科学研究所 / テキサス大学MDアンダーソンがんセンター放射線腫瘍科)

12:40-13:35 Poster Session 2-10 / ポスターセッション 2-10

**P2-10** Lung Cancer/Thoracic Cancer7 (Basic Research)  
呼吸器7 (基礎)

Chair : Kaoru Kubota (Department of Pulmonary Medicine and Oncology)  
司会 : 久保田 馨 (日本医科大学 呼吸器内科学)

**P2-074**  **$\alpha$  7nAChR signaling in lung cancer**

Yao-Tsung Yeh (Aging and Disease Prevention Research Center, Fooyin University, Kaohsiung, Taiwan / Department of Medical Laboratory Science and Biotechnology, Fooyin University, Kaohsiung, Taiwan)

**P2-075** 演題取下

**P2-076** **Elevated expression of lumican in lung cancer cells promotes bone metastasis through an autocrine regulatory mechanism**

Ko-Jiunn Liu (National Institute of Cancer Research, National Health Research Institutes, Taiwan)

**P2-077** **Differentially expressed circular RNAs in human pleural metastatic lung cancer and clinical significance**

Xueling Wu (Department of Respiratory Medicine, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China)

**P2-078** **The inhibitory activity of gallic acid against DNA methylation: application of GA on epigenetic therapy of human cancers**

Encore

Yui-Ping Weng (Graduate Institute of Biomedical Science, Chung Hwa University of Medical Technology, Tainan, Taiwan)

**P2-079** **Plasma exosomal microRNAs for pulmonary ground-glass nodules**

Xiang-Peng Chu (Guangdong Provincial People's Hospital; Guangdong Lung Cancer Institute, China)

**P2-080** **A specific missense mutation in *GTF2I* occurs exclusively in thymomas**

Rumi Higuchi (Department of Thoracic Surgery, Yamanashi prefectural Central Hospital)  
樋口 留美 (山梨県立中央病院 呼吸器外科)

**P2-081** **Seasonal variation of physical activity among preoperative lung cancer patients**

Sunga Kong (Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Korea)

**P2-082** **PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma**

Akira Ooki (Cancer Institute Hospital of Japanese Foundation for Cancer Research)  
大木 暁 (がん研究会 有明病院)

**P2-11** Lung Cancer/Thoracic Cancer8 (NSCLC - Immunotherapy1)  
呼吸器 8 (非小細胞肺癌-免疫療法1)

Chair : Kazuya Fukuoka (Clinical Research Center, Kindai University Hospital)

司会 : 福岡 和也 (近畿大学病院 臨床研究センター)

**P2-083 PD-L1 高発現の進行・再発非小細胞肺癌でPembrolizumabを投与したが奏効しなかった症例の検討**  
Akira Nakao (Department of Respiratory Medicine, Faculty of Medicine, Fukuoka University)  
中尾 明 (福岡大学病院 呼吸器内科)**P2-084 抗PD-1 抗体治療歴を有する進行非小細胞肺癌に対する抗PD-L1 抗体の検討**  
Maiko Niki (Department of Thoracic Oncology, Hyogo College of Medicine / Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine)  
二木 麻衣子 (兵庫医科大学内科学講座呼吸器科/兵庫医科大学胸部腫瘍学特定講座)**P2-085 a retrospective analysis of the treatment with immune checkpoint inhibitor for previously treated patients of NSCLC**

Kazunari Tateishi (First Department of Internal Medicine, Shinshu University School of Medicine)

**既治療非小細胞肺癌に対する免疫チェックポイント阻害薬治療の後方視的解析**

立石 一成 (信州大学医学部 内科学第一教室)

**P2-086 非小細胞肺癌に対して抗PD-1 抗体で治療後にAtezolizumabを投与した症例の検討**

Ryo Sawada (Department of Medical Oncology, Fukuchiyama City Hospital)

澤田 凌 (市立福知山市民病院 腫瘍内科)

**P2-087 Efficacy and safety of Atezolizumab for advanced NSCLC**

Shigeaki Iwatsubo (Kyoto Katsura Hospital)

**当院における進行非小細胞肺癌に対するAtezolizumabの効果と安全性の検討**

岩坪 重彰 (京都桂病院)

**P2-088 A single-center observational study of atezolizumab on efficacy and safety in patients with non-small-cell lung cancer**

Natsuki Takano (Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School)

**進行再発非小細胞肺癌に対するアテゾリズマブ単剤療法の有効性と安全性に関する後方視的検討**

高野 夏希 (日本医科大学大学院医学研究科 呼吸器内科学分野)

**P2-089 当院での進行非小細胞肺癌に対するアテゾリズマブ投与症例の治療成績**

Kenya Sato (Saiseikai Yokohamashi Tobu Hospital)

佐藤 賢弥 (済生会横浜市東部病院)

**P2-090 肉腫様成分を含んだ非小細胞肺癌に対する免疫チェックポイント阻害剤の有効性**

Shun Futamura (Department of Medical Oncology, Fukuchiyama City Hospital)

二村 俊 (市立福知山市民病院 腫瘍内科)

**P2-091 免疫チェックポイント阻害薬による薬剤性肺炎症例の検討**

Kahori Nakahama (Department of Thoracic Oncology, Kansai Medical University Hospital / First Department of Internal Medicine, Kansai Medical University)

中濱 かほり (関西医科大学附属病院 呼吸器腫瘍内科/関西医科大学 内科学第一講座)

**P2-092 NSCLCに対する免疫チェックポイント阻害薬の治療効果判定におけるFDG-PET検査並びにタリウムシンチの有用性についての前向き検討**

Kayoko Kibata (Department of Thoracic Oncology, Kansai Medical University Hospital / First Department of Internal Medicine, Kansai Medical University)

木畑 佳代子 (関西医科大学附属病院呼吸器腫瘍内科 / 関西医科大学内科学第一講座)

12:40-13:35 Poster Session 2-12 / ポスターセッション 2-12

**P2-12 Lung Cancer/Thoracic Cancer9 (Locally Advanced Lung Cancer/Small Cell Lung Cancer/Mesothelioma/Other) 呼吸器9 (局所進行・小細胞がん・中皮腫・その他)**

Chair : Shoichi Kuyama (Department of Respiratory Medicine NHO Iwakuni Clinical Center)

司会 : 久山 彰一 (国立病院機構 岩国医療センター 呼吸器内科)

**P2-093 Phase II trial of amrubicin and cisplatin chemotherapy for invasive thymoma:****Encore WJOG5509L**

Akira Ono (Shizuoka Cancer Center)

小野 哲 (静岡県立静岡がんセンター)

**P2-094 Phase II study of S-1 in patients (Pts) with previously treated Invasive thymoma (IT) and thymic carcinoma (TC): NJLCG 1203****Encore**

Shoichi Kuyama (Department of respiratory medicine, Iwakuni Clinical Center)

久山 彰一 (岩国医療センター)

**P2-095 Diffuse malignant mesothelioma confirmed by autopsy in a patient with indirect asbestos exposure**

Kazuhisa Konishi (Department of Respiratory Medicine, Saka General Hospital)

小西 一央 (坂総合病院 呼吸器科)

**P2-096 Thymoma Associated with Neuromyelitis Optica Spectrum Disorder: A Case Report**

PIYAKARN WATCHARENWONG (Division of Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand)

**P2-097 Impact of combined evaluation using tumor volume and metastatic nodal extent in stage III NSCLC treated with CRT**

Yutaro Tamiya (Department of Respiratory Medicine, Nagoya University Graduate School of Medicine)

田宮 裕太郎 (名古屋大学大学院医学系研究科 呼吸器内科学)

**P2-098 Phase II study of adjuvant chemotherapy with carboplatin and nab-paclitaxel for completely resected NSCLC**

Motoko Tachihara (Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine)

立原 素子 (神戸大学大学院医学研究科内科学講座呼吸器内科学分野)

**P2-099 Treatment with durvalumab in clinic following radical chemoradiation therapy**

Ken Uchibori (Department of Thoracic Medical Oncology, the Cancer Institute Hospital, Japanese Foundation for Cancer Research)

内堀 健 (がん研究会有明病院 呼吸器内科)

**P2-100 Utility of Neutrophil-to-lymphocyte Ratio as a Prognostic Factor in Large Cell Neuroendocrine carcinoma**

Masayuki Shirasawa (Department of Thoracic Oncology, National Cancer Center Hospital)

白澤 昌之 (国立がん研究センター中央病院呼吸器内科)



**P2-101 Solvent-based paclitaxel or nab-paclitaxel for heavily treated relapsed/refractory small cell lung cancer**

Ayano Mise (Department of Medical Oncology, Nagoya Medical Center)  
 三瀬 綾乃 (名古屋医療センター 腫瘍内科)

**P2-102 Laparoscopic adrenal gland biopsy showed recurrent adenocarcinoma after chemoradiotherapy for LD-SCLC**

Takeshi Yoshida (Department of Medical Oncology, Kindai University Faculty of Medicine)  
 吉田 健史 (近畿大学医学部内科学腫瘍内科部門)

12:40-13:35 Poster Session 2-13 / ポスターセッション 2-13

**P2-13 Lung Cancer/Thoracic Cancer10 (NSCLC - Immunotherapy2)**  
 呼吸器 10 (非小細胞肺癌-免疫療法 2)

Chair : Masahiro Kodani (Division of Medical Oncology and Molecular Respiriology, Faculty of Medicine, Tottori University)  
 司会 : 小谷 昌広 (鳥取大学 医学部分子制御内科学)

**P2-103 Clinical utility of precision immunoprofiling n patients with advanced NSCLC treated with Atezolizumab (EPOC1702)**

Keisuke Kirita (Department of Thoracic Oncology, National Cancer Center Hospital East)  
 桐田 圭輔 (国立がん研究センター東病院 呼吸器内科)

**P2-104 A retrospective analysis about non-small cell lung cancer patients without durable response with PD-1/PD-L1 inhibitors**

Yuhei Harutani (Wakayama Medical University Hospital)  
 春谷 勇平 (和歌山県立医科大学附属病院)

**P2-105 The efficacy and safety of immune checkpoint inhibitors in super elderly NSCLC patients aged ≥ 85 years**

Toshio Kubo (Center for Clinical Oncology, Okayama University Hospital)  
 久保 寿夫 (岡山大学病院 腫瘍センター)

**P2-106 PD-L1 expression level and liver metastasis associated with the efficacy of pembrolizumab in PD-L1 strong-positive NSCLC**

Yuki Takeyasu (Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan)  
 竹安 優貴 (国立がん研究センター中央病院 呼吸器腫瘍内科)

**P2-107 Association between immune-related adverse events and clinical outcomes in NSCLC treated with pembrolizumab monotherapy**

Kazuhiro Shimomura (Department of Pharmacy, Aichi Cancer Center / Biostatistics Center, Graduate School of Medicine, Kurume University)  
 下村 一景 (愛知県がんセンター薬剤部 / 久留米大学バイオ統計センター)

**P2-108 Real-World Effectiveness and Safety of Nivolumab in Elderly NSCLC Patients in Japan: A Multicenter-Retrospective Study**

Makiko Yomota (Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital / Nivolumab Japan Real World Study Group)  
 四方田 真紀子 (がん・感染症センター東京都立駒込病院 呼吸器内科 / Nivolumab Japan Real World Study Group)

- P2-109** **Changes in plasma CXCL2 and MMP2 levels reflect response to anti-PD-1 therapy in non-small-cell lung cancer patients**  
 Norikazu Matsuo (Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine)  
 松尾 規和 (久留米大学病院 内科学講座 呼吸器・神経・膠原病内科部門)
- P2-110** **Impact of Baseline Number of Metastases on the Efficacy of Pembrolizumab Monotherapy for NSCLC with PD-L1 TPS 50-100%**  
 Taichi Miyawaki (Division of Thoracic Oncology, Shizuoka Cancer Center)  
 宮脇 太一 (静岡県立静岡がんセンター 呼吸器内科)
- P2-111** **Specific TP53 Mutation Subtypes as Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC**  
 Hao Sun (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, China)
- P2-112** **Feasibility study on the detection of plasma exosomal PD-L1 in non-small cell lung cancer**  
 Xiao-Xiao Peng (Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, China)

12:40-13:35 Poster Session 2-14 / ポスターセッション 2-14

- P2-14** **Breast Cancer1 (Diagnosis/Neoadjuvant/Adjuvant)**  
 乳腺1 (診断・術前/術後療法)  
 Chair : Tsutomu Iwasa (Department of Medical Oncology, Kindai University Faculty of Medicine)  
 司会 : 岩朝 勤 (近畿大学医学部附属病院 腫瘍内科)
- P2-113** **Mammographic Density Distribution and its Naturally Decreasing Trend with Age in Taiwanese Women**  
 Ling Hui HUANG (Breast Cancer Center, Changhua Christian Hospital, Taiwan)
- P2-114** **Knowledge and Attitudes of Productive Age Women About Mammography in Early Screening of Breast Cancer in Klungkung, Bali**  
 Agung Bagus Sista Satyarsa (Medical student, Faculty of medicine, Udayana University, Indonesia)
- P2-115** **Dose-dense neoadjuvant nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer**  
 Akiko Matsumoto (Department of Surgery, Teikyo University)  
 松本 暁子 (帝京大学)
- P2-116** **演題取下**
- P2-117** **当院における早期乳癌術前補助化学療法の長期成績**  
 Miho Tamura (Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine)  
 田村 美宝 (東京慈恵会医科大学附属病院 腫瘍・血液内科)
- P2-118** **The possibility of non-anthracycline anti-cancer drug rejimen for HER2 type breast cancer**  
 Hirokazu Takechi (Tokushima University Hospital)  
**HER2 type 乳癌初期治療時におけるアンスラサイクリン系抗癌剤回避レジメンの有効性**  
 武知 浩和 (徳島大学病院)

- P2-119** **A case of drug-induced alveolar hemorrhage caused by FEC therapy**  
 Minako Nishio (Osaka International Cancer Institute)  
**FEC療法が原因と考えられた薬剤性肺胞出血の1例**  
 西尾 美奈子 (大阪国際がんセンター)
- 
- P2-120** **Study of patients with breast cancer metaplastic carcinoma with or without postoperative adjuvant chemotherapy**  
 Yuko Kawai (Department of Surgery, Keio University)  
**当科における乳癌Metaplastic carcinoma症例の術後補助化学療法の有無での臨床的特徴の比較検討**  
 河合 佑子 (慶應義塾大学 医学部 一般・消化器外科 乳腺班)
- 
- P2-121** **Assessment of Cardiotoxicity with Trastuzumab for HER2-positive Early Stage Breast Cancer in our Facility**  
 Akira Tsunoda (Department of Medical Oncology, Mie University Hospital)  
**当院におけるHER2陽性早期乳癌に対するtrastuzumabの心毒性の検討**  
 角田 瑛 (三重大学医学部附属病院 腫瘍内科)
- 
- P2-122** **Incidence rate of febrile neutropenia by Docetaxel with Cyclophosphamide and, effect to RDI and treatment effect**  
 Kenichi Nakanishi (Ichinomiya municipal hospital)  
**当院における乳癌TC療法的好中球減少症発症率およびRDI、治療効果に対する影響**  
 中西 賢一 (一宮市立市民病院 乳腺内分泌外科)
- 
- P2-123** **EC療法、DTX療法におけるペグフィルグラステムの必要性についての検討**  
 Tatsunari Sasada (Department of Breast Surgery, Onomichi General Hospital)  
 佐々田 達成 (尾道総合病院 乳腺外科)

12:40-13:35 Poster Session 2-15 / ポスターセッション 2-15

**P2-15** Breast Cancer2 (CDK4/6 inhibitors, Anti-HER2 agents)  
 乳腺2 (CDK4/6 阻害薬・抗HER2療法)

Chair : Toshiro Mizuno (Department of Medical Oncology, Mie University Hospital)  
 司会 : 水野 聡朗 (三重大学医学部附属病院 腫瘍内科)

- P2-124** **Palbociclib induced hematologic toxicities; incidence and risk factors**  
 Jun Hashimoto (Division of Medical Oncology, St. Luke's International Hospital)  
 橋本 淳 (聖路加国際病院 腫瘍内科)
- 
- P2-125** **Palbociclib in clinical use for metastatic breast cancer at a single institution**  
 Mitsuo Terada (Breast Oncology Department, Aichi Cancer Center)  
 寺田 満雄 (愛知県がんセンター 乳腺科)
- 
- P2-126** **Study of parvociclib administration patients at our hospital**  
 Mahito Funakoshi (Hiroshima City Asa Citizens Hospital)  
**当院におけるパルボシクリブ投与例の検討**  
 船越 真人 (広島市立安佐市民病院 乳腺外科)
- 
- P2-127** **Retrospective study of clinical efficacy of palbociclib on heavily treated metastatic invasive breast cancer**  
 Masaaki Sasaki (Medical Oncology Department, Kyoundo Hospital)  
**ホルモン受容体陽性転移・再発乳癌のlate lineにおけるパルボシクリブの有用性の検討**  
 佐々木 政興 (杏雲堂病院)

**P2-128** **mTOR阻害薬についてpalbociclibによって生じた転移再発乳がん患者における難治性間質性肺炎の一例**  
 Saeko Sakaeda (Breast & Endocrine Surgery Department, Tokai university)  
 栄枝 三江子 (東海大学医学部付属病院)

**P2-129** **Efficacy of oral fluoropyrimidine in patients with metastatic breast cancer right after palbociclib-containing therapy**  
 Takayuki Kobayashi (Breast Medical Oncology Department, Cancer Institute Hospital of JFCR)  
**転移性乳癌患者におけるパルボシクリブ投与後の経口フッ化ピリミジン薬の有効性に関する検討**  
 小林 隆之 (がん研究会有明病院 乳腺内科)

**P2-130** **S-1 combined with trastuzumab emtansine (T-DM1) for HER2 positive metastatic breast cancer: follow up of phase Ib study**  
 Yasuyuki Kojima (St.Marianna university School of Medicine)  
 小島 康幸 (聖マリアンナ医科大学)

**P2-131** **A study on tolerability of T-DM1 in elderly patients HER2-positive advanced breast cancer at our institution**  
 Ritsuko Sasaki (Department of Breast Oncology, Juntendo University)  
**当院における高齢者HER2陽性進行再発乳癌に対するT-DM1療法の忍容性に関する検討**  
 佐々木 律子 (順天堂大学大学院医学研究科 乳腺腫瘍学講座)

**P2-132** **Relationship between the site of metastasis and the therapeutic effect of pertuzumab-based therapy for HER2-positive MBC**  
 Ryohei Katsuragi (Department of Breast Surgery, KITANO HOSPITAL)  
**HER2陽性乳癌の転移臓器とPertuzumab併用化学療法における治療効果との関連に関する検討**  
 葛城 遼平 (北野病院 乳腺外科)

12:40-13:35 Poster Session 2-16 / ポスターセッション 2-16

**P2-16** **Breast Cancer3 (Others)**  
**乳腺3 (その他)**  
 Chair : Yuko Tanabe (Toranomon Hospital)  
 司会 : 田辺 裕子 (虎の門病院 臨床腫瘍科)

**P2-133** **Development and Psychometric Evaluation of a Coping Scale for Breast Cancer Survivors**  
 ChiungYu Huang (Nursing Department, I-Shou University, Taiwan)

**P2-134** **Does pregnancy-associated breast cancer portend poor prognosis? A clinicopathological study from a cancer care center**  
**Encore**  
 Jeewan Ram (All India institute of Medical Sciences, Jodhpur, India / King George's Medical University, Lucknow)

**P2-135** **Change of skeletal muscle during neoadjuvant chemotherapy in breast cancer patient**  
 Tomoyoshi Aoyagi (Funabashi Municipal Medical Center)  
**乳癌化学療法前後での筋骨格量の変化**  
 青柳 智義 (船橋市立医療センター)

**P2-136** **Analysis of change of nutrition related indexes during adjuvant chemotherapy in breast cancer**  
 Tokiko Ito (Division of Breast and Endocrine Surgery, Shinshu University School of Medicine)  
**乳癌の補助化学療法中の栄養関連指標の変化の解析**  
 伊藤 勲子 (信州大学医学部 乳腺内分泌外科)

- 
- P2-137** **Association of body mass index and gastrointestinal chemotherapy toxicity in breast cancer patients: A preliminary study**  
Natasya Reina Gunawan (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- 
- P2-138** **Long-term results of conservative and rapid rehabilitation of patients with breast cancer**  
Saidrakhim N. Lukmonov (Oncology Department, Tashkent Medical Academy, Uzbekistan)
- 
- P2-139** **Anemia before chemotherapy associated with quality of life in breast cancer patients: A preliminary study**  
Olivia J. D. A. Saroso (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- 
- P2-140** **Association of Gastrointestinal Chemotoxicity to the Performance Status of Breast Cancer Patients: A Preliminary Study**  
Fernando Dharmaraja (Faculty of medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
- 
- P2-141** **Association between QoL and Gastrointestinal Chemotherapy Toxicity in Breast Cancer Patient: A Preliminary study**  
Felix Wijovi (Faculty of Medicine, Pelita Harapan University, Tangerang, Banten, Indonesia)
-

## 国立京都国際会館 イベントホール

12:40-13:35 Poster Session 2-17 / ポスターセッション 2-17

**P2-17** Head and Neck Cancer1 (Case Reports)  
頭頸部がん 1 (症例報告)Chair : Yasuo Iwamoto (Medical Oncology)  
司会 : 岩本 康男 (広島市立広島市民病院 腫瘍内科)**P2-142** Pilot study of 3-combined therapy (chemotherapy, target therapy and IO) for recurrent/metastatic head and neck cancer  
Jin-Ching Lin (Department of Radiation Oncology, Taichung Veterans General Hospital, Taiwan)**P2-143** 不応となった細胞障害性レジメンをNivolumab療法後に再施行した頭頸部扁平上皮癌3例の解析  
Keitaro Doi (Kyoto University Hospital)  
土井 恵太郎 (京都大学医学部附属病院)**P2-144** Induction SBRT followed by chemotherapy/immunotherapy for locally advanced maxillary cancer. Case report  
Masao Toji (Otorhinolaryngology Department, Shin-yurigaoka General Hospital)  
SBRT導入放射線化学療法と引き続き免疫療法により治癒に至ったIVB期上顎扁平上皮癌の一例  
田路 正夫 (新百合ヶ丘総合病院 耳鼻咽喉科)**P2-145** Hypopharyngeal cancer patient with autoimmune myositis and myasthenia gravis emerged after nivolumab administration  
Masao Toji (Otorhinolaryngology Department, Shin-yurigaoka General Hospital)  
nivolumab投与により重症筋無力症合併を疑わせる自己免疫性筋炎を発症した高齢者下咽頭癌の一例  
田路 正夫 (新百合ヶ丘総合病院 耳鼻咽喉科)**P2-146** Non Calcitonin-Producing Neuroendocrine Tumor of Thyroid Origin Diagnosed as Atypical Medullary Carcinoma. Case Report  
Masao Toji (Otorhinolaryngology Department, Shin-yurigaoka General Hospital)  
症例報告 亜型髄様癌と診断しえたカルシトニン非産生甲状腺由来神経内分泌腫瘍の一例  
田路 正夫 (新百合ヶ丘総合病院 耳鼻咽喉科)**P2-147** Parapharyngeal space carcinoma ex pleomorphic adenoma with multiple lung metastases : a case report  
Miake Yamamoto (Tokyo Metropolitan Tama Medical Center)  
間質性肺炎の経過観察中に出現した副咽頭間隙多形腺腫由来癌、多発肺転移の1例  
山本 美暁 (東京都立多摩総合医療センター)**P2-148** ニボルマブが著効した再発性左顎下腺筋上皮癌の一例  
Yasutomo Miyaji (Department of Medical Oncology, Kameda medical center)  
宮地 康僚 (亀田総合病院)**P2-149** 唾液腺導管癌 多発肺転移に対してニボルマブが著効した1例  
Moe Matsuo (Department of Medical Oncology, Kyushu Medical Center)  
松尾 萌 (九州医療センター 腫瘍内科)

12:40-13:35 Poster Session 2-18 / ポスターセッション 2-18

**P2-18** Head and Neck Cancer2 (Immune Checkpoint Inhibitors/TKIs)  
頭頸部がん 2 (免疫チェックポイント阻害薬・TKI)

Chair : Satoshi Hamauchi (Division of Gastrointestinal Oncology, Shizuoka Cancer Center)  
司会 : 濱内 諭 (静岡県立静岡がんセンター 消化器内科)

**P2-150** Experience of lenvatinib therapy for patients with differentiated thyroid cancer in our hospital

Keisuke Miwa (Multidisciplinary Treatment Cancer Center, Kurume University Hospital / Department of Surgery, Kurume University School of Medicine)  
三輪 啓介 (久留米大学病院 がん集学治療センター/久留米大学医学部外科学講座)

**P2-151** Lenvatinib, In Treating Advanced Malignant Thyroid Tumours, Real Life Experience from University Malaya Medical Centre

Yin Keong Teo (Department of Radiotherapy and Oncology, Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia)

**P2-152** The effect of tumor burden and growth rate on the treatment outcomes of nivolumab in head and neck cancer

Encore

Chiaki Suzuki (Department of Medical Oncology/Hematology, Kobe University Graduate School of Medicine / Department of Otolaryngology-Head and Neck Surgery Graduate School of Medicine, Kyoto University)  
鈴木 千晶 (神戸大学医学部附属病院 腫瘍・血液内科/京都大学大学院医学研究科 耳鼻咽喉科・頭頸部外科)

**P2-153** A Safety and Efficacy Analysis of Nivolumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Kenro Tanoue (Department of Medical Oncology, Kyushu Medical Center)

再発・転移頭頸部扁平上皮癌に対するニボルマブ投与症例の安全性と有効性の検討  
田ノ上 純郎 (九州医療センター 腫瘍内科)

**P2-154** A retrospective analysis of efficacy and safety of nivolumab for patients with recurrent/metastatic head and neck cancer

Ken Saijo (Department of Medical Oncology, Tohoku University Hospital)

再発・転移頭頸部癌患者に対するnivolumabの有効性および安全性についての後方視的解析  
西條 憲 (東北大学病院 腫瘍内科)

12:40-13:35 Poster Session 2-19 / ポスターセッション 2-19

**P2-19** Head and Neck Cancer3 (CNS Tumors/Thyroid Cancer/Translational Research)  
頭頸部がん 3 (中枢神経腫瘍・甲状腺・TR)

Chair : Natsuko Satomi (Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital)  
司会 : 里見 奈都子 (国立がん研究センター中央病院 脳脊髄腫瘍科)

**P2-155** Racial Disparities in Incidence and Mortality Trends of Glioblastoma; A Population-Based Study

Inas A Ruhban (Pathology department, Faculty of Medicine, Damascus University, Damascus, Syria, Egypt)

**P2-156** Synthetic Lethality of Combined PARP and Autophagy Inhibition in Glioblastoma: Mechanism and Superior antitumor Efficacy

Wei Chen (Department of Microbiological and Biochemical Pharmacy, Fudan University, China / Department of Ophthalmology, Stanford University School of Medicine, Palo Alto CA 94304, USA)

- P2-157** **Relevance of FAT1 gene in the regulation of tumor suppressor gene PTEN via miR-221 in human glioblastoma**  
Nargis Malik (Dept of Biochemistry AIIMS New Delhi, India)
- 
- P2-158** **Reciprocal relation of HIC1 and SIRT1 in modulating glioma cancer stem cells pluripotency**  
mohita bhagat (All India Institute Of Medical Sciences, India)
- 
- P2-159** **Mitochondrial stress induces cancer immunoescape via mtDNA-mediated STING-interferon signaling and extracellular vesicle**  
Alan Yueh-Luen Lee (National Institute of Cancer Research, National Health Research Institutes, Taiwan)
- 
- P2-160** **Characterization of URST5 as a biomarker and therapeutic target for oral cancer**  
Bayarbat Tsevegjav (Department of Medical Oncology, Shiga University of Medical Science) シェベグジヤブ バヤルバット(滋賀医科大学 臨床腫瘍学講座)
- 
- P2-161** **Real-world experience of Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer from Taiwan**  
Hui-Jen Tsai (National Institute of Cancer Research, National Health Research Institutes, Taiwan / Division of Hematology and Oncology, Department of Internal Medicine, National Cheng Kung University Hospital / Department of Internal Medicine, Kaohsiung Medical University Hospital)
- 
- P2-162** **Successful treatment by surgery and lenvatinib of a patient with adrenal metastasis of papillary thyroid cancer**  
Hajime Nakamura (Department of Medical Oncology, Sapporo Medical University School of Medicine) 中村 元(札幌医科大学医学部腫瘍内科学講座)

12:40-13:35 Poster Session 2-20 / ポスターセッション 2-20

**P2-20** **Head and Neck Cancer4**  
頭頸部がん4

Chair : Hitoshi Noguchi (Noguchi Thyroid Clinic and Hospital Foundation)  
司会 : 野口 仁志 (野口記念会 野口病院)

- P2-163** **Clinical outcomes of nivolumab monotherapy for head and neck cancer; single institute experience**  
Yoshitaka Homma (Head and Neck Medical Oncology Division, Gastrointestinal Medical Oncology Division, National Cancer Center Hospital) 本間 義崇 (国立がん研究センター中央病院 頭頸部内科・消化管内科)
- 
- P2-164** **Immunological analysis of drug-induced pneumonia induced by anti-PD-1 antibody**  
Hirofumi Ohmura (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences) 大村 洋文 (九州大学大学院 医学研究院 病態修復内科学)
- 
- P2-165** **Efficacy and Safety of Nivolumab in Previously Treated Patients with Head and Neck Cancer**  
Kaoru Tanaka (Department of Medical Oncology, Kindai University Faculty of Medicine) 田中 薫 (近畿大学医学部内科学教室腫瘍内科部門)
- 
- P2-166** **Elective neck dissection during salvage surgery for recurrent laryngeal carcinomas: A retrospective analysis**  
Pavan Karella (Surgical Oncology Department, Gujarat Cancer and Research Institute, India)



**P2-167 TRANSORAL CO2 LASER MICROSURGERY IN THE TREATMENT OF EARLY LARYNGEAL CANCERS**

Phuc Huu Nguyen (Ho Chi Minh City Oncology Hospital, Viet Nam)

**P2-168 Induction TPF chemotherapy followed by concurrent CRT for unresectable sinonasal undifferentiated carcinoma**

Sho Watanabe (Department of Head and Neck Medical Oncology, National Cancer Center Hospital)  
渡辺 翔 (国立がん研究センター中央病院 頭頸部内科)

**P2-169 Late side-effects and support of chemoradiotherapy compare to surgery in hypopharyngeal and laryngeal cancer**

Tomoko Yamazaki (Head and Neck Cancer Oncology, Miyagi Cancer Center)  
山崎 知子 (宮城県立がんセンター)

12:40-13:35 Poster Session 2-21 / ポスターセッション 2-21

**P2-21 Translational Research7 TR7**

Chair : Masachika Ikegami (Division of Gllular Signaling National Cancer Center Insutite)  
司会 : 池上 政周 (国立がん研究センター研究所 細胞情報学分野)

**P2-170 演題取下**

**P2-171 Arecoline-regulated ataxia telangiectasia mutated expression during oral squamous cell carcinoma progression**

**Encore**  
Tzong-Ming Shieh (Department of Dental Hygiene, College of Health Care, China Medical University, Taiwan)

**P2-172 The differential expression of the salivary peptidome in radiotherapy-induced Xerostomia**

Yin-Hwa Shih (Department of Healthcare Administration, Asia University, Taichung, Taiwan)

**P2-173 H-ALA-mediated photodynamic therapy suppressed nasopharyngeal carcinoma cell growth through down-regulation of EGFR**

Ricky W.K. Wu (School of Medical and Health Sciences, Tung Wah College, Hong Kong, China, Hong Kong)

**P2-174 Difference of PDT induced apoptotic gene expression in 2D and 3D nasopharyngeal carcinoma cell models**

Ricky W.K. Wu (School of Medical and Health Sciences, Tung Wah College, Hong Kong, China, Hong Kong)

**P2-175 Polo-like kinase inhibitor with radiation in betel-nuts related HNSCC in Taiwan**

Jo-Pai Chen (Oncology Department, Yun-lin Branch in National Taiwan University Hospital, Taiwan)

**P2-176 Asiatic acid induce cell apoptosis in human cisplatin-resistance nasopharyngeal cancer cells**

Yi-Ching Chuang (Oral Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan)

**P2-177 Activation of memory T cells and T-helper 1 polarization in malignant melanoma patients treated with nivolumab**  
 Kyoko Yamaguchi (Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences)  
 山口 享子 (九州大学大学院 病態修復内科学)

12:40-13:35 Poster Session 2-22 / ポスターセッション 2-22

**P2-22** Translational Research8 TR8

Chair : Shinji Kohsaka (Division of Cellular Signaling, National Cancer Center Research Institute)  
 司会 : 高阪 真路 (国立がん研究センター研究所 細胞情報学分野)

**P2-178 Analysis of Patient Background and Responses in Providing Informed Consent for National Cancer Center Biobank Project**  
 Teiko Yamane (Biobank Translational Research Support Section, National Cancer Center Hospital)  
**国立がん研究センターバイオバンク同意/非同意患者の背景とその解析**  
 山根 禎子 (国立がん研究センター中央病院 バイオバンク・TR支援室)

**P2-179 MicroRNA-145 Regulates Invasion In Upper Tract Urothelial Carcinoma By Targeting ARF6**  
 Wei-Chi Hsu (Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan / Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung Medical University)

**P2-180 Evaluation of Qubit RNA IQ as an indicator in RNA quality assay of pathological tissue samples for cancer genome therapy**  
 Masakazu Souda (Clinical Genomics Center, Nagasaki University Hospital)  
**ゲノム診療用病理組織検体のRNA品質検定における指標としてのQubit RNA IQの評価**  
 早田 正和 (長崎大学病院 ゲノム診療センター)

**P2-181 New regulatory mechanism of tumor suppressor microRNA let-7s (comprehensive approach for tumor suppressors in vitro)**  
 Ryota Kurimoto (Department of Sytems BioMedicine, Tokyo Medical and Dental University)  
**腫瘍抑制 microRNA let-7 familyの新たな制御機構の解明 (in vitro approachによる新たな腫瘍抑制遺伝子の網羅的探索)**  
 栗本 遼太 (東京医科歯科大学 システム発生再生医学分野)

**P2-182 CD26 is a potential therapeutic target by humanized monoclonal antibody in multiple myeloma**  
**Encore**  
 Hiroko Nishida (Department of Pathology, Keio University, School of Medicine)  
**多発性骨髄腫においてCD26はヒト化モノクローナル抗体投与の治療標的となる**  
 西田 浩子 (慶應義塾大学医学部 病理学)

**P2-183 Primary tumor resection after nivolumab treatment for metastatic renal cell carcinoma: A case report**  
 Tokiyoshi Tanegashima (Department of Urology, Graduate School of Medical Sciences, Kyushu University / Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center)  
 種子島 時祥 (九州大学大学院医学研究院泌尿器科学分野 / 国立がん研究センター先端開発医療センター免疫TR分野)

**P2-184** **CEBPD-regulated microRNAs in urothelial carcinoma**  
 A-Mei Huang (Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Taiwan / Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University / Department of Biochemistry, College of Medicine, Kaohsiung Medical University)

**P2-185** **Role of miR-125b in testicular germ cell tumors growth via tumor-associated macrophages recruitment**  
**Encore**  
 Aalia Batool (The State Key Laboratory of Stem cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, China)

**P2-186** **EGFR induced interleukin-8-mediated migration through NF-κB and p38 pathways in docetaxel-resistant prostate cancer**  
 Tzyh-Chyuan Hour (Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan)

12:40-13:35 Poster Session 2-23 / ポスターセッション 2-23

**P2-23** Translational Research9 TR9

Chair : Hiromichi Ebi (Division of Molecular Therapeutics, Aichi Cancer Center)  
 司会 : 衣斐 寛倫 (愛知県がんセンター がん標的治療TR分野)

**P2-187** **Comparison of sample types with success rates of next-generation sequencing**  
 Tomohiro Sakamoto (Division of Medical Ontology and Molecular Respiriology, Tottori University Hospital)  
**肺癌の検体採取方法とNGS解析成功割合**  
 阪本 智宏 (鳥取大学医学部附属病院 呼吸器内科・膠原病内科)

**P2-188** **コンパニオン診断薬MSI (FALCO) の検査院内化により見えた癌種横断的検査の重要性と課題**  
 Yuki Nagakubo (Division of Genetics and Clinical Laboratory, Yamanashi Central Hospital)  
 長久保 由貴 (山梨県立中央病院 検査部ゲノム検査科)

**P2-189** **The therapeutic effect and immune-related adverse event of nivolumab in Anjo Kosei Hospital**  
 Yuichiro Inagaki (Department of Hematology and Oncology, Anjo Kosei Hospital)  
**安城更生病院におけるニボルマブの治療効果・有害事象の検討**  
 稲垣 裕一郎 (安城更生病院 血液・腫瘍内科)

**P2-190** **Predictive biomarker of ramucirumab for advanced gastric cancer**  
 Makoto Natsume (Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences)  
 夏目 まこと (名古屋市立大学病院)

**P2-191** **Lenvatinib induced cell death of human hepatocellular carcinoma with an activated FGF signal under nutrient starvation**  
**Encore**  
 Taisuke Hoshi (Eisai Co., Ltd.)  
**Lenvatinibは血管新生阻害を模倣した栄養飢餓条件においてFGFシグナル阻害を介しヒト肝細胞癌株の細胞死を誘導する**  
 星 太輔 (エーザイ株式会社)

**P2-192** **抗抗菌薬投与が免疫チェックポイント阻害薬効果へ及ぼす影響**  
 Momoka Nakatani (Toyama University Hospital, Clinical Oncology)  
 中谷 百花 (富山大学附属病院 臨床腫瘍部)

- P2-193 Combinatorial host biomarkers for the clinical response to the PD-1 blockade therapy in NSCLC patients**  
Ryusuke Hatae (Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University)  
波多江 龍亮 (京都大学 大学院医学研究科 免疫ゲノム医学)
- P2-194 The current status of genomic medicine outpatient clinic at Nagoya University Hospital**  
Yuka Murasaki (Center for Advanced Medicine and Clinical Research Department of Advanced Medicine, Nagoya University Hospital)  
**名古屋大学病院における「がんゲノム外来」の現状**  
村崎 由佳 (名古屋大学医学部附属病院 先端医療開発部 先端医療・臨床研究支援センター)
- P2-195 L-Arginine metabolism alteration by L-Lysine intervention increased cell death in triple negative breast cancer cell**  
Reza Yarani (Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Denmark / Department of Clinical Research, Type 1 Diabetes Biology, Steno Diabetes Center, Copenhagen, Denmark)

12:40-13:35 Poster Session 2-24 / ポスターセッション 2-24

- P2-24 Cross-sectional Program3 (Imaging/Immunotherapy-Related Toxicities)**  
臓器横断プログラム3 (画像・irAEのマネジメント)  
Chair : Keisuke Aoe (Department of Medical Oncology, Yamaguchi-Ube Medical Center)  
司会 : 青江 啓介 (山口宇部医療センター 腫瘍内科)
- P2-196 The value of Diffusion Weighted MRI in delineation of tumor volume for Glioma in radiotherapy planning**  
Eva YW Cheung (Tung Wah College, Hong Kong)
- P2-197 Differentiation of Benign and Malignant Adrenal Masses by Using Unenhanced and Enhanced CT Attenuation Values**  
Jaturat Kanpittaya (Department of Radiology, Faculty of Medicine, Khon Kaen University, Thailand)
- P2-198 Antitumor effect of immune checkpoint inhibitor for subsequent therapy**  
Shigeru Tanaka (Department of Clinical Oncology, Okazaki City Hospital)  
**後治療に対する免疫チェックポイント阻害剤の抗腫瘍効果に関する後方視的検討**  
田中 繁 (岡崎市民病院 腫瘍内科)
- P2-199 A retrospective study of immune-related adverse events in various solid tumors**  
Keitaro Shimozaki (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine)  
**当院における免疫チェックポイント阻害薬による免疫関連有害事象の実際臓器別・薬剤別の特徴を踏まえた検討**  
下嵯 啓太郎 (慶應義塾大学医学部 消化器内科)
- P2-200 Management of Liver Dysfunction Developing as an Immune-Related Adverse Event**  
Makoto Arai (Department of Medical Oncology, Chiba University)  
**自己免疫疾患関連副作用 (irAE) としての肝障害の管理**  
新井 誠人 (千葉大学医学部附属病院 腫瘍内科)

**P2-201 Combined treatment with nivolumab plus denosumab for various cancers with bone metastasis: retrospective study**  
 Yukinori Ozaki (Medical Oncology, Toranomon Hospital)  
 尾崎 由記範 (虎の門病院)

**P2-202 Long lasting response to nivolumab for a patient with Lynch syndrome-associated lung adenocarcinoma**  
 Keita Masuzawa (Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine)  
**ニボルマブが長期間奏功しているリンチ症候群合併肺腺癌の一例**  
 増澤 啓太 (慶應義塾大学医学部 呼吸器内科)

12:40-13:35 Poster Session 2-25 / ポスターセッション 2-25

**P2-25 Cross-sectional Program4 (Cancer Genomic medicine)**  
**臓器横断プログラム4 (がんゲノム診療)**

Chair : Hiroki Ueda (Wakayama Medical University Respiratory Medicine and Medical Oncology)  
 司会 : 上田 弘樹 (和歌山県立医科大学 呼吸器内科・腫瘍内科)

**P2-203 Investigating the environmental and genetic risk factors of pancreatic ductal adenocarcinoma**  
 Jeffrey S Chang (National Health Research Institutes, Taiwan)

**P2-204 Effect of cancer gene panel inspection on cancer genomic medicine for patients**  
 Koseki Hirade (Department of Pharmacy, Kizawa Memorial Hospital / Center for Cancer Genomic Diagnosis and Treatment, Kizawa Memorial Hospital)  
**網羅的がん遺伝子検査・解析およびがんゲノム医療提供体制の構築と評価**  
 平本 耕石 (社会医療法人厚生会 木沢記念病院 薬剤部 / 医療法人厚生会 木沢記念病院 がんゲノム診断・診療センター)

**P2-205 To establish the procedures of microsatellite instability testing for the solid cancer in our hospital**  
 Akihiro Shinji (Department of Medical Oncology, Suwa red cross hospital)  
**当院における固形がんに対するマイクロサテライト不安定性検査の体制整備**  
 進士 明宏 (諏訪赤十字病院 腫瘍内科)

**P2-206 Companion diagnosis by BRACAnalysis CDx™ and therapeutic experience of Olaparib for HER2-negative breast cancer**  
 Yuri Kimura (Department of Breast surgery, Hiroshima General Hospital)  
**HER2陰性進行・再発乳癌に対するBRACAnalysis診断システム™によるコンパニオン診断の現状とOlaparibの治療経験**  
 木村 優里 (JA広島総合病院)

**P2-207 The role of medical oncologists in introducing MSI testing to our hospital**  
 Naotoshi Sugimoto (Department of Medical Oncology, Osaka International Cancer Institute)  
**MSI検査導入における腫瘍内科医の役割**  
 杉本 直俊 (大阪国際がんセンター)

**P2-208 Current progress and issues of cancer genomic medicine in Kyushu University Hospital**  
 Mamoru Ito (Department of Hematology, Oncology & Cardiovascular medicine, Kyushu University)  
**九州大学病院におけるがんゲノム医療の現状と課題**  
 伊東 守 (九州大学病院血液・腫瘍・心血管内科)

- P2-209 Introduction of genomic medicine at a general community hospital**  
 Daisuke Yamaguchi (Medical Oncology Department, Kyoto Katsura Hospital)  
**一般市中病院におけるがんゲノム医療連携病院としての取り組み**  
 山口 大介 (京都桂病院 腫瘍内科)

12:40-13:35 Poster Session 2-26 / ポスターセッション 2-26

**P2-26 Multidisciplinary Team Program4 (Pharmaceutical Care)**  
 多職種連携 4 (薬剤師指導)

- Chair : Yoshinori Makino (Department of Pharmacy, National Cancer Center Hospital)  
 司会 : 牧野 好倫 (国立がん研究センター中央病院 薬剤部)

- P2-210 Role of Clinical Pharmacist in Chemotherapy Regimen Management**  
 Ryoko Udagawa (Department of Pharmacy, National Cancer Center Hospital)  
**がん化学療法レジメン管理における薬剤師の介入状況調査**  
 宇田川 涼子 (国立がん研究センター中央病院 薬剤部)

- P2-211 外科外来で経口抗がん剤を導入された患者に対する薬剤師の介入**  
 Kosuke Miyoshi (Pharmacy, Iizuka Hospital)  
 三好 康介 (飯塚病院 薬剤部)

- P2-212 外来化学療法室における薬剤師業務の現状と課題**  
 Mitsutaka Kyotani (Kanagawa Cancer Center, department of pharmacy)  
 京谷 充崇 (神奈川県立がんセンター 薬剤科)

- P2-213 レジメン別投与管理表の作成・運用と評価について**  
 Hideyuki Kushihara (Department of Pharmacy, Japanese Red Cross Nagoya Daiichi Hospital)  
 榎原 秀之 (名古屋第一赤十字病院 薬剤部)

- P2-214 一般名処方導入後の内服抗がん薬処方状況調査**  
 Seiichi Osaki (Department of pharmacy, Hiroshima Nishi Medical Center)  
 尾崎 誠一 (国立病院機構広島西医療センター 薬剤部)

- P2-215 外来化学療法センター常駐薬剤師による5年間の薬学的介入事例**  
 Yumiko Furuta (Department of Pharmacy, Kyoto-Katsura Hospital)  
 古田 祐美子 (京都桂病院)

12:40-13:35 Poster Session 2-27 / ポスターセッション 2-27

**P2-27 Multidisciplinary Team Program5 (Introduction of New Systems)**  
 多職種連携 5 (新規システム導入)

- Chair : Seiko Bun (National Center for Child Health and Development)  
 司会 : 文 靖子 (国立成育医療研究センター 薬剤部)

- P2-216 Unattended overnight preparation of anticancer drugs by support robot device DARWIN-Chemo® in Kyushu University Hospital**  
 Toshihiro Iriasa (Department of Pharmacy, Kyushu University Hospital)  
**九州大学病院における抗がん薬調製支援装置 DARWIN-Chemo による抗がん薬自動調製の夜間無人化**  
 入佐 俊弘 (九州大学病院 薬剤部)

**P2-217** **Development of emergency response system and staff education in outpatient treatment room**  
 Misato Kinoshita (Department of Nursing, Kobe University Hospital / Divisions of Cancer Center, Kobe University Hospital)

**通院治療室における急変時対応システムの構築と職員教育**  
 木下 実里 (神戸大学医学部附属病院 看護部 / 神戸大学医学部附属病院 腫瘍センター)

**P2-218** **Attempt to promote knowledge of anticancer drugs for pharmacists at acute general hospital**  
 Mikinori Yoshida (Department of Pharmacy, Center Hospital of the National Center for Global Health and Medicine)

**急性期総合病院における薬剤師の抗がん剤に関する知識向上に向けた取り組み**  
 吉田 幹宜 (国立国際医療研究センター病院 薬剤部)

**P2-219** **In-hospital countermeasures against the increase in the number of order sets after deadline time of regimen ordering**  
 Takuya Honda (Clinical Oncology Center, Nagasaki University Hospital)

**がん薬物療法時間外オーダー件数の増加に対する院内対策とその結果**  
 本田 琢也 (長崎大学病院がん診療センター)

**P2-220** **Acoustic Radiation Force Impulse (ARFI) for Assessment of Lymphedema; a Case Report**  
 Hee Kyung Cho (Department of Rehabilitation Medicine, Catholic University of Daegu School of Medicine, Korea)

**P2-221** **患者指導の効率化を目的としたアプリ開発**  
 Reiko Makihara (Department of pharmacy, National Cancer Center Hospital)  
 牧原 玲子 (国立がん研究センター中央病院 薬剤部)

12:40-13:35 Poster Session 2-28 / ポスターセッション 2-28

**P2-28** **Multidisciplinary Team Program6 (Health Professionals Education)**  
**多職種連携 6 (スタッフ教育)**

Chair : Yoshihisa Tomioka (Graduate School of Pharmaceutical Sciences, Tohoku University)  
 司会 : 富岡 佳久 (東北大学大学院 薬学研究科がん化学療法薬学分野)

**P2-222** **がんゲノム医療実装に向けた看護師を対象とする勉強会の取り組み**  
 Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)  
 池田 貞勝 (東京医科歯科大学 腫瘍センター)

**P2-223** **Construction of a New Support System for Review on Anticancer Drug Prescriptions Using a Quality Control Technique**  
 Masahiro Yasuda (Department of Pharmacy, Gifu Municipal Hospital)  
**Quality Control手法を活用した抗がん剤処方鑑査支援システムの構築**  
 安田 昌宏 (岐阜市市民病院 薬剤部)

**P2-224** **スペシャリスト育成に向けた管理者としての関わり  
 ～自部署で実践した研修を活かした人材育成～**  
 Asami Wada (Iizuka Hospital Cancer Multidisciplinary therapy Center)  
 和田 麻美 (飯塚病院 がん集学治療センター)

**P2-225** **在宅患者訪問看護指導の取り組みと評価**  
 Hiroko Kubo (University of Fukui Hospital / Department of Community Health Care Partnership)  
 久保 博子 (福井大学医学部附属病院 / 福井大学病院患者総合支援センター 地域医療連携部)

**P2-226** **病棟・外来の継続看護のための取り組み  
～病棟カンファレンスに外来看護師が参加する取り組みの評価報告～**  
Mari Mikami (St. Lukes International Hospital)  
三上 茉莉 (聖路加国際病院)

12:40-13:35 Poster Session 2-29 / ポスターセッション 2-29

**P2-29** **Clinical Trial Facilitation Program2 (Trials in Progress1)  
臨床試験推進プログラム 2 (Trials in Progress1)**

Chair : Minoru Fukuda (Clinical Oncology Center, Nagasaki University Hospital)  
司会 : 福田 実 (長崎大学病院 がん診療センター)

**P2-227** **NivOlumaB and chemoradiotherapy for Esophageal cancer (NOBEL) (Trial in progress)**  
Motoo Nomura (Department of Medical Oncology, Kyoto University Graduate School of Medicine)  
**食道癌患者を対象とした根治的的化学放射線療法と Nivolumab 併用による探索的多施設共同非盲検医師主導治験 (NOBEL)**  
野村 基雄 (京都大学 腫瘍内科)

**P2-228** **Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II**  
**Encore**  
Yu Jo Chua (Medical Oncology Clinical Trials, Canberra Hospital, Canberra, ACT, Australia)

**P2-229** **HGCSG1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment for gastric cancer**  
Rio Honma (Department of Medical Oncology, Tonan Hospital)  
**初回化学療法に不応の切除不能進行・再発胃癌に対するイリノテカン・ラムシルマブ併用療法の多施設共同医師主導前向き第II相試験**  
本間 理央 (斗南病院 腫瘍内科)

**P2-230** **Prospective study of oxaliplatin-based chemotherapy in homologous recombination deficient advanced pancreatic cancer**  
Tomohiro Kondo (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University / Clinical Genetics Unit, Kyoto University Hospital.)  
近藤 知大 (京都大学大学院 医学研究科 腫瘍薬物治療学 / 京都大学医学部附属病院 遺伝子診療部)

**P2-231** **Multicenter prospective cohort study to evaluate of eye disorder induced by chemotherapy including S-1 in GI cancer**  
Masayoshi Dazai (Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan)  
太宰 昌佳 (NTT東日本札幌病院 消化器内科)

**P2-232** **Multicenter feasibility study of mFOLFOX7 in hemodialysis patients with colorectal cancer**  
Shigeki Kataoka (Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University)  
**血液透析中の消化器癌患者に対するFOLFOX療法の安全性と有効性に関する多施設共同臨床試験**  
片岡 滋貴 (京都大学医学部大学院医学研究科 腫瘍薬物治療学講座)

**P2-233** **A global phase 3 trial of ASP-1929 photoimmunotherapy vs. physician's choice for rHNSCC**  
**Encore**  
Makoto Tahara (Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan)



**P2-234** **N of 1 trials comparing nebulized morphine, nebulized furosemide in palliated patients with refractory breathlessness**  
 Pongput Pimsa (Medical Oncology Department, Ramathibodi Hospital, Mahidol University, Thailand)

**P2-235** **Multidisciplinary effort for improving research biopsy procedure and adequacy of research biopsy at an academic hospital**  
 Soo-Yeon Park (Clinical Trial Center, Asan Medical Center, Korea)

12:40-13:35 Poster Session 2-30 / ポスターセッション 2-30

**P2-30** Clinical Trial Facilitation Program3 (Trials in Progress2)  
 臨床試験推進プログラム 3 (Trials in Progress2)  
 Chair : Atsushi Sato (Department of Medical Oncology, Hirosaki University Graduate School of Medicine)  
 司会 : 佐藤 温 (弘前大学大学院医学研究科 腫瘍内科学講座)

**P2-236** **KEYNOTE-756: randomized, double-blind, phase 3 study of pembrolizumab + neoadjuvant CT + adjuvant ET for ER+/HER2- BC**  
 Encore Shigehira Saji (Fukushima Medical University, Fukushima, Japan)

**P2-237** **Phase 3 study of [fam-] trastuzumab deruxtecan vs investigator's choice in T-DM1-pretreated HER2+ breast cancer**  
 Encore Eriko Tokunaga (NHO Kyushu Cancer Center)  
 徳永 えり子 (国立病院機構九州がんセンター)

**P2-238** **Phase 3 study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 in advanced HER2-positive breast cancer**  
 Encore Toshinari Yamashita (Kanagawa Cancer Center)  
 山下 年成 (神奈川県立がんセンター)

**P2-239** **A phase 3 trial of [fam-] trastuzumab deruxtecan (DS-8201a) vs investigator's choice in HER2-low breast cancer**  
 Encore Shoichiro Ohtani (Hiroshima City Hiroshima Citizens Hospital)  
 大谷 彰一郎 (広島市立広島市民病院)

**P2-240** **Phase 3 study of pembrolizumab plus chemotherapy with olaparib maintenance for 1L treatment of advanced ovarian cancer**  
 Encore Kosei Hasegawa (Saitama Medical University International, Saitama Prefecture, Japan)

**P2-241** **Phase 3 randomized study of pembrolizumab plus chemotherapy for first-line treatment of advanced cervical cancer**  
 Encore Kosei Hasegawa (Saitama Medical University International, Saitama Prefecture, Japan)

**P2-242** **切除不能かつ化学療法歴を有するHER2 : 1+以上の進行・再発子宮癌肉腫に対するDS-8201aの医師主導治験**  
 Mamiko Kawasaki (National Cancer Center Hospital, Clinical Trial Support Office)  
 川崎 真実子 (国立がん研究センター中央病院 臨床研究支援部門 研究企画推進部)

**P2-243** **ROCK Trial (NCCH1709): Nivolumab monotherapy in Rare cancer patients with mismatch repair deficiency biomarker: phase II**  
 Yosuke Amaya (Clinical Research Support Office, National Cancer Center Hospital)  
**ROCK 試験 (NCCH1709) :**  
**ミスマッチ修復機能異常のある希少がんに対するニボルマブ単剤療法の第II相試験**  
 天谷 洋介 (国立がん研究センター中央病院 臨床研究支援部門)

**P2-244 TACKLE: A phase II study of alectinib in patients with unresectable rare cancer harboring ALK alterations (NCCH1712)**

Shoko Narita (National Cancer Center Hospital)

**TACKLE試験：ALK遺伝子転座または活性化型変異を有する希少がんに対するアレクチニブの医師主導治験 (NCCH1712)**

成田 翔子 (国立がん研究センター中央病院)

**P2-245 KEYNOTE-811: Pembrolizumab + trastuzumab and chemotherapy for HER2+ metastatic gastric/gastroesophageal junction cancer**

Encore

Taroh Satoh (Osaka University, Osaka, Japan)

**P2-246 HER2遺伝子の増幅を認める進行性固形癌患者を対象としたトラスツズマブ+ペルツズマブ併用療法の第2相試験**

Sadakatsu Ikeda (Cancer Center, Tokyo Medical and Dental University)

池田 貞勝 (東京医科歯科大学 腫瘍センター)

12:40-13:35 Poster Session 2-31 / ポスターセッション 2-31

**P2-31 Patient Advocacy/Suivivorship 1 (Employment support/Education)**

患者支援・サバイバーシップ1 (就労・教育)

Chair : Shigemi Matsumoto (Department of Therapeutic oncology, Graduate School of Medicine, Kyoto University)

司会 : 松本 繁巳 (京都大学大学院医学研究科 腫瘍薬物治療学講座)

**P2-247 A病院で外来化学療法を受ける患者の就労状況と課題**

Mitsuko Shionoya (Cancer Chemotherapy Center, Nagano Municipal Hospital)

塩ノ谷 美津子 (長野市民病院 化学療法センター)

**P2-248 地域がん診療拠点病院のがん相談支援センターで行うがん患者の治療と仕事の両立支援の現状と課題**

Yuki Mukaigawa (Prefectural Hiroshima Hospital Nursing Department)

迎川 ゆき (県立広島病院 看護部)

**P2-249 Employment status of cancer patients receiving chemotherapy at our hospital**

Yukie Chida (Teine Keijinkai Hospital Nursing unit)

**A病院における抗がん薬治療を受ける患者の就労の実態**

千田 友紀恵 (手稲溪仁会病院 看護部)

**P2-250 Report of a support program for cancer patients and their families at Jichi Medical University Hospital**

Rie Yamamoto (Department of Clinical Oncology, Jichi Medical University Hospital)

**自治医科大学附属病院におけるがんサロンの活動経過報告および今後の展開に関する検討**

山本 理栄 (自治医科大学附属病院 臨床腫瘍科)

**P2-251 Effects of Nurse Navigators on Health Outcomes of Lymphoma Patients**

Pei-Hua Wu (Chi Mei Medical Center, Liouying, Taiwan)

**P2-252 外来化学療法における病薬連携向上のための取り組み**

Mami Eto (Fukuokawajiro Hospital)

江藤 真未 (福岡和白病院)

**P2-253 Action of the pharmacist to equalize a medical standard of the cancer treatment**

Atsuko Sone (Tokai University Hospital Division of Pharmacy)

**がん医療水準の均てん化に向けた薬剤師の取り組み**

曽根 敦子 (東海大学医学部付属病院薬剤部)

P2-254	<p><b>Experience of an oncologist in cancer education at a local elementary school</b>          Atsushi Ishiguro (Medical Oncology Department, Teine Keijinkai Hospital)  <b>当該医療圏にある小学校においてがんに関する授業を担当した経験</b>          石黒 敦 (手稲溪仁会病院)</p>
P2-255	<p><b>パールリボンキャラバンの振り返りと今後の課題</b>          Mitsuyo Chou (Orange Home Nursing)          長 光代 (おれんじ訪問看護ステーション)</p>
P2-256	<p><b>The Pancreatic Cancer Seminar, Questionnaires for the patients who receive chemotherapy</b>          Suetsumi Okagaki (Osaka International Cancer Institute)  <b>膵がん教室「抗がん剤と療養生活」の実際と取り組み～質問紙調査からみえる今後の課題～</b>          岡垣 すえつみ (大阪国際がんセンター)</p>
12:40-13:35 Poster Session 2-32 / ポスターセッション 2-32	
P2-32	<p><b>Patient Advocacy/Suivorship2 (Others)</b>          患者支援・サバイバーシップ2 (その他)</p> <p>Chair : Yasuo Saijo (Niigata University Medical Oncology)          司会 : 西條 康夫 (新潟大学大学院医歯学総合研究科 腫瘍内科学分野)</p>
P2-257	<p><b>Prevalence and associated factors of weight gain after early breast cancer diagnosis</b>          Kruawan Tessomboon (Department of Medicine, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Thailand)</p>
P2-258	<p><b>Diabetes management for cancer survivors in primary care practice of local hospital</b>          Makoto Kodaira (Internal Medicine and Medical Oncology, Kodaira Hospital)  <b>糖尿病を抱えるがんサバイバーに対する地域の内科外来における診療実態</b>          公平 誠 (公平病院 内科・腫瘍内科)</p>
P2-259	<p><b>The role of primary care physician for " Silver Tsunami" increasing numbers of old-old elderly cancer survivor</b>          Eriko Nara (Internal Medicine and Medical Oncology, Kodaira Hospital)  <b>がんサバイバーの高齢化 ("Silver Tsunami") に対する地域プライマリーケア医の役割</b>          奈良 江梨子 (公平病院 腫瘍内科)</p>
P2-260	<p><b>Progressed thoracic carcinoid patient experienced pregnancy, childbirth and child-raising during chemotherapy</b>          Junji Uchida (Osaka General Medical Center)  <b>進行胸部カルチノイド患者が妊娠出産育児を経験しながらも化学療法を施行したことについて</b>          内田 純二 (大阪急性期・総合医療センター)</p>
P2-261	<p><b>Survey of outpatient visits associated with cancer chemotherapy</b>          Junko Yamaya (Teine Keijinkai Hospital)  <b>A病院における継続的がん薬物療法を要する患者の通院に関する調査</b>          山谷 淳子 (手稲溪仁会病院)</p>
P2-262	<p><b>血液腫瘍における75歳以上の患者の vitality index は治療継続を判断する指標となる</b>          Masaru Sibata (Kawanishi city hospital)          柴田 大 (市立川西病院)</p>

- P2-263 Correlation factors for adherence of oral chemotherapy medication clinic patients in Apeksha Hospital, Sri Lanka**  
Kasuni C Yamasinghe (General Sir John Kotelawala Defence University, Sri Lanka)
- 
- P2-264 がんに対する認識調査**  
Kazuki Ogawa (Toyama University Hospital, Clinical Oncology)  
小川 和起 (富山大学附属病院 臨床腫瘍部)
- 
- P2-265 Resilience and coping styles as predictors of lower adverse health outcomes in breast cancer patients**  
ChiungYu Huang (Nursing Department, I-Shou University, Taiwan)
- 
- 12:40-13:35 Poster Session 2-33 / ポスターセッション 2-33
- P2-33 Patient Advocacy/Suvivorship3 (AYA/Geriatric Oncology)**  
患者支援・サバイバーシップ3 (AYA・高齢者)
- Chair : Takatoshi Hirayama (National Cancer Center Hospital, Japan)  
司会 : 平山 貴敏 (国立がん研究センター中央病院 精神腫瘍科)
- 
- P2-266 Preferences of young adult cancer patients for communication when receiving bad news**  
Yosuke Uchitomi (National Cancer Center Hospital)  
内富 庸介 (国立がん研究センター中央病院)
- 
- P2-267 Survey of pain of cancer patients and their families in the AYA generation in cancer nursing outpatients**  
Emi Nagaishi (Nagasaki University Hospital)  
**がん看護外来における AYA 世代のがん患者および家族の苦痛に関する実態調査**  
永石 恵美 (長崎大学病院)
- 
- P2-268 AYA (Adolescents and Young Adults) 世代がん患者の治療初期のつらさの理由—性別の比較—**  
Saki Horiguchi (Department of Nursing, National Cancer Center Hospital / Adult Nursing, National College of Nursing, Japan)  
堀口 沙希 (国立がん研究センター中央病院 看護部 / 国立看護大学校 成人看護学)
- 
- P2-269 周術期看護外来における AYA 世代の患者の相談内容と支援の課題**  
Erika Onuki (National Cancer Center Hospital Department Of Nursing)  
小貫 恵理佳 (国立がん研究センター中央病院 看護部)
- 
- P2-270 思春期・若年成人 (Adolescents and Young Adult; AYA) がん患者が望む医師とのコミュニケーション**  
Saran Yoshida (Graduate School of Education, Tohoku University)  
吉田 沙蘭 (東北大学大学院教育学研究科)
- 
- P2-271 がん専門病院における AYA 世代がん患者の妊孕性温存の取り組み**  
Makiko Ono (Department of Medical Oncology, Cancer Institute Hospital of JFCR)  
小野 麻紀子 (がん研究会有明病院 総合腫瘍科)
- 
- P2-272 Comparison of Cancer Occurance among AYA (Adolescent and Young Adult) Cancer, Adult Cancer and Geriatric Cancer**  
ABDULLAH AL MAMUN KHAN (MD (Medical Oncology), Bangladesh)

**P2-273 Application of Geriatric Assessment (GA) for elderly malignant lymphoma patients**  
 Hidenori Sasaki (Division of Medical Oncology, Hematology and Infectious Diseases, Fukuoka University Hospital)

**高齢悪性リンパ腫患者に対する高齢者機能評価 (GA) の応用**  
 佐々木 秀法 (福岡大学病院 腫瘍血液感染症内科)

**P2-274 Prevalence Geriatric in Hospitalized Cancer Patient**  
 Ralph Gunarsa (medical oncology, MRCCC Siloam Hospital, Indonesia)

**P2-275 Geriatric Oncology Survey: medical education, research and clinical practice**  
 Tomohiro Nishijima (Section of Geriatric Oncology, Kyushu Cancer Center)

**高齢者がん医療調査－医学教育・研究・診療について**  
 西嶋 智洋 (九州がんセンター 老年腫瘍科)

12:40-13:35 Poster Session 2-34 / ポスターセッション 2-34

**P2-34 Others**  
 その他

Chair : Ayako Mitsuma (Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital)  
 司会 : 満岡 綾子 (名古屋大学医学部附属病院 化学療法部)

**P2-276 がん教育が中学 1 年生の死生観に及ぼす影響**  
 Riho Horibe (Kobe Pharmaceutical University)  
 堀部 里帆 (神戸薬科大学)

**P2-277 中学生に対するがん教育の実施**  
 - 中学 2 年生に「顕微鏡を使ってがん細胞を見てみよう」を実施して -  
 Hazuki Tanaka (Kobe Pharmaceutical University)  
 田中 葉月 (神戸薬科大学)

**P2-278 launch of a medical oncology training program for residents in the palliative care department**  
 Yuta Ishiyama (Palliative Care Department, Aso Izuka Hospital)  
**緩和ケア科内における研修医向け臨床腫瘍トレーニングプログラムの立ち上げ報告**  
 石山 雄太 (飯塚病院 緩和ケア科)

**P2-279 Our novel approaches to obtain tailor-made informed consent for hematological malignancies**  
 Akihito Matsuoka (Department of Hematology, Sakaide City Hospital)  
 松岡 亮仁 (坂出市立病院 血液内科)

**P2-280 Bariatric surgery and risk of cancer: a propensity score matched study**  
 Tingting Wu (Department of Family Medicine and Primary Care, The University of Hong Kong, Hong Kong)

**P2-281 診断的開腹術により生検を行った腹部腫瘍症例の検討**  
 Fumihiko Yoneyama (Department of Surgery, Nagoya Ekisai-kai Hospital)  
 米山 文彦 (名古屋掖済会病院外科)

**P2-282 Absence of Thanatology: How do we show the real to the present generation of Japanese?**  
 Ryuhei Tanaka (Dept. of Pediatr Oncol., Int. Med. Ctr., Saitama Medical Univ.)  
**死生学の欠如した現代日本人に教える「がん教育」とは何か？**  
 田中 竜平 (埼玉医科大学国際医療センター小児腫瘍科)

**P2-283 Simultaneous and sequential treatment of cancer with tuberculosis: Experience from a tuberculosis control unit in Japan**  
 Yoshitaka Seki (Division of Respiriology, Department of Internal Medicine, The Jikei Daisan Hospital, Japan)  
**結核合併がん症例の治療経験：当院における結核病棟でのがん診療**  
 関 好孝 (東京慈恵会医科大学附属第三病院 呼吸器内科)

**P2-284 Developing an information sheet to warn patients not to receive an unproven medical intervention**  
 Keiko Sato (Department of Patient Safety, Kyoto University Hospital)  
**根拠なき治療に近づかないよう患者・市民に注意喚起することの必要性**  
 佐藤 恵子 (京都大学医学部附属病院)

12:40-13:35 Poster Session 2-35 / ポスターセッション 2-35

**P2-35 Case Reports/Series4 (Colorectal Cancer) 症例報告 4 (大腸)**  
 Chair : Eiji Oki (Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University)  
 司会 : 沖 英次 (九州大学大学院 消化器・総合外科)

**P2-285 8 advanced colorectal cancer cases of modified FOLFOXIRI chemotherapy with molecular target drug**  
 Yoshiaki Shindo (Nakadori General Hospital)  
**当院で施行した分子標的治療薬併用 modified FOLFOXIRI 療法の 8 例**  
 進藤 吉明 (中通総合病院)

**P2-286 Efficacy and safety of Paclitaxel/Ramucirumab for advanced gastric cancer and FOLFIRI/Ramucirumab for colorectal cancer**  
 Manabu Yamamoto (Department of Surgery, Fukuoka Sanno Hospital)  
**胃癌・大腸癌における Ramucirumab 療法の治療効果と有害事象に関する検討**  
 山本 学 (福岡山王病院)

**P2-287 4 cases of metastatic colorectal cancer treated by FOLFIRI+Aflibercept (FOLFIRI+AFL) after 3rd line**  
 Shinichi Takemura (Department of Surgery, Shirakawa Kosei General Hospital)  
**3rd line以降に FOLFIRI+Aflibercept (FOLFIRI+AFL) 療法を施行した切除不能再発大腸癌 4 症例の検討**  
 竹村 真一 (白河厚生総合病院 外科)

**P2-288 当科における集学的治療後に長期の無再発生存を維持しており現在無治療の結腸直腸がん (Stage IV) 症例の臨床病理学的検討**  
 Kyoka Ito (Medical Oncology Department, National Hospital Organization Sendai Medical Center)  
 伊藤 恭加 (国立病院機構 仙台医療センター 腫瘍内科)

- P2-289** 当院における75歳以上の切除不能進行・再発大腸癌患者に対する化学療法の検討  
 Kouya Sawai (Department of Medical Oncology, Sapporo Kosei General Hospital)  
 澤井 康弥 (札幌厚生病院 化学療法内科)
- 
- P2-290** An elderly case of recurrent colon cancer with carcinomatous pleurisy responding to Bevacizumab and CPT-11  
 Takahisa Fujikawa (Department of Surgery, Kokura Memorial Hospital)  
**高齢者再発大腸癌・癌性胸膜炎に対しBevacizumab + CPT-11 療法が著効し長期病勢コントロールを得ている一例**  
 藤川 貴久 (小倉記念病院 外科)
- 
- P2-291** オキサリプラチンによる類洞閉塞症候群 (SOS) : 多様な臨床像を示した3症例  
 Tomoki Sumiya (Department of Gastroenterology, Kurashiki Central Hospital)  
 住谷 知紀 (倉敷中央病院 消化器内科)
- 
- P2-292** 進行・再発大腸癌に対してFOLFIRI+Bevacizumab療法を施行中に高アンモニア血症に起因する意識障害を発症した一例  
 Kosuke Sagara (National Hospital Organization Kyushu Cancer Center)  
 相良 浩輔 (九州がんセンター)
- 
- P2-293** ベバシズマブ併用化学療法中に左室内血栓を来したStage IV結腸癌の1例  
 Yasushi Sekino (Department of Surgery, Nagano Municipal Hospital)  
 関野 康 (長野市民病院 外科)
- 
- P2-294** Comparison of thrombocytopenia between XELOX and mFOLFOX6 in patients with colorectal cancer  
 Taichi Abe (Pharmaceutical Department, Yokohama City Minato Red Cross Hospital)  
**大腸癌患者におけるXELOXとmFOLFOX 6による血小板減少症の比較**  
 阿部 多一 (横浜市立みなと赤十字病院 薬剤部)

12:40-13:35 Poster Session 2-36 / ポスターセッション 2-36

- P2-36** Case Reports/Series5 (Lung Cancer - Immunotherapy1)  
 症例報告 5 (呼吸器-免疫療法 1)
- Chair : Hirofumi Utsumi (Division of Respiratory diseases, Department of Internal Medicine, Jikei University School of Medicine)  
 司会 : 内海 裕文 (東京慈恵会医科大学附属病院 呼吸器内科)
- 
- P2-295** NSCLCに対する1次治療としてのPembrolizumab + Pt-doubletの使用経験  
 Yoshiaki Negi (Hyogo College Of Medicine)  
 柘木 芳樹 (兵庫医科大学)
- 
- P2-296** 大腸癌転移再発との鑑別を要し、pembrolizumabが奏功した腸型肺腺癌の一例  
 Hideyasu Sugimoto (Respiratory Medicine Department, Yamato Tokushukai Hospital)  
 杉本 栄康 (大和徳洲会病院 呼吸器内科)
- 
- P2-297** 肺癌への免疫チェックポイント阻害薬投与中に脳転移は病勢維持されるも癌性髄膜症の発症した症例の報告  
 Takashi Osaki (National Hospital Organization Shibukawa Medical Center)  
 大崎 隆 (渋川医療センター)
- 
- P2-298** MSI-Highを有する進展型小細胞肺癌患者に対してペムブロリズマブを投与した1例  
 Keiichi Ota (Research Institute for Diseases of the Chest Graduate School of Medical Sciences, Kyushu University / Fukuoka Higashi Medical Center)  
 大田 恵一 (九州大学大学院医学研究院附属胸部疾患研究施設/福岡東医療センター)

- P2-299** **ペムブロリズマブ単剤療法中にACTH単独欠損症を来した非小細胞肺癌の1例**  
 Yuta Okumura (Department of Internal medicine, Kyushu University Beppu Hospital)  
 奥村 祐太 (九州大学病院別府病院 内科)
- 
- P2-300** **IV期肺扁平上皮癌に対して殺細胞性抗がん剤と免疫チェックポイント阻害剤を併用した際に、ニューモシスチス肺炎を発症した1例**  
 Akio Nomura (Department of Respiratory Medicine, Hiroshima Prefectural Hospital)  
 野村 晃生 (県立広島病院 呼吸器内科)
- 
- P2-301** **Myelitis after durvalumab administration following chemoradiotherapy for advanced non-small cell lung cancer**  
 Hiroaki Yamane (Hiroshima Prefectural Hospital)  
**放射線化学療法後のデュルバルマブ加療中に脊髄炎を発症した局所進行肺癌の一例**  
 山根 宏昭 (県立広島病院)
- 
- P2-302** **Nivolumab-induced polymyalgia rheumatica in a patient with lung adenocarcinoma**  
 Toshiyuki Kita (Respiratory Medicine, National Hospital Organization, Kanazawa Medical Center)  
**ニブルマブによりリウマチ性多発筋痛症を発症した肺腺癌の一例**  
 北 俊之 (国立病院機構金沢医療センター 呼吸器内科)
- 
- P2-303** **A lung adenocarcinoma patient developing psoriasisform dermatitis and vitiligo after treatment with pembrolizumab**  
 Hiromasa Takeda (Department of internal medicine, Tsuyama chuo hospital)  
**ペムブロリズマブ治療後に乾癬様皮膚炎および白斑を呈した肺腺がん患者の一例**  
 武田 洋正 (津山中央病院 内科)
- 
- P2-304** **Corticosteroid-induced osteoporosis of the treatment for immune-related adverse events**  
 Fumihiko Hirai (National Hospital Organization Fukuoka Hospital)  
 平井 文彦 (福岡病院)
- 
- P2-305** **A case of immune-mediated thrombocytopenia during Nivolumab treatment for lung adenocarcinoma**  
 Yutaka Natori (Department of Medical Oncology Fukushima Medical University)  
**ニボルマブ治療中に免疫性血小板減少性紫斑病を発症し治療に難渋した一例**  
 名取 穰 (福島県立医科大学)

12:40-13:35 Poster Session 2-37 / ポスターセッション 2-37

**P2-37** Case Reports/Series6 (Lung Cancer - TKIs, Chemotherapy)  
 症例報告 6 (呼吸器 - TKI・化学療法)

Chair : Yoshiko Urata (Department of Thoracic Oncology, Hyogo Cancer Center)  
 司会 : 浦田 佳子 (兵庫県立がんセンター 呼吸器内科)

- P2-306** **Prognostic value of Neutrophil-to-Lymphocyte Ratio (NLR) for Advanced NSCLC: A Retrospective Observational Study**  
 Masashi Ishihara (Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine)  
**進行期非小細胞肺癌における予後予測因子としての好中球・リンパ球比 (NLR) の検討**  
 石原 昌志 (帝京大学医学部附属病院 腫瘍内科)



- 
- P2-307** **Two cases of Osimertinib-induced clinical response in patients with squamous lung cancer harboring EGFR mutations**  
 Satoshi Shoji (Department of Respiratory Medicine and Infectious Disease, Niigata University Medical and Dental Hospital)  
**初回化学療法としてのオシメルチニブが奏効したEGFR遺伝子変異陽性肺扁平上皮癌の2例**  
 庄子 聡 (新潟大学医歯学総合病院 呼吸器感染症内科)
- 
- P2-308** **Successful treatment with osimertinib for leptomeningeal carcinomatosis from NSCLC with the EGFR T790M mutation**  
 Naruo Yoshimura (Department of Pulmonology, Tohoku Medical And Pharmaceutical University)  
**EGFR T790変異を獲得した肺腺がんのがん性髄膜炎に対するオシメルチニブ治療の有効例**  
 吉村 成央 (東北医科薬科大学 内科学第一 (呼吸器内科))
- 
- P2-309** **A case of successful treatment with Osimertinib for mucoepidermoid carcinoma of the lung with EGFR mutation**  
 Koichiro Nozaki (Department of Respiratory Medicine and Infectious Diseases, Niigata University Medical & Dental Hospital)  
**EGFR遺伝子変異陽性肺粘表皮癌に対して1次治療でOsimertinibが奏効した一例**  
 野寺 幸一郎 (新潟大学医歯学総合病院 呼吸器感染症内科)
- 
- P2-310** **Two cases of congestive heart failure during osimertinib treatment for EGFR mutant NSCLC**  
 Satoshi Hara (Respiratory Division, Department of Internal Medicine, Itami City Hospital)  
**オシメルチニブ投与中にうっ血性心不全を来した非小細胞肺癌の2症例**  
 原 聡志 (市立伊丹病院)
- 
- P2-311** **Retrospective study of case with EGFR T790M positive lung cancer: The actual sequential therapy in clinical setting**  
 Osamu Honjo (Respiratory Medicine, Sapporo Minami-Sanjo Hospital)  
**EGFR T790M陽性肺癌治療患者の後方視的研究：実臨床の場の実際の治療シーケンス**  
 本庄 統 (札幌南三条病院 呼吸器内科)
- 
- P2-312** **Syndrome of inappropriate secretion of antidiuretic hormone associated with erlotinib**  
 Kenichirou Kudou (Department of respiratory medicine, Iwakuni Medical Center)  
**エルロチニブが原因と考えられたSIADHの1例**  
 工藤 健一郎 (岩国医療センター 呼吸器内科)
- 
- P2-313** **Clinical effect of alectinib in patients with ALK-positive non-small cell lung cancer**  
 Koichi Nishi (Department of Respiratory Medicine, Ishikwa Prefectural Central Hospital)  
**ALK遺伝子転座陽性非小細胞肺癌に対するアレクチニブの臨床効果の検討**  
 西 耕一 (石川県立中央病院 呼吸器内科)
- 
- P2-314** **Retrospective study of docetaxel in non-small-cell lung cancer patients with chronic kidney disease stage 3b or higher**  
 Satoshi Anai (Harasanshin Hospital)  
 穴井 諭 (原三信病院)
- 
- P2-315** **A multicenter experience of combination therapy with pemetrexed and cisplatin in advanced non small cell lung cancer**  
 Manoj Kumar Behera (Clinical Oncology, HCG & AHRCC, India)